uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.892 | Q17 | What gene does the drug Citalopram target? | The drug Citalopram targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%citalopram%" OR LOWER(tradeNames_string) LIKE "%citalopram%" OR LOWER(drugSynonyms_string) LIKE "%citalopram%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1197', 'drugName': 'Citalopram Hydrobromide', 'tradeNames_string': 'Celexa, Cipramil, Citalopram hydrobromide, Paxoran', 'drugSynonyms_string': 'Citalopram (as hydrobromide), Citalopram hbr, Citalopram hydrobromide, LU 10-171-B, LU-10-171-B, NSC-758684', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Panic Disorder (EFO_0004262), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5074', 'drugName': 'Citalopram', 'tradeNames_string': '', 'drugSynonyms_string': 'Celexa, Citadur, Citalopram', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Agitation (HP_0000713), Irritable Bowel Syndrome (EFO_0000555), Panic Disorder (EFO_0004262), Hot Flashes (HP_0031217), Alcohol Abuse (MONDO_0002046), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Acute Coronary Syndrome (EFO_0005672), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_767', 'drugName': 'Escitalopram', 'tradeNames_string': 'Cipralex', 'drugSynonyms_string': 'Escitalopram, Esertia, Esitol, LU-26-054', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Pulmonary Hypertension (MONDO_0005149), Substance Abuse (MONDO_0002491), Bipolar I Disorder (EFO_0009963), Anxiety Disorder (EFO_0006788), Panic Disorder (EFO_0004262), Gastrointestinal Disease (EFO_0010282), Hepatitis C Virus Infection (EFO_0003047), Spinal Cord Injury (EFO_1001919), Post-Traumatic Stress Disorder (EFO_0001358), Aphasia (HP_0002381), Dementia (HP_0000726), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Cocaine Dependence (EFO_0002610), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Borderline Personality Disorder (HP_0012076), Stroke (EFO_0000712), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Social Anxiety Disorder (EFO_1001917), Unipolar Depression (EFO_0003761), Chronic Kidney Disease (EFO_0003884), Major Depressive Disorder (MONDO_0002009), Phobic Disorder (EFO_1001908), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4125', 'drugName': 'Escitalopram Oxalate', 'tradeNames_string': 'Escitalopram oxalate, Lexapro', 'drugSynonyms_string': 'Citalopram oxalate, (s)-, Escitalopram (as oxalate), Escitalopram oxalate, LU 26-054-0, LU-26-054-0, LU-26-054-O, NSC-758934', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Anxiety Disorder (EFO_0006788), Generalized Anxiety Disorder (EFO_1001892), Panic Disorder (EFO_0004262), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.82 | Q17 | What gene does the drug Lofexidine target? | The drug Lofexidine targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lofexidine%" OR LOWER(tradeNames_string) LIKE "%lofexidine%" OR LOWER(drugSynonyms_string) LIKE "%lofexidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3839', 'drugName': 'Lofexidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Lofexidine', 'linkedDiseasesDrug_string': 'Opioid Use Disorder (EFO_0010702), Substance Withdrawal Syndrome (EFO_0005800), Drug Dependence (EFO_0003890), Hepatic Failure (HP_0001399), Cannabis Dependence (EFO_0007191), Cocaine Dependence (EFO_0002610), Heroin Dependence (EFO_0004240), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3056', 'drugName': 'Lofexidine Hydrochloride', 'tradeNames_string': 'Britlofex, Lofexidine, Lucemyra', 'drugSynonyms_string': 'Lofexidine hcl, Lofexidine hydrochloride, MDL 14,042, MDL-14042, NSC-759654', 'linkedDiseasesDrug_string': 'Substance Withdrawal Syndrome (EFO_0005800), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1182 | Q17 | What gene does the drug Pipecuronium Bromide target? | The drug Pipecuronium Bromide targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pipecuronium bromide%" OR LOWER(tradeNames_string) LIKE "%pipecuronium bromide%" OR LOWER(drugSynonyms_string) LIKE "%pipecuronium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5171', 'drugName': 'Pipecuronium Bromide', 'tradeNames_string': 'Arduan', 'drugSynonyms_string': 'Pipecurium bromide, Pipecuronium bromide, Pipecuronium bromide anhydrous, Pipecuronium bromide dihydrate, Pipecuronium bromide hydrate, RGH 1106, RGH-1106', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.821 | Q17 | What gene does the drug Ampreloxetine target? | The drug Ampreloxetine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ampreloxetine%" OR LOWER(tradeNames_string) LIKE "%ampreloxetine%" OR LOWER(drugSynonyms_string) LIKE "%ampreloxetine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2684', 'drugName': 'Ampreloxetine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ampreloxetine, TD-9855, Td-9855', 'linkedDiseasesDrug_string': 'Orthostatic Hypotension (EFO_0005252), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Fibromyalgia (EFO_0005687), Multiple System Atrophy (EFO_1001050)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1283 | Q17 | What gene does the drug Terodiline target? | The drug Terodiline targets 31 genes: CACNA1C, CACNA1H, CACNG2, CACNG7, CACNA2D1, CACNG6, CACNA1B, CACNG5, CHRM5, CACNG3, CACNG1, CACNB3, CACNB4, CACNA1S, CACNA2D3, CACNA1A, CACNA2D4, CACNA1D, CHRM2, CACNB2, CACNA1G, CACNA1I, CACNG8, CACNB1, CACNG4, CHRM3, CACNA1E, CHRM4, CACNA2D2, CHRM1 and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%terodiline%" OR LOWER(tradeNames_string) LIKE "%terodiline%" OR LOWER(drugSynonyms_string) LIKE "%terodiline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6292', 'drugName': 'Terodiline', 'tradeNames_string': '', 'drugSynonyms_string': 'Terodiline', 'linkedDiseasesDrug_string': 'Urinary Incontinence (HP_0000020), Polyuria (HP_0000103)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 31}, {'UUID': 'DrugGeneTargets_v2_6291', 'drugName': 'Terodiline', 'tradeNames_string': '', 'drugSynonyms_string': 'Terodiline', 'linkedDiseasesDrug_string': 'Urinary Incontinence (HP_0000020), Polyuria (HP_0000103)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 31}, {'UUID': 'DrugGeneTargets_v2_311', 'drugName': 'Terodiline Hydrochloride', 'tradeNames_string': 'Micturin 12.5, Micturin 25', 'drugSynonyms_string': 'Terodiline hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 31}, {'UUID': 'DrugGeneTargets_v2_310', 'drugName': 'Terodiline Hydrochloride', 'tradeNames_string': 'Micturin 12.5, Micturin 25', 'drugSynonyms_string': 'Terodiline hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM4 (ENSG00000180720), CHRM1 (ENSG00000168539), CHRM2 (ENSG00000181072), CHRM5 (ENSG00000184984), CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 31}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.678 | Q17 | What gene does the drug Goserelin target? | The drug Goserelin targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%goserelin%" OR LOWER(tradeNames_string) LIKE "%goserelin%" OR LOWER(drugSynonyms_string) LIKE "%goserelin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_246', 'drugName': 'Goserelin Acetate', 'tradeNames_string': 'Novgos, Zoladex, Zoladex la', 'drugSynonyms_string': 'Fertilan, Goserelin Acetate, Goserelin acetate', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Fallopian Tube Cancer (MONDO_0002158), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Male Breast Carcinoma (EFO_0006861), Metabolic Syndrome (EFO_0000195), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2259', 'drugName': 'Goserelin', 'tradeNames_string': 'Zoladex', 'drugSynonyms_string': 'Goserelin, Goserelin acetate, ICI 118,630, ICI-118630', 'linkedDiseasesDrug_string': 'Uterine Fibroid (EFO_0000731), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Adenomyosis (EFO_1001757), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Premature Ovarian Insufficiency (HP_0008209), Male Breast Carcinoma (EFO_0006861), Endometriosis (EFO_0001065), Menopause (EFO_0003922), Salivary Gland Carcinoma (MONDO_0000521), Infertility (EFO_0000545), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Invasive Lobular Carcinoma (EFO_0000553), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1533 | Q17 | What gene does the drug Hydrocortisone Sodium Succinate target? | The drug Hydrocortisone Sodium Succinate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocortisone sodium succinate%" OR LOWER(tradeNames_string) LIKE "%hydrocortisone sodium succinate%" OR LOWER(drugSynonyms_string) LIKE "%hydrocortisone sodium succinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1162', 'drugName': 'Hydrocortisone Sodium Succinate', 'tradeNames_string': 'A-hydrocort, Hcss, Hydrocortisone sodium succinate, Solu-cortef', 'drugSynonyms_string': 'Cortisol 21-(sodium succinate), Hydrocortisone 21-sodium succinate, Hydrocortisone sodium succinate, Hydrocortisoni natrii succinas, NSC-9152, SOLU-CORTEF', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Leukemia (EFO_0000565), Septic Shock (EFO_0006834), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Acute Lymphoblastic Leukemia (EFO_0000220), Anaplastic Large Cell Lymphoma (EFO_0003032), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.59 | Q17 | What gene does the drug Dutasteride target? | The drug Dutasteride targets 3 genes: SRD5A2, SRD5A1 and SRD5A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dutasteride%" OR LOWER(tradeNames_string) LIKE "%dutasteride%" OR LOWER(drugSynonyms_string) LIKE "%dutasteride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_433', 'drugName': 'Dutasteride', 'tradeNames_string': 'Avodart, Dutasteride', 'drugSynonyms_string': 'Avolve, Duastride, Dutasteride, GG-745, GI 198745, GI-198745, NSC-740477, NSC-759880', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Hypogonadism (MONDO_0002146), Alopecia (MONDO_0004907), Prostate Cancer (MONDO_0008315), Amyotrophic Lateral Sclerosis (MONDO_0004976), Kennedy Disease (MONDO_0010735), Benign Prostatic Hyperplasia (EFO_0000284), Covid-19 (MONDO_0100096), Prostatitis (EFO_0003830), Aging (GO_0007568), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SRD5A1 (ENSG00000145545), SRD5A2 (ENSG00000277893), SRD5A3 (ENSG00000128039)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.136 | Q17 | What gene does the drug Latanoprostene Bunod target? | The drug Latanoprostene Bunod targets the gene PTGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%latanoprostene bunod%" OR LOWER(tradeNames_string) LIKE "%latanoprostene bunod%" OR LOWER(drugSynonyms_string) LIKE "%latanoprostene bunod%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2312', 'drugName': 'Latanoprostene Bunod', 'tradeNames_string': 'Vesneo, Vyzulta', 'drugSynonyms_string': 'BOL-303259-X, Bol-303259-x, Latanoprostene bunod, NCX 116, NCX-116, PF-3187207', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1150 | Q17 | What gene does the drug Dabigatran Etexilate Mesylate target? | The drug Dabigatran Etexilate Mesylate targets the gene F2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dabigatran etexilate mesylate%" OR LOWER(tradeNames_string) LIKE "%dabigatran etexilate mesylate%" OR LOWER(drugSynonyms_string) LIKE "%dabigatran etexilate mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5711', 'drugName': 'Dabigatran Etexilate Mesylate', 'tradeNames_string': 'Pradaxa', 'drugSynonyms_string': 'BIBR 1048 MS, BIBR-1048-MS, Dabigatran etexilate mesilate, Dabigatran etexilate mesylate', 'linkedDiseasesDrug_string': 'Acute Pancreatitis (EFO_1000652), Stroke (EFO_0000712), Deep Vein Thrombosis (EFO_0003907), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.942 | Q17 | What gene does the drug Belantamab Mafodotin target? | The drug Belantamab Mafodotin targets 16 genes: TUBB, TUBA4A, TUBA3E, TNFRSF17, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%belantamab mafodotin%" OR LOWER(tradeNames_string) LIKE "%belantamab mafodotin%" OR LOWER(drugSynonyms_string) LIKE "%belantamab mafodotin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1871', 'drugName': 'Belantamab Mafodotin', 'tradeNames_string': 'Blenrep', 'drugSynonyms_string': 'Belantamab mafodotin, Belantamab mafodotin blmf, Belantamab mafodotin-blmf, GSK-2857916, GSK2857916', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Diffuse Large B-Cell Lymphoma (EFO_0000403), Multiple Myeloma (EFO_0001378), Al Amyloidosis (MONDO_0019438)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_1872', 'drugName': 'Belantamab Mafodotin', 'tradeNames_string': 'Blenrep', 'drugSynonyms_string': 'Belantamab mafodotin, Belantamab mafodotin blmf, Belantamab mafodotin-blmf, GSK-2857916, GSK2857916', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Diffuse Large B-Cell Lymphoma (EFO_0000403), Multiple Myeloma (EFO_0001378), Al Amyloidosis (MONDO_0019438)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014), TNFRSF17 (ENSG00000048462)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1685 | Q17 | What gene does the drug Desipramine Hydrochloride target? | The drug Desipramine Hydrochloride targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desipramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%desipramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%desipramine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3926', 'drugName': 'Desipramine Hydrochloride', 'tradeNames_string': 'Desipramine hydrochloride, Norpramin, Pertofran, Pertofrane', 'drugSynonyms_string': '18-8181, DMI, Desipramine hcl, Desipramine hydrochloride, EX 4355, EX-4355, G-35020, JB-8181, NSC-114901, RMI 9,384A, RMI-9384A', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050), Unipolar Depression (EFO_0003761), Small Cell Lung Carcinoma (EFO_0000702), Back Pain (HP_0003418)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.830 | Q17 | What gene does the drug Paricalcitol target? | The drug Paricalcitol targets the gene VDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%paricalcitol%" OR LOWER(tradeNames_string) LIKE "%paricalcitol%" OR LOWER(drugSynonyms_string) LIKE "%paricalcitol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2779', 'drugName': 'Paricalcitol', 'tradeNames_string': 'Paricalcitol, Zemplar', 'drugSynonyms_string': 'COMPOUND 49510, COMPOUND-49510, Paricalcitol', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Secondary Hyperparathyroidism (EFO_1001173), Iga Glomerulonephritis (EFO_0004194), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Left Ventricular Hypertrophy (EFO_0003896), Hyperparathyroidism (EFO_0008506), Parathyroid Disease (EFO_0005754), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Pancreatic Carcinoma (EFO_0002618), Proteinuria (HP_0000093), Albuminuria (EFO_0004285), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Neoplasm (EFO_0000616), Diabetic Nephropathy (EFO_0000401), Kidney Disease (EFO_0003086), Type 2 Diabetes Mellitus (MONDO_0005148), Hypocalcemia (HP_0002901)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1224 | Q17 | What gene does the drug Prochlorperazine Maleate target? | The drug Prochlorperazine Maleate targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prochlorperazine maleate%" OR LOWER(tradeNames_string) LIKE "%prochlorperazine maleate%" OR LOWER(drugSynonyms_string) LIKE "%prochlorperazine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5222', 'drugName': 'Prochlorperazine Maleate', 'tradeNames_string': 'Buccastem, Buccastem m, Compazine, Prochlorperazine maleate, Procomp, Proziere, Vertigon', 'drugSynonyms_string': 'Prochlorperazine dimaleate, Prochlorperazine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.510 | Q17 | What gene does the drug Emapalumab target? | The drug Emapalumab targets the gene IFNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emapalumab%" OR LOWER(tradeNames_string) LIKE "%emapalumab%" OR LOWER(drugSynonyms_string) LIKE "%emapalumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3856', 'drugName': 'Emapalumab', 'tradeNames_string': 'Gamifant', 'drugSynonyms_string': 'Emapalumab, Emapalumab lzsg, Emapalumab-lzsg, NI-0501', 'linkedDiseasesDrug_string': "Primary Hemophagocytic Lymphohistiocytosis (Orphanet_158038), Macrophage Activation Syndrome (EFO_1001806), Covid-19 (MONDO_0100096), Adult-Onset Still'S Disease (EFO_0007135), Hemophagocytic Syndrome (MONDO_0015540), Systemic Lupus Erythematosus (MONDO_0007915), Acute Graft Vs. Host Disease (EFO_0004599), Chronic Granulomatous Disease (MONDO_0018305), Immune System Disease (EFO_0000540)", 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNG (ENSG00000111537)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1776 | Q17 | What gene does the drug Clorazepate Dipotassium target? | The drug Clorazepate Dipotassium targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clorazepate dipotassium%" OR LOWER(tradeNames_string) LIKE "%clorazepate dipotassium%" OR LOWER(drugSynonyms_string) LIKE "%clorazepate dipotassium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5271', 'drugName': 'Clorazepate Dipotassium', 'tradeNames_string': 'Clorazepate dipotassium, Gen-xene, Tranxene, Tranxene sd', 'drugSynonyms_string': '4306 CB, 4306-CB, 4306CB, AB 35616, ABBOTT-35616, CB 4306, CM 4306, Clorazepate dipotassium, Clorazepate dipotassium civ, Clorazepic acid dipotassium salt, Dipotassium clorazepate, Potassium Clorazepate, TR 19119', 'linkedDiseasesDrug_string': 'Anxiety Disorder (EFO_0006788), Seizure (HP_0001250)', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.351 | Q17 | What gene does the drug Pseudoephedrine target? | The drug Pseudoephedrine targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pseudoephedrine%" OR LOWER(tradeNames_string) LIKE "%pseudoephedrine%" OR LOWER(drugSynonyms_string) LIKE "%pseudoephedrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1353', 'drugName': 'Pseudoephedrine Sulfate', 'tradeNames_string': 'Afrinol', 'drugSynonyms_string': 'D-pseudoephedrine sulfate, Pseudoephedrine sulfate, Pseudoephedrine sulphate, SCH 4855, SCH-4855', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956), Allergic Rhinitis (EFO_0005854)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5086', 'drugName': 'Pseudoephedrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Acunaso, Isoephedrine, d-, Neodurasina, Pseudoephedrine, Pseudoephedrine polistirex', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Orthostatic Hypotension (EFO_0005252), Common Cold (EFO_0007214), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Pain (EFO_0003843), Migraine Disorder (MONDO_0005277), Enuresis (MONDO_0024290), Cough (HP_0012735), Vasomotor Rhinitis (EFO_0007533), Respiratory Tract Infectious Disorder (MONDO_0024355), Multiple System Atrophy (EFO_1001050), Allergic Rhinitis (EFO_0005854), Influenza (EFO_0007328), Nasal Congestion (HP_0001742), Inflammation (MP_0001845), Allergic Disease (MONDO_0005271), Rhinitis (EFO_0008521)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2493', 'drugName': 'Pseudoephedrine Polistirex', 'tradeNames_string': 'Pseudo-12', 'drugSynonyms_string': 'Pseudoephedrine polistirex', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_151', 'drugName': 'Pseudoephedrine Hydrochloride', 'tradeNames_string': 'Actifed, Contac, Dimotane plus, Dimotane plus l.a., Galpseud, Galpseud plus, Novafed, Otrivine mu-cron, Pseudoephedrine hydrochloride, Pseudophed, Sinutab, Sudafed, Sudafed 12 hour, Sudafed 12 hr decongest, Sudafed 24 hour, Sudafed plus, Sudafed-sa', 'drugSynonyms_string': 'Efidac 24, Galsud, NSC-106567, NSC-33634, Otrinol, Pseudoephedrine hcl, Pseudoephedrine hydrochloride, Rhinalair', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Common Cold (EFO_0007214), Enuresis (MONDO_0024290), Seasonal Allergic Rhinitis (EFO_0003956), Pain (EFO_0003843), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Influenza (EFO_0007328), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.392 | Q17 | What gene does the drug Plonmarlimab target? | The drug Plonmarlimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CSF2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%plonmarlimab%" OR LOWER(tradeNames_string) LIKE "%plonmarlimab%" OR LOWER(drugSynonyms_string) LIKE "%plonmarlimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_512', 'drugName': 'Plonmarlimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Plonmarlimab, TJ-003234, TJ003234, TJM-2, Tj 003234, Tj003234', 'linkedDiseasesDrug_string': 'Covid-19 (MONDO_0100096), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF2 (ENSG00000164400)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1033 | Q17 | What gene does the drug Capsaicin target? | The drug Capsaicin targets the gene TRPV1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%capsaicin%" OR LOWER(tradeNames_string) LIKE "%capsaicin%" OR LOWER(drugSynonyms_string) LIKE "%capsaicin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_686', 'drugName': 'Capsaicin', 'tradeNames_string': 'Qutenza, Zacin, Zostrix, Zostrix hp', 'drugSynonyms_string': 'ALGRX 4975, ALGRX-4975, Ausanil, Axsain, Capsaicin, Capzasin-hp, Cntx-4975, Dolenon, FEMA NO. 3404, Mioton, NGX-1998, NGX-4010, NSC-56353, Ngx-1998, Ovocap, Ratden pe 40, Togarashi orenji, Trans-capsaicin', 'linkedDiseasesDrug_string': 'Myofascial Pain Syndrome (EFO_1001054), Lateral Epicondylitis (EFO_1001896), Tendinopathy (EFO_1001434), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Pain (EFO_0003843), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Pulmonary Arterial Hypertension (EFO_0001361), Muscle Spasm (HP_0003394), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Neuroma (EFO_0009619), Osteoarthritis, Knee (EFO_0004616), Neuropathic Pain (EFO_0005762), Non-Allergic Rhinitis (EFO_0009364), Frozen Shoulder (EFO_1000941), Arthritis (EFO_0005856), Herpes Zoster (EFO_0006510), Pruritus (HP_0000989), Diabetic Polyneuropathy (MONDO_0001583), Stroke (EFO_0000712), Back Pain (HP_0003418), Sprain (EFO_0009582), Brain Injury (MONDO_0043510), Myalgia (HP_0003326), Facial Pain (EFO_0009625), Head And Neck Malignant Neoplasia (EFO_0006859), Hiv Infection (EFO_0000764), Arthralgia (HP_0002829), Postherpetic Neuralgia (MONDO_0041052), Diabetic Neuropathy (EFO_1000783), Osteoarthritis (MONDO_0005178), Amyotrophic Lateral Sclerosis (MONDO_0004976), Peripheral Nervous System Disease (EFO_0009387), Vomiting (HP_0002013), Neuralgia (EFO_0009430)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPV1 (ENSG00000196689)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_366', 'drugName': 'Zucapsaicin', 'tradeNames_string': '', 'drugSynonyms_string': 'Civamide, Zucapsaicin', 'linkedDiseasesDrug_string': 'Arthralgia (HP_0002829), Postherpetic Neuralgia (MONDO_0041052), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Dry Eye Syndrome (EFO_1000906), Myalgia (HP_0003326)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRPV1 (ENSG00000196689)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.901 | Q17 | What gene does the drug Erdafitinib target? | The drug Erdafitinib targets 4 genes: FGFR2, FGFR1, FGFR3 and FGFR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%erdafitinib%" OR LOWER(tradeNames_string) LIKE "%erdafitinib%" OR LOWER(drugSynonyms_string) LIKE "%erdafitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5765', 'drugName': 'Erdafitinib', 'tradeNames_string': 'Balversa', 'drugSynonyms_string': 'Erdafitinib, JNJ-42756493, Jnj-42756493', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Urogenital Neoplasm (EFO_0003863), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Lymphoma (EFO_0000574), Urothelial Carcinoma (EFO_0008528), Squamous Cell Lung Carcinoma (EFO_0000708), Prostate Adenocarcinoma (EFO_0000673), Bladder Tumor (EFO_0000294)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.835 | Q17 | What gene does the drug Dabrafenib Mesylate target? | The drug Dabrafenib Mesylate targets the gene BRAF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dabrafenib mesylate%" OR LOWER(tradeNames_string) LIKE "%dabrafenib mesylate%" OR LOWER(drugSynonyms_string) LIKE "%dabrafenib mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_441', 'drugName': 'Dabrafenib Mesylate', 'tradeNames_string': 'Tafinlar', 'drugSynonyms_string': 'Dabrafenib mesilate, Dabrafenib mesylate, GSK-2118436 METHANESULFONATE SALT, GSK-2118436B, GSK-2118436B MESYLATE, GSK-2118436B METHANESULFONATE SALT, GSK2118436B, GSK2118436B, METHANE SULFONATE SALT, METHANE SULFONATE SALT', 'linkedDiseasesDrug_string': 'Erdheim-Chester Disease (EFO_1000926), Multiple Myeloma (EFO_0001378), Thyroid Carcinoma (EFO_0002892), Melanoma (EFO_0000756), Thyroid Cancer (MONDO_0002108), Metastatic Melanoma (EFO_0002617), Cutaneous Melanoma (EFO_0000389)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1894 | Q17 | What gene does the drug Zavegepant target? | The drug Zavegepant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: RAMP1 and CALCRL | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zavegepant%" OR LOWER(tradeNames_string) LIKE "%zavegepant%" OR LOWER(drugSynonyms_string) LIKE "%zavegepant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_851', 'drugName': 'Zavegepant', 'tradeNames_string': '', 'drugSynonyms_string': 'BHV-3500, BMS-742413, BMS-742413-01, Vazegepant, Zavegepant', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Covid-19 (MONDO_0100096), Asthma (MONDO_0004979)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'RAMP1 (ENSG00000132329), CALCRL (ENSG00000064989)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.481 | Q17 | What gene does the drug Turofexorate Isopropyl target? | The drug Turofexorate Isopropyl is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NR1H4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%turofexorate isopropyl%" OR LOWER(tradeNames_string) LIKE "%turofexorate isopropyl%" OR LOWER(drugSynonyms_string) LIKE "%turofexorate isopropyl%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4186', 'drugName': 'Turofexorate Isopropyl', 'tradeNames_string': '', 'drugSynonyms_string': 'FXR-450, Turofexorate isopropyl, WAY-362450, XL-335, XL335', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'NR1H4 (ENSG00000012504)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1472 | Q17 | What gene does the drug Etifoxine target? | The drug Etifoxine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etifoxine%" OR LOWER(tradeNames_string) LIKE "%etifoxine%" OR LOWER(drugSynonyms_string) LIKE "%etifoxine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_885', 'drugName': 'Etifoxine', 'tradeNames_string': '', 'drugSynonyms_string': '36-801, Etifoxine, HOE 36801, HOE-36801', 'linkedDiseasesDrug_string': 'Anxiety (EFO_0005230)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1887 | Q17 | What gene does the drug Alosetron target? | The drug Alosetron targets the gene HTR3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alosetron%" OR LOWER(tradeNames_string) LIKE "%alosetron%" OR LOWER(drugSynonyms_string) LIKE "%alosetron%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4889', 'drugName': 'Alosetron', 'tradeNames_string': '', 'drugSynonyms_string': 'A03AE01, Alosetron, Lotronex', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5986', 'drugName': 'Alosetron Hydrochloride', 'tradeNames_string': 'Alosetron hydrochloride, Lotronex', 'drugSynonyms_string': 'Alosetron hcl, Alosetron hydrochloride, GR 68755C, GR-68755C, Lotrpnex', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1398 | Q17 | What gene does the drug Apixaban target? | The drug Apixaban targets the gene F10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apixaban%" OR LOWER(tradeNames_string) LIKE "%apixaban%" OR LOWER(drugSynonyms_string) LIKE "%apixaban%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4326', 'drugName': 'Apixaban', 'tradeNames_string': 'Eliquis', 'drugSynonyms_string': 'Apixaban, BMS-562247, BMS-562247-01', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hemorrhage (MP_0001914), Covid-19 (MONDO_0100096), Venous Thrombosis (HP_0004936), Pulmonary Embolism (EFO_0003827), Atrial Fibrillation (EFO_0000275), Nephrotic Syndrome (EFO_0004255), Recurrent Thrombophlebitis (HP_0004419), Ischemic Stroke (HP_0002140), Patent Foramen Ovale (HP_0001655), Acute Lymphoblastic Leukemia (EFO_0000220), Thrombotic Disease (MONDO_0000831), Acute Coronary Syndrome (EFO_0005672), Thromboembolism (HP_0001907), Renal Insufficiency (HP_0000083), Takotsubo Cardiomyopathy (EFO_1002000), Hematoma (EFO_0010680), Atrial Flutter (EFO_0003911), Aortic Stenosis (EFO_0000266), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Venous Thromboembolism (EFO_0004286), Chronic Kidney Disease (EFO_0003884), Heart Failure (EFO_0003144), Deep Vein Thrombosis (EFO_0003907), Ischemia (EFO_0000556), Blood Coagulation Disease (EFO_0009314), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.659 | Q17 | What gene does the drug Nateglinide target? | The drug Nateglinide targets 2 genes: KCNJ11 and ABCC8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nateglinide%" OR LOWER(tradeNames_string) LIKE "%nateglinide%" OR LOWER(drugSynonyms_string) LIKE "%nateglinide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5811', 'drugName': 'Nateglinide', 'tradeNames_string': 'Nateglinide, Starlix, Starsis', 'drugSynonyms_string': 'A-4166, AY-4166, AY4166, D-nateglinide, DJN 608, DJN-608, NSC-758695, Nateglinide, SDZ DJN 608, SDZ-DJN-608, Senaglinide', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.175 | Q17 | What gene does the drug Thioridazine target? | The drug Thioridazine targets 5 genes: DRD4, HTR2A, DRD2, HTR2C and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thioridazine%" OR LOWER(tradeNames_string) LIKE "%thioridazine%" OR LOWER(drugSynonyms_string) LIKE "%thioridazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6304', 'drugName': 'Thioridazine Hydrochloride', 'tradeNames_string': 'Mellaril, Thioridazine hydrochloride, Thioridazine hydrochloride intensol', 'drugSynonyms_string': 'NSC-186060, Thioridazine hcl, Thioridazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_6306', 'drugName': 'Thioridazine Hydrochloride', 'tradeNames_string': 'Mellaril, Thioridazine hydrochloride, Thioridazine hydrochloride intensol', 'drugSynonyms_string': 'NSC-186060, Thioridazine hcl, Thioridazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3351', 'drugName': 'Thioridazine', 'tradeNames_string': 'Mellaril, Mellaril-s, Melleril, Rideril', 'drugSynonyms_string': 'Dl-thioridazine, Mellaril, Mellerette, Novoridazine, Sonapax, TP-21, Thioridazine, Thioridazine prolongatum, Thioril', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4488', 'drugName': 'Mesoridazine', 'tradeNames_string': 'Lidanar', 'drugSynonyms_string': 'Mesoridazine, NC-123, NSC-186066, Serentil, TPS-23, Thioridazine-2-sulfoxide', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4487', 'drugName': 'Mesoridazine', 'tradeNames_string': 'Lidanar', 'drugSynonyms_string': 'Mesoridazine, NC-123, NSC-186066, Serentil, TPS-23, Thioridazine-2-sulfoxide', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6305', 'drugName': 'Thioridazine Hydrochloride', 'tradeNames_string': 'Mellaril, Thioridazine hydrochloride, Thioridazine hydrochloride intensol', 'drugSynonyms_string': 'NSC-186060, Thioridazine hcl, Thioridazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3352', 'drugName': 'Thioridazine', 'tradeNames_string': 'Mellaril, Mellaril-s, Melleril, Rideril', 'drugSynonyms_string': 'Dl-thioridazine, Mellaril, Mellerette, Novoridazine, Sonapax, TP-21, Thioridazine, Thioridazine prolongatum, Thioril', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3350', 'drugName': 'Thioridazine', 'tradeNames_string': 'Mellaril, Mellaril-s, Melleril, Rideril', 'drugSynonyms_string': 'Dl-thioridazine, Mellaril, Mellerette, Novoridazine, Sonapax, TP-21, Thioridazine, Thioridazine prolongatum, Thioril', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1159 | Q17 | What gene does the drug Tisagenlecleucel target? | The drug Tisagenlecleucel targets the gene CD19. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tisagenlecleucel%" OR LOWER(tradeNames_string) LIKE "%tisagenlecleucel%" OR LOWER(drugSynonyms_string) LIKE "%tisagenlecleucel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5643', 'drugName': 'Tisagenlecleucel', 'tradeNames_string': '', 'drugSynonyms_string': 'CART-19, CART19, CTL-019, CTL019, Car.cd19-redirected t cells, Kymriah, Tisagenlecleucel, Tisagenlecleucel-t', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Multiple Myeloma (EFO_0001378), Follicular Lymphoma (MONDO_0018906), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Leukemia (EFO_0000565), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Lymphoblastic Lymphoma (MONDO_0000873), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.39 | Q17 | What gene does the drug Remoxipride Hydrochloride target? | The drug Remoxipride Hydrochloride targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remoxipride hydrochloride%" OR LOWER(tradeNames_string) LIKE "%remoxipride hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%remoxipride hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3071', 'drugName': 'Remoxipride Hydrochloride', 'tradeNames_string': 'Roxiam, Roxiam ir', 'drugSynonyms_string': '(-)-FLA-731, A 33547.HCL.H20, FLA 731(-), FLA-731, Remoxipride hcl, Remoxipride hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.720 | Q17 | What gene does the drug Afatinib Dimaleate target? | The drug Afatinib Dimaleate targets 3 genes: ERBB2, ERBB4 and EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%afatinib dimaleate%" OR LOWER(tradeNames_string) LIKE "%afatinib dimaleate%" OR LOWER(drugSynonyms_string) LIKE "%afatinib dimaleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2558', 'drugName': 'Afatinib Dimaleate', 'tradeNames_string': 'Gilotrif', 'drugSynonyms_string': 'Afatinib dimaleate, Afatinib maleate, BIBW-2992 MA2, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW2992-MA2', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2559', 'drugName': 'Afatinib Dimaleate', 'tradeNames_string': 'Gilotrif', 'drugSynonyms_string': 'Afatinib dimaleate, Afatinib maleate, BIBW-2992 MA2, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW2992-MA2', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2560', 'drugName': 'Afatinib Dimaleate', 'tradeNames_string': 'Gilotrif', 'drugSynonyms_string': 'Afatinib dimaleate, Afatinib maleate, BIBW-2992 MA2, BIBW-2992-MA2, BIBW-2992MA2, BIBW2992 MA2, BIBW2992-MA2', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ERBB4 (ENSG00000178568), EGFR (ENSG00000146648), ERBB2 (ENSG00000141736)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.93 | Q17 | What gene does the drug Brompheniramine target? | The drug Brompheniramine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brompheniramine%" OR LOWER(tradeNames_string) LIKE "%brompheniramine%" OR LOWER(drugSynonyms_string) LIKE "%brompheniramine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6367', 'drugName': 'Brompheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'BPN, Bromfed, Bromfenex, Brompheniramine, Brotane, Dimetane, Dimetapp, Lodrane', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Cough (HP_0012735), Common Cold (EFO_0007214)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1014', 'drugName': 'Brompheniramine Maleate', 'tradeNames_string': 'Brompheniramine maleate, Dimegan, Dimetane, Dimetane-ten, Dimotane, Dimotane l.a.', 'drugSynonyms_string': '(+)-Brompheniramine Maleate, Brompheniramine fumarate, Brompheniramine maleate, NSC-758652, Parabromdylamine maleate', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Cough (HP_0012735), Common Cold (EFO_0007214)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_431', 'drugName': 'Dexbrompheniramine Maleate', 'tradeNames_string': 'Disomer', 'drugSynonyms_string': 'Brompheniramine d-form maleate, Dexbrompheniramine fumarate, Dexbrompheniramine maleate', 'linkedDiseasesDrug_string': 'Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4355', 'drugName': 'Dexbrompheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Brompheniramine d-form, Brompheniramine, (s)-, Dexbrompheniramine', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Seasonal Allergic Rhinitis (EFO_0003956)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1937 | Q17 | What gene does the drug Aducanumab target? | The drug Aducanumab targets the gene APP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aducanumab%" OR LOWER(tradeNames_string) LIKE "%aducanumab%" OR LOWER(drugSynonyms_string) LIKE "%aducanumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4177', 'drugName': 'Aducanumab', 'tradeNames_string': 'Aduhelm', 'drugSynonyms_string': 'Aducanumab, Aducanumab avwa, Aducanumab-avwa, BIIB-037, BIIB037', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Dementia (HP_0000726)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1215 | Q17 | What gene does the drug Vasopressin target? | The drug Vasopressin targets 3 genes: AVPR2, AVPR1A and AVPR1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vasopressin%" OR LOWER(tradeNames_string) LIKE "%vasopressin%" OR LOWER(drugSynonyms_string) LIKE "%vasopressin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5786', 'drugName': 'Vasopressin Tannate', 'tradeNames_string': 'Pitressin tannate', 'drugSynonyms_string': 'Vasopressin tannate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1B (ENSG00000198049), AVPR1A (ENSG00000166148)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3226', 'drugName': 'Vasopressin', 'tradeNames_string': 'Beta-Hypophamine, Leiormone, Pitressin, Vasophysin, Vasostrict', 'drugSynonyms_string': 'Arginine Vasopressin, Arginine vasopressin, Argipressin or lypressin, Vasopressin, Vasopressin injection, Vasopressin, unspecified', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cardiac Arrest (EFO_0009492), Diabetes Insipidus (MONDO_0004782), Heart Disease (EFO_0003777), Pulmonary Hypertension (MONDO_0005149), Acute Lung Injury (EFO_0004610), Leiomyoma (MONDO_0001572), Hypotension (EFO_0005251), Septic Shock (EFO_0006834), Sepsis (HP_0100806), Benign Muscle Neoplasm (MONDO_0003061), Pain (EFO_0003843), Shock (HP_0031273), Sudden Cardiac Arrest (EFO_0004278), Major Depressive Disorder (MONDO_0002009), Pleural Effusion (EFO_0009637), Autism Spectrum Disorder (EFO_0003756), Congenital Heart Disease (EFO_0005207)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2491', 'drugName': 'Lypressin', 'tradeNames_string': 'Diapid', 'drugSynonyms_string': '8-l-lysinevasopressin, L-8, Lypressin, Lysine vasopressin, Vasopressin pig, Vasopressin, 8-l-lysine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5787', 'drugName': 'Vasopressin Tannate', 'tradeNames_string': 'Pitressin tannate', 'drugSynonyms_string': 'Vasopressin tannate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1B (ENSG00000198049), AVPR1A (ENSG00000166148)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5785', 'drugName': 'Vasopressin Tannate', 'tradeNames_string': 'Pitressin tannate', 'drugSynonyms_string': 'Vasopressin tannate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1B (ENSG00000198049), AVPR1A (ENSG00000166148)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.882 | Q17 | What gene does the drug Acitretin target? | The drug Acitretin targets 6 genes: RARG, RARA, RARB, RXRB, RXRG and RXRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acitretin%" OR LOWER(tradeNames_string) LIKE "%acitretin%" OR LOWER(drugSynonyms_string) LIKE "%acitretin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5080', 'drugName': 'Acitretin', 'tradeNames_string': 'Acitretin, Neotigason, Soriatane', 'drugSynonyms_string': 'Acitretin, Etretin, RO 10-1670, RO 10-1670/000, RO-101670000', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Alzheimer Disease (MONDO_0004975), Hiv Infection (EFO_0000764), Melanoma (EFO_0000756), Psoriasis Vulgaris (EFO_1001494), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RXRB (ENSG00000204231), RARG (ENSG00000172819), RXRG (ENSG00000143171), RARB (ENSG00000077092), RARA (ENSG00000131759), RXRA (ENSG00000186350)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_343', 'drugName': 'Etretinate', 'tradeNames_string': 'Tegison, Tigason', 'drugSynonyms_string': 'Acitretin related compound b, Ethyl etrinoate, Etretinate, NSC-297936, RO 10-9359, RO-10-9359, RO-109359', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RXRB (ENSG00000204231), RARG (ENSG00000172819), RXRG (ENSG00000143171), RARB (ENSG00000077092), RARA (ENSG00000131759), RXRA (ENSG00000186350)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1353 | Q17 | What gene does the drug Droperidol target? | The drug Droperidol targets 4 genes: DRD3, HTR2A, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%droperidol%" OR LOWER(tradeNames_string) LIKE "%droperidol%" OR LOWER(drugSynonyms_string) LIKE "%droperidol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1228', 'drugName': 'Droperidol', 'tradeNames_string': 'Dridol, Droleptan, Droperidol, Inapsine', 'drugSynonyms_string': 'Droperidol, MCN-JR-4749, NSC-169874, R-4749', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Nausea And Vomiting (HP_0002017), Pain (EFO_0003843), Post Operative Nausea And Vomiting (EFO_0004888)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1229', 'drugName': 'Droperidol', 'tradeNames_string': 'Dridol, Droleptan, Droperidol, Inapsine', 'drugSynonyms_string': 'Droperidol, MCN-JR-4749, NSC-169874, R-4749', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Nausea And Vomiting (HP_0002017), Pain (EFO_0003843), Post Operative Nausea And Vomiting (EFO_0004888)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1891 | Q17 | What gene does the drug Xl-999 target? | The drug Xl-999 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 11 genes: FGFR2, FGFR3, FLT4, FLT3, KIT, FGFR4, FLT1, KDR, FGFR1, PDGFRB and PDGFRA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xl-999%" OR LOWER(tradeNames_string) LIKE "%xl-999%" OR LOWER(drugSynonyms_string) LIKE "%xl-999%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3964', 'drugName': 'Xl-999', 'tradeNames_string': '', 'drugSynonyms_string': 'XL-999, Xl 999, Xl-999', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Acute Myeloid Leukemia (EFO_0000222), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_3961', 'drugName': 'Xl-999', 'tradeNames_string': '', 'drugSynonyms_string': 'XL-999, Xl 999, Xl-999', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Acute Myeloid Leukemia (EFO_0000222), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_3962', 'drugName': 'Xl-999', 'tradeNames_string': '', 'drugSynonyms_string': 'XL-999, Xl 999, Xl-999', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Acute Myeloid Leukemia (EFO_0000222), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_3965', 'drugName': 'Xl-999', 'tradeNames_string': '', 'drugSynonyms_string': 'XL-999, Xl 999, Xl-999', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Acute Myeloid Leukemia (EFO_0000222), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 11}, {'UUID': 'DrugGeneTargets_v2_3963', 'drugName': 'Xl-999', 'tradeNames_string': '', 'drugSynonyms_string': 'XL-999, Xl 999, Xl-999', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Small Cell Lung Carcinoma (EFO_0003060), Renal Cell Carcinoma (EFO_0000681), Acute Myeloid Leukemia (EFO_0000222), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FLT3 (ENSG00000122025), KIT (ENSG00000157404)', 'numberLinkedTargets': 11}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1102 | Q17 | What gene does the drug Whi-P131 target? | The drug Whi-P131 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene JAK3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%whi-p131%" OR LOWER(tradeNames_string) LIKE "%whi-p131%" OR LOWER(drugSynonyms_string) LIKE "%whi-p131%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2179', 'drugName': 'Whi-P131', 'tradeNames_string': '', 'drugSynonyms_string': 'JANEX-1, Janex 1, WHI-P131, Whi-p131', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1165 | Q17 | What gene does the drug Ags-16C3F target? | The drug Ags-16C3F is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 16 genes: TUBB, ENPP3, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ags-16c3f%" OR LOWER(tradeNames_string) LIKE "%ags-16c3f%" OR LOWER(drugSynonyms_string) LIKE "%ags-16c3f%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4455', 'drugName': 'Ags-16C3F', 'tradeNames_string': '', 'drugSynonyms_string': 'ADC AGS-16C3F, AGS-16C3F, Ags-16c3f, Ags-16c3f (anti-enpp3 antibody)', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Clear Cell Renal Carcinoma (EFO_0000349)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_4456', 'drugName': 'Ags-16C3F', 'tradeNames_string': '', 'drugSynonyms_string': 'ADC AGS-16C3F, AGS-16C3F, Ags-16c3f, Ags-16c3f (anti-enpp3 antibody)', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Clear Cell Renal Carcinoma (EFO_0000349)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ENPP3 (ENSG00000154269), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1365 | Q17 | What gene does the drug Dobutamine Hydrochloride target? | The drug Dobutamine Hydrochloride targets 2 genes: ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dobutamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dobutamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dobutamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2852', 'drugName': 'Dobutamine Hydrochloride', 'tradeNames_string': 'Dobutamine hydrochloride, Dobutrex, Posiject', 'drugSynonyms_string': '46236, Dl-dobutamine hydrochloride, Dobutamine hcl, Dobutamine hydrochloride, NSC-299583', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2853', 'drugName': 'Dobutamine Hydrochloride', 'tradeNames_string': 'Dobutamine hydrochloride, Dobutrex, Posiject', 'drugSynonyms_string': '46236, Dl-dobutamine hydrochloride, Dobutamine hcl, Dobutamine hydrochloride, NSC-299583', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1959 | Q17 | What gene does the drug Irinotecan target? | The drug Irinotecan targets the gene TOP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%irinotecan%" OR LOWER(tradeNames_string) LIKE "%irinotecan%" OR LOWER(drugSynonyms_string) LIKE "%irinotecan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5193', 'drugName': 'Irinotecan Hydrochloride', 'tradeNames_string': 'Campto, Camptosar, Irinotecan hydrochloride, Onivyde', 'drugSynonyms_string': 'CPT-11, DQ-2805, Irinotecan hydrochloride, Irinotecan hydrochloride anhydrous, Irinotecan hydrochloride hydrate, Irinotecan hydrochloride trihydrate, Irinotecan monohydrochloride trihydrate, NSC-759878, U-101,440E, U-101440E', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Verrucous Carcinoma (EFO_0007535), Oligodendroglioma (EFO_0000632), Lung Carcinoma (EFO_0001071), Malignant Colon Neoplasm (MONDO_0021063), Pineoblastoma (EFO_1000475), Malignant Glioma (MONDO_0100342), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Lymphoma, Aids-Related (EFO_1001365), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Basal Cell Carcinoma (EFO_0004193), Olfactory Neuroblastoma (EFO_1000407), Diffuse Large B-Cell Lymphoma (EFO_0000403), Inverted Papilloma (MONDO_0002537), Gastric Carcinoma (EFO_0000178), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Lethal Midline Granuloma (EFO_1001013), Appendix Carcinoma (MONDO_0003196), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Neuroblastoma (EFO_0000621), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Diarrhea (HP_0002014), Breast Cancer (MONDO_0007254), Embryonal Rhabdomyosarcoma (EFO_0000437), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Biliary Tract Cancer (MONDO_0003060), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Gallbladder Cancer (MONDO_0005411), Ganglioneuroblastoma (EFO_0000502), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Grade Iii Meningioma (MONDO_0020634), Medulloblastoma (EFO_0002939), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Colorectal Neoplasm (EFO_0004142), Cerebral Astrocytoma (MONDO_0021633), Urethra Cancer (MONDO_0004192), Endometrial Carcinoma (EFO_1001512), Esophageal Cancer (MONDO_0007576), Lymphoblastic Lymphoma (MONDO_0000873), Alveolar Rhabdomyosarcoma (EFO_0000248), Renal Cell Carcinoma (EFO_0000681), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Mesenchymoma (EFO_1001042), Kidney Cancer (MONDO_0002367), Choroid Plexus Neoplasm (MONDO_0016717)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4299', 'drugName': 'Irinotecan', 'tradeNames_string': '', 'drugSynonyms_string': 'Biotecan, Camptosar, Irinotecan, NSC-728073', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Verrucous Carcinoma (EFO_0007535), Oligodendroglioma (EFO_0000632), Lung Carcinoma (EFO_0001071), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Pineoblastoma (EFO_1000475), Malignant Glioma (MONDO_0100342), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lymphoma, Aids-Related (EFO_1001365), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Follicular Lymphoma (MONDO_0018906), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Malignant Bone Neoplasm (EFO_1000350), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mucinous Carcinoma (EFO_0000197), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Basal Cell Carcinoma (EFO_0004193), Olfactory Neuroblastoma (EFO_1000407), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Diffuse Large B-Cell Lymphoma (EFO_0000403), Inverted Papilloma (MONDO_0002537), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Lethal Midline Granuloma (EFO_1001013), Appendix Carcinoma (MONDO_0003196), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Neuroblastoma (EFO_0000621), Intrahepatic Cholangiocarcinoma (EFO_1001961), Hepatoblastoma (EFO_1000292), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Diarrhea (HP_0002014), Breast Cancer (MONDO_0007254), Embryonal Rhabdomyosarcoma (EFO_0000437), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Wilms Tumor (MONDO_0006058), Mycosis Fungoides (EFO_1001051), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Penile Cancer (MONDO_0001325), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Rhabdomyosarcoma (EFO_0002918), Gallbladder Cancer (MONDO_0005411), Colorectal Cancer (MONDO_0005575), Ganglioneuroblastoma (EFO_0000502), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Biliary Tract Neoplasm (EFO_0003891), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Choroid Plexus Neoplasm (MONDO_0016717), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Kidney Wilms Tumor (MONDO_0019004), Stomach Neoplasm (EFO_0003897), Grade Iii Meningioma (MONDO_0020634), Medulloblastoma (EFO_0002939), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Desmoplastic Small Round Cell Tumor (EFO_1000895), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Colorectal Neoplasm (EFO_0004142), Cervical Carcinoma (EFO_0001061), Pancreatic Endocrine Carcinoma (EFO_0007416), Cerebral Astrocytoma (MONDO_0021633), Urethra Cancer (MONDO_0004192), Endometrial Carcinoma (EFO_1001512), Rectal Neoplasm (MONDO_0002165), Lymphoblastic Lymphoma (MONDO_0000873), Alveolar Rhabdomyosarcoma (EFO_0000248), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Digestive System Neoplasm (EFO_0008549), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Mesenchymoma (EFO_1001042), Kidney Cancer (MONDO_0002367), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2149', 'drugName': 'Irinotecan Sucrosofate', 'tradeNames_string': '', 'drugSynonyms_string': 'Irinotecan sucrosofate, MM-398, PEP-02', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4848', 'drugName': 'Etirinotecan Pegol', 'tradeNames_string': '', 'drugSynonyms_string': 'Etirinotecan pegol, NKTR-102', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Cancer (MONDO_0004992), Anaplastic Oligodendroglioma (EFO_0002501), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5907', 'drugName': '7-Ethyl-10-Hydroxycamptothecin', 'tradeNames_string': '', 'drugSynonyms_string': '7-Ethyl-10-Hydroxy-Camptothecin, 7-ethyl-10-hydroxycamptothecin, Camptothecin, 7-ethyl-10-hydroxy-, IT-141, Irinotecan related compound b, It-141, NK 012, NK-012, NK012, Nk012, SN 38, SN-38', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.505 | Q17 | What gene does the drug Axatilimab target? | The drug Axatilimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CSF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%axatilimab%" OR LOWER(tradeNames_string) LIKE "%axatilimab%" OR LOWER(drugSynonyms_string) LIKE "%axatilimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2424', 'drugName': 'Axatilimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Axatilimab, SNDX-6352, Sndx-6352, UCB-6352, UCB6352', 'linkedDiseasesDrug_string': 'Metastatic Neoplasm (EFO_0009709), Cholangiocarcinoma (EFO_0005221), Triple-Negative Breast Cancer (EFO_0005537), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CSF1R (ENSG00000182578)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.342 | Q17 | What gene does the drug Enasidenib Mesylate target? | The drug Enasidenib Mesylate targets the gene IDH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enasidenib mesylate%" OR LOWER(tradeNames_string) LIKE "%enasidenib mesylate%" OR LOWER(drugSynonyms_string) LIKE "%enasidenib mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5694', 'drugName': 'Enasidenib Mesylate', 'tradeNames_string': 'Idhifa', 'drugSynonyms_string': 'AG-221 mesylate, CC-90007, Enasidenib mesilate, Enasidenib mesylate, Enasidenib methanesulfonate', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IDH2 (ENSG00000182054)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1198 | Q17 | What gene does the drug Eflornithine target? | The drug Eflornithine targets the gene ODC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eflornithine%" OR LOWER(tradeNames_string) LIKE "%eflornithine%" OR LOWER(drugSynonyms_string) LIKE "%eflornithine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1880', 'drugName': 'Eflornithine Hydrochloride', 'tradeNames_string': 'Ornidyl, Vaniqa', 'drugSynonyms_string': 'Dfmo hcl, Difluromethylornithine, Eflornithine hcl, Eflornithine hydrochloride, Eflornithine hydrochloride monohydrate, MDL 71,782 A, MDL-71782-A, MDL-71782A, NSC-270295, NSC-337250, RMI-71782-A', 'linkedDiseasesDrug_string': 'Familial Adenomatous Polyposis (Orphanet_733), Neuroblastoma (EFO_0000621)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ODC1 (ENSG00000115758)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6018', 'drugName': 'Eflornithine', 'tradeNames_string': '', 'drugSynonyms_string': 'Eflornithine, Ornidyl, Vaniqa', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Neuroblastoma (EFO_0000621), Familial Adenomatous Polyposis (Orphanet_733), Human African Trypanosomiasis (EFO_0005225), Prostate Cancer (MONDO_0008315), Leishmaniasis (EFO_0005044), Colorectal Neoplasm (EFO_0004142), Urinary Bladder Cancer (MONDO_0001187), Precancerous Condition (MONDO_0021074), Carcinoma (EFO_0000313), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Cervical Cancer (MONDO_0002974), Esophageal Cancer (MONDO_0007576), Trypanosomiasis (DOID_10113)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ODC1 (ENSG00000115758)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.29 | Q17 | What gene does the drug Allopurinol target? | The drug Allopurinol targets the gene XDH. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%allopurinol%" OR LOWER(tradeNames_string) LIKE "%allopurinol%" OR LOWER(drugSynonyms_string) LIKE "%allopurinol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5751', 'drugName': 'Allopurinol', 'tradeNames_string': 'Allopurinol, Aloral, Aluline 100, Aluline 300, Caplenal, Cosuric, Hamarin 100, Hamarin 300, Ledopur, Lopurin, Uricto, Xanthomax-100, Xanthomax-300, Zyloprim, Zyloric, Zyloric-300', 'drugSynonyms_string': 'Allopurinol, Allopurinolum, BW 56-158, BW-56-158, NSC-101655, NSC-1390, Suspendol, Takanarumin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Obesity (EFO_0001073), Essential Hypertension (MONDO_0001134), Myelodysplastic Syndrome (EFO_0000198), Ulcerative Colitis (EFO_0000729), Nephrolithiasis (EFO_0004253), Ovarian Cancer (MONDO_0008170), Inflammatory Bowel Disease (EFO_0003767), Hyperuricemia (EFO_0009104), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Hand-Foot Syndrome (EFO_1001893), Hypertension (EFO_0000537), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Small Cell Lung Carcinoma (EFO_0000702), Leishmaniasis (EFO_0005044), Peritoneum Cancer (MONDO_0002087), Sprain (EFO_0009582), Bipolar Disorder (MONDO_0004985), Tumor Lysis Syndrome (EFO_1001479), Congenital Heart Disease (EFO_0005207), Gout (EFO_0004274), Heart Disease (EFO_0003777), Chronic Kidney Disease (EFO_0003884), Fetal Hypoxia (EFO_1001793), Fallopian Tube Cancer (MONDO_0002158), Leukemia (EFO_0000565), Myeloproliferative Disorder (EFO_0004251), Osteoarthritis (MONDO_0005178), Heart Failure (EFO_0003144), Tuberculosis (MONDO_0018076), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'XDH (ENSG00000158125)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3457', 'drugName': 'Allopurinol Sodium', 'tradeNames_string': 'Allopurinol sodium, Aloprim', 'drugSynonyms_string': 'Allopurinol sodium, Allopurinol sodium salt, NSC-108836', 'linkedDiseasesDrug_string': 'Fetal Hypoxia (EFO_1001793)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'XDH (ENSG00000158125)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1227 | Q17 | What gene does the drug Binimetinib target? | The drug Binimetinib targets 2 genes: MAP2K2 and MAP2K1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%binimetinib%" OR LOWER(tradeNames_string) LIKE "%binimetinib%" OR LOWER(drugSynonyms_string) LIKE "%binimetinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3339', 'drugName': 'Binimetinib', 'tradeNames_string': 'Mektovi', 'drugSynonyms_string': 'ARRY 438162, ARRY-162, ARRY-438162, Binimetinib, MEK-162, MEK162, Mek-162, NVP-MEK162', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Cardiac Hypertrophy (EFO_0002503), Pancreatic Carcinoma (EFO_0002618), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Rectum Cancer (EFO_1000657), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAP2K2 (ENSG00000126934), MAP2K1 (ENSG00000169032)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3340', 'drugName': 'Binimetinib', 'tradeNames_string': 'Mektovi', 'drugSynonyms_string': 'ARRY 438162, ARRY-162, ARRY-438162, Binimetinib, MEK-162, MEK162, Mek-162, NVP-MEK162', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Cardiac Hypertrophy (EFO_0002503), Pancreatic Carcinoma (EFO_0002618), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Rheumatoid Arthritis (EFO_0000685), Carcinoma (EFO_0000313), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Rectum Cancer (EFO_1000657), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAP2K2 (ENSG00000126934), MAP2K1 (ENSG00000169032)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1434 | Q17 | What gene does the drug Pimurutamab target? | The drug Pimurutamab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pimurutamab%" OR LOWER(tradeNames_string) LIKE "%pimurutamab%" OR LOWER(drugSynonyms_string) LIKE "%pimurutamab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2484', 'drugName': 'Pimurutamab', 'tradeNames_string': '', 'drugSynonyms_string': 'HLX-07, HLX07, Hlx07, Pimurutamab', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1954 | Q17 | What gene does the drug Cal target? | The drug Cal is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PTHLH. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cal%" OR LOWER(tradeNames_string) LIKE "%cal%" OR LOWER(drugSynonyms_string) LIKE "%cal%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2661', 'drugName': 'Abciximab', 'tradeNames_string': 'Reopro', 'drugSynonyms_string': 'Abciximab, Abciximab (genetical recombination), C7E3', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Angina Pectoris (EFO_0003913), Internal Carotid Artery Stenosis (EFO_0002615), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Acute Myocardial Infarction (EFO_0008583), Brain Ischemia (MONDO_0005299), St Elevation Myocardial Infarction (EFO_0008585), Intermediate Coronary Syndrome (EFO_1000985)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961), ITGAV (ENSG00000138448)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1088', 'drugName': 'Lenograstim', 'tradeNames_string': 'Granocyte-13, Granocyte-34', 'drugSynonyms_string': 'G-csf (cho cell derived), Glycosylated recombinant g-csf, Granocyte, Granulocyte colony-stimulating factor lenograstim, Lenograstim, Lenograstim (genetical recombination), Lenograstim rdna, Neutrogin, RG-CSF', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Acute Myocardial Infarction (EFO_0008583), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CSF3R (ENSG00000119535)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4748', 'drugName': 'Calcitonin Salmon Recombinant', 'tradeNames_string': 'Fortical', 'drugSynonyms_string': 'Calcitonin (salmon synthetic), Calcitonin salmon recombinant', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Parathyroid Disease (EFO_0005754), Postmenopausal Osteoporosis (EFO_0003854)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2279', 'drugName': 'Ecallantide', 'tradeNames_string': '', 'drugSynonyms_string': 'DX-88, Ecallantide, Escallantide', 'linkedDiseasesDrug_string': 'Angioedema (EFO_0005532), Hereditary Angioedema (MONDO_0019623)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KLKB1 (ENSG00000164344)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4195', 'drugName': 'Rituximab', 'tradeNames_string': 'Mabthera, Mabthera rituxan, Rituxan', 'drugSynonyms_string': 'ABP-798, ABP798, BI695500, Bi 695500, Bi-695500, Blitzima, CT-P10, Gp2013, HS-006, HS-006 (RITUXIMAB BIOSIMILAR), HS006, IDEC-102, IDEC-C2B8, Mk-8808, Pf-05280586, R-105 IDEC-102, RG-105, RHCACD20MA, Riabni, Ritemvia, Rituximab, Rituximab (genetical recombination), Rituximab abbs, Rituximab arrx, Rituximab biosimilar - celltrion, Rituximab biosimilar -merck, Rituximab pvvr, Rituximab-abbs, Rituximab-arrx, Rituximab-boehringer ingelheim, Rituximab-ct-p10, Rituximab-pfizer, Rituximab-pvvr, Ruxience, SAIT-101, SAIT101, Truxima, Tuxella, Usp mab 001, monoclonal igg1, Zuberitamab', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Encephalomyelitis (EFO_0001423), Behcet'S Syndrome (EFO_0003780), Lymphoplasmacytic Lymphoma (MONDO_0000432), Vasculitis (EFO_0006803), Lymphoid Neoplasm (EFO_0001642), Graves Ophthalmopathy (EFO_1001466), Pemphigus Vulgaris (EFO_0004719), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Myelopathy (HP_0002196), Sickle Cell Anemia (MONDO_0011382), Chronic Progressive Multiple Sclerosis (EFO_0003840), Chronic Fatigue Syndrome (EFO_0004540), Castleman Disease (MONDO_0015564), Malt Lymphoma (EFO_0000191), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), T-Lymphoblastic Lymphoma (MONDO_0044917), Chronic Inflammatory Demyelinating Polyneuropathy (EFO_0009538), Follicular Lymphoma (MONDO_0018906), Diabetic Neuropathy (EFO_1000783), Leukemia (EFO_0000565), Churg-Strauss Syndrome (EFO_0007208), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Japanese Encephalitis (EFO_0007332), Kidney Disease (EFO_0003086), Schizophrenia (MONDO_0005090), Lupus Nephritis (EFO_0005761), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Opsoclonus-Myoclonus Syndrome (EFO_1001383), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Sjogren Syndrome (EFO_0000699), Multiple Sclerosis (MONDO_0005301), Juvenile Dermatomyositis (EFO_0000557), Neuromyelitis Optica (EFO_0004256), Anaplastic Large Cell Lymphoma (EFO_0003032), Myelodysplastic Syndrome (EFO_0000198), Autoimmune Disease (EFO_0005140), Urticaria (EFO_0005531), Mantle Cell Lymphoma (EFO_1001469), Gangliosidosis (MONDO_0017719), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Hemophilia A (MONDO_0010602), Interstitial Lung Disease (EFO_0004244), Diffuse Large B-Cell Lymphoma (EFO_0000403), Antiphospholipid Syndrome (EFO_0002689), Secondary Progressive Multiple Sclerosis (EFO_0008522), Anemia, Hemolytic, Autoimmune (EFO_1001264), Hodgkins Lymphoma (EFO_0000183), Marginal Zone B-Cell Lymphoma (EFO_1000630), Pulmonary Alveolar Proteinosis (MONDO_0001437), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Frontotemporal Dementia (MONDO_0017276), Prolymphocytic Leukemia (MONDO_0001023), Colonic Neoplasm (EFO_0004288), Polyneuropathy (EFO_0009562), Neuroblastoma (EFO_0000621), Langerhans Cell Histiocytosis (EFO_1000318), Peripheral Neuropathy (EFO_0003100), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Glomerulonephritis (MONDO_0002462), Aids (EFO_0000765), Mast-Cell Leukemia (EFO_0007359), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Primary Biliary Cirrhosis (EFO_1001486), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Neoplasm (EFO_0003869), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Mycosis Fungoides (EFO_1001051), Microscopic Polyangiitis (EFO_1000784), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Proteinuria (HP_0000093), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Sarcoidosis (MONDO_0019338), Pemphigus (EFO_1000749), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Primary Membranoproliferative Glomerulonephritis (MONDO_0018904), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Human T-Lymphotropic Virus 1 Infectious Disease (EFO_0007316), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lymphoproliferative Syndrome (MONDO_0016537), Macular Degeneration (EFO_0009606), Graft Versus Host Disease (MONDO_0013730), Ocular Cicatricial Pemphigoid (EFO_0008610), Kidney Failure (EFO_1002048), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Myasthenia Gravis (EFO_0004991), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Ulcerative Colitis (EFO_0000729), B-Cell Neoplasm (MONDO_0004095), Chronic Myelogenous Leukemia (EFO_0000339), Pneumococcal Infection (EFO_0000772), Nephrotic Syndrome (EFO_0004255), Scleritis (MONDO_0001718), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Stiff-Person Syndrome (EFO_0007498), Bullous Pemphigoid (EFO_0007187), Parkinson Disease (MONDO_0005180), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Myopathy (EFO_0004145), Membranous Glomerulonephritis (EFO_0004254), Hemolytic-Uremic Syndrome (MONDO_0001549), Lymphoblastic Lymphoma (MONDO_0000873), Lung Neoplasm (MONDO_0021117), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Lymphoid Leukemia (EFO_0004289), Squamous Cell Carcinoma (EFO_0000707), Pancreatic Neoplasm (EFO_0003860)", 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4251', 'drugName': 'Atorvastatin Calcium', 'tradeNames_string': 'Atorvastatin calcium, Lipitor', 'drugSynonyms_string': 'Atorvastatin calcium, Atorvastatin calcium (anhydrous), Atorvastatin calcium anhydrous, Atorvastatin calcium hydrate, Atorvastatin calcium salt anhydrous, Atorvastatin calcium salt trihydrate, Atorvastatin calcium trihydrate, CI-981, NSC-758617', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Intracranial Subdural Hematoma (EFO_1001801), Cerebral Infarction (MONDO_0002679), Iga Glomerulonephritis (EFO_0004194), Avascular Necrosis (MONDO_0018373), St Elevation Myocardial Infarction (EFO_0008585), Acute Chest Syndrome (EFO_0007129), Scleroderma (EFO_1001993), Polycystic Ovary Syndrome (EFO_0000660), Graves Ophthalmopathy (EFO_1001466), Ischemic Stroke (HP_0002140), Hypertension (EFO_0000537), Acute Myocardial Infarction (EFO_0008583), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Inflammatory Breast Carcinoma (EFO_1000984), Sleep Disorder (EFO_0008568), Cardiac Edema (EFO_1001771), Brain Aneurysm (EFO_0003870), Sickle Cell Anemia (MONDO_0011382), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Venous Thromboembolism (EFO_0004286), Hyperlipoproteinemia Type 3 (MONDO_0018473), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Diabetes Insipidus (MONDO_0004782), Atherosclerosis (EFO_0003914), Necrosis (EFO_0009426), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Combined Hyperlipidemia (Orphanet_79211), Myelodysplastic Syndrome (EFO_0000198), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Non-Alcoholic Steatohepatitis (EFO_1001249), Acute Myeloid Leukemia (EFO_0000222), Abnormal Circulating Lipid Concentration (HP_0003119), Vitiligo (EFO_0004208), Asthma (MONDO_0004979), Stroke (EFO_0000712), Influenza (EFO_0007328), Obstructive Sleep Apnea (EFO_0003918), Carotid Atherosclerosis (EFO_0009783), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Stricture (EFO_0006818), Metabolic Syndrome (EFO_0000195), Vascular Disease (EFO_0004264), Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Acute Kidney Failure (MONDO_0002492), Coronary Artery Disease (EFO_0001645), Alzheimer Disease (MONDO_0004975), Non-St Elevation Myocardial Infarction (EFO_0008586), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Focal Segmental Glomerulosclerosis (EFO_0004236), Atrial Fibrillation (EFO_0000275), Breast Neoplasm (EFO_0003869), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Osteoarthritis, Knee (EFO_0004616), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Coronary Syndrome (EFO_0005672), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Periodontitis (EFO_0000649), Epilepsy (EFO_0000474), Renal Insufficiency (HP_0000083), Lynch Syndrome (MONDO_0005835), Familial Hypercholesterolemia (EFO_0004911), Myocardial Infarction (EFO_0000612), Age-Related Macular Degeneration (EFO_0001365), Hyperlipoproteinemia Type 4 (Orphanet_413), Sarcoidosis (MONDO_0019338), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Tuberculosis (MONDO_0018076), Hypertrophic Cardiomyopathy (EFO_0000538), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Hypertriglyceridemia (EFO_0004211), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Endometrial Cancer (MONDO_0011962), Prostate Adenocarcinoma (EFO_0000673), Hepatitis C Virus Infection (EFO_0003047), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Coronary Atherosclerosis (MONDO_0021661), Chagas Disease (MONDO_0001444), Disorder Of Lipid Metabolism (Orphanet_309005), Sepsis (HP_0100806), Renal Cell Carcinoma (EFO_0000681), Rheumatoid Arthritis (EFO_0000685), Mucocutaneous Lymph Node Syndrome (EFO_0004246), Cognitive Impairment (HP_0100543), Nasopharyngeal Neoplasm (EFO_0004252), Bicuspid Aortic Valve (HP_0001647), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1142', 'drugName': 'Alemtuzumab', 'tradeNames_string': 'Campath, Campath Mabcampath, Lemtrada, Campath mabcampath, Lemtrada, Mabcampath', 'drugSynonyms_string': 'Alemtuzumab, Alemtuzumab (genetical recombination), Allo 647, CAMPATH-1H, GZ-402673, GZ402673, LDP-03', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Hemoglobinopathy (MONDO_0044348), Non-Hodgkins Lymphoma (EFO_0005952), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Chronic Lymphocytic Leukemia (EFO_0000095), Cancer (MONDO_0004992), Multiple Sclerosis (MONDO_0005301), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Fanconi Anemia (MONDO_0019391), Graft Versus Host Disease (MONDO_0013730), Liver Disease (EFO_0001421), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Neuroepithelial Neoplasm (MONDO_0021193), Hemophagocytic Syndrome (MONDO_0015540), Kidney Failure (EFO_1002048), Vasculitis (EFO_0006803), Myelodysplastic Syndrome (EFO_0000198), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Acute Erythroblastic Leukemia (EFO_1001257), Crohn'S Disease (EFO_0000384), Beta-Thalassemia (Orphanet_848), Thalassemia (EFO_1001996), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloid Leukemia (EFO_0000222), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Aplastic Anemia (HP_0001915), Mycosis Fungoides (EFO_1001051), Chronic Granulomatous Disease (MONDO_0018305), Inclusion Body Myositis (EFO_0007323), Diffuse Large B-Cell Lymphoma (EFO_0000403), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Anemia (Phenotype) (EFO_0004272), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Severe Aplastic Anemia (EFO_0006927), Sickle Cell Anemia (MONDO_0011382), Anemia, Hemolytic, Autoimmune (EFO_1001264), Severe Combined Immunodeficiency (MONDO_0015974), Peritoneum Cancer (MONDO_0002087), Waldenstrom Macroglobulinemia (EFO_0009441), Rheumatoid Arthritis (EFO_0000685), Hodgkins Lymphoma (EFO_0000183), Chronic Myeloproliferative Disorder (EFO_0002428), Lymphoid Leukemia (EFO_0004289), Prolymphocytic Leukemia (MONDO_0001023), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), T-Cell Prolymphocytic Leukemia (EFO_1000560), Kidney Cancer (MONDO_0002367), Kidney Disease (EFO_0003086), Histiocytosis (HP_0100727), Epidermolysis Bullosa (EFO_1000690), Type 1 Diabetes Mellitus (MONDO_0005147), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Osteopetrosis (MONDO_0017198)", 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD52 (ENSG00000169442)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_134', 'drugName': 'Calcitonin', 'tradeNames_string': 'Calcimar, Calcitare, Calsynar, Cibacalcin, Forcaltonin, Fortical, Miacalcic', 'drugSynonyms_string': 'Calcitonin, Calcitonin, unspecified, Throcalcitonin', 'linkedDiseasesDrug_string': 'Calcinosis (MONDO_0002123), Giant Cell Reparative Granuloma (EFO_1000950), Postmenopausal Osteoporosis (EFO_0003854)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6052', 'drugName': 'Loperamide Hydrochloride', 'tradeNames_string': 'Arret, Diah-limit, Diaquitte, Diareze, Diarrhoea relief, Diasorb, Diocalm, Diocaps, Dioraleze, Entrocalm, Gppe pack, Imodium, Imodium Advanced, Imodium a-d, Imodium a-d ez chews, Imodium classic, Imodium ibs relief, Imodium instant melts, Imodium instants, Imodium liquicaps, Lodiar, Loperagen, Loperamide hydrochloride, Norimode, Normaloe', 'drugSynonyms_string': 'Loperamide hcl, Loperamide hydrochloride, Loperamidi hydrochloridum, NSC-696356, R 18,553, R-18553', 'linkedDiseasesDrug_string': 'Diarrhea (HP_0002014)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5401', 'drugName': 'Calcitonin Salmon', 'tradeNames_string': 'Calcimar, Calcitonin-salmon, Miacalcin', 'drugSynonyms_string': 'Calcitonin salmon', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Postmenopausal Osteoporosis (EFO_0003854), Menopause (EFO_0003922), Osteitis Deformans (EFO_0004261), Hypercalcemia (HP_0003072)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3357', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugSynonyms_string': 'Amitriptyline hcl, Amitriptyline hydrochloride, Amitriptylini hydrochloridum, Etravil, NIH 10794, NSC-104210, Novoprotect, Syneudon', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Pruritus (HP_0000989), Peripheral Nervous System Disease (EFO_0009387)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_221', 'drugName': 'Chlorpheniramine Maleate', 'tradeNames_string': 'Allercalm allergy relief, Allerief, Alunex, Antagonate, Calimal, Chlor-trimeton, Chlorphenamine, Chlorpheniramine maleate, Efidac 24 chlorpheniramine maleate, Hayleve, Kloromin, Phenetron, Piriject, Piriton, Piriton allergy, Pyridamal 100, Rhino-syrup allergy, Rimarin, Teldrin', 'drugSynonyms_string': '(+)-Chlorpheniramine Maleate, Chlorphenamine hydrogen maleate, Chlorphenamine maleate, Chlorphenamini hydrogenomaleas, Chlorpheniramine Maleate, Chlorpheniramine maleate, Chlorprophenpyridamine maleate, Efidac, Histaspan, NSC-756684, Neorestamin, Pyridamal, Synistamin', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1703', 'drugName': 'Mepolizumab', 'tradeNames_string': 'Bosatria, Nucala', 'drugSynonyms_string': 'Mepolizumab, SB-240563', 'linkedDiseasesDrug_string': 'Eosinophilia (HP_0001880), Asthma (MONDO_0004979), Churg-Strauss Syndrome (EFO_0007208), Chronic Rhinosinusitis (EFO_1000024), Atopic Eczema (EFO_0000274), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Eosinophilic Esophagitis (EFO_0004232), Hypereosinophilic Syndrome (EFO_1001467), Vasculitis (EFO_0006803), Granulomatosis With Polyangiitis (EFO_0005297), Urticaria (EFO_0005531), Nasal Cavity Polyp (EFO_1000391)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL5 (ENSG00000113525)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1910', 'drugName': 'Nitroglycerin', 'tradeNames_string': 'Coro-nitro, Deponit 10, Deponit 5, Glytrin, Gonitro, Lenitral 7.5, Minitran, Minitran 10, Minitran 15, Minitran 5, Natirose, Nitriderm tts, Nitro iv, Nitro-bid, Nitro-dur, Nitro-mack ret, Nitrocine, Nitrocontin continus, Nitroglycerin, Nitrol, Nitrolingual, Nitrolingual pumpspray, Nitromin, Nitromist, Nitronal, Nitrostat, Percutol, Rectiv, Rectogesic, Suscard buccal, Sustac, Transderm-nitro, Transiderm-nitro 10, Transiderm-nitro 5, Tridil, Trintek 10, Trintek 15, Trintek 5', 'drugSynonyms_string': 'C01DA02, Chlormethine oxide hydrochloride, Diluted nitroglycerin, Glonoinum, Glyceryl Trinitrate, Glyceryl trinitrate, Glyceryl trinitrate solution, Imx-150, Mechlorethamine oxide hcl, Mitomen, Mustron, Nitora, Nitroglycerin, Nitroglycerin tablets, Nitromin hydrochloride, Transderm-Nitro, Trinitrin, Trinitrin tablets, Trinitrine', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Infection (EFO_0000544), Peripheral Arterial Disease (EFO_0004265), Pain (EFO_0003843), Injury (EFO_0000546), Hypotension (EFO_0005251), Muscle Cramp (EFO_0009846), Colorectal Carcinoma (EFO_1001951), Hot Flashes (HP_0031217), Scleroderma (EFO_1001993), Myocardial Ischemia (EFO_1001375), Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Tendinitis (MONDO_0004857), Stroke (EFO_0000712), Hemorrhoid (EFO_0009552), Shock (HP_0031273), Myocardial Infarction (EFO_0000612), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Rectum Cancer (EFO_1000657), Diabetic Neuropathy (EFO_1000783), Ischemia Reperfusion Injury (EFO_0002687), Lung Cancer (MONDO_0008903), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Raynaud Disease (EFO_1001145), Phlebitis (EFO_1001395)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2693', 'drugName': 'Sincalide', 'tradeNames_string': 'Kinevac', 'drugSynonyms_string': 'Cck c-terminal octapeptide, Cck-8, Cholecystokinin, Cholecystokinin c-terminal octapeptide, Pancreozymin, SQ 19844, SQ-19844, Sincalide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CCKAR (ENSG00000163394)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1951', 'drugName': 'Calcitonin Human', 'tradeNames_string': 'Cibacalcin', 'drugSynonyms_string': 'Calcitonin (human synthetic), Calcitonin human', 'linkedDiseasesDrug_string': 'Parathyroid Disease (EFO_0005754)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_680', 'drugName': 'Tremelimumab', 'tradeNames_string': 'Imjudo', 'drugSynonyms_string': 'CP-675,206, CP-675206, PF-06753388, TICILIMUMAB, Ticilimumab, Tremelimumab, Tremelimumab (genetical recombination), Tremelimumab-actl', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Peritoneal Neoplasm (EFO_1001100), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Squamous Cell Lung Carcinoma (EFO_0000708), Intrahepatic Cholangiocarcinoma (EFO_1001961), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Breast Carcinoma (EFO_0000305), Prostate Adenocarcinoma (EFO_0000673), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Seminoma (MONDO_0003001), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Colorectal Neoplasm (EFO_0004142), Lymphoma (EFO_0000574), Female Reproductive System Neoplasm (MONDO_0021148), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Oral Squamous Cell Carcinoma (EFO_0000199), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Dysgerminoma (MONDO_0003002), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Carcinoma (EFO_0000313), Biliary Tract Neoplasm (EFO_0003891), Cutaneous Melanoma (EFO_0000389), Urogenital Neoplasm (EFO_0003863), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Hiv Infection (EFO_0000764), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CTLA4 (ENSG00000163599)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2884', 'drugName': 'Nitric Oxide', 'tradeNames_string': 'Genosyl, Inomax', 'drugSynonyms_string': 'Amidogen, oxo-, Inovent, Nitric oxide, Nitric oxide trimer, Nitrogen oxide (no), Nitrosyl radical, OHM-11771', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Infection (EFO_0000544), Pulmonary Hypertension (MONDO_0005149), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), St Elevation Myocardial Infarction (EFO_0008585), Pulmonary Embolism (EFO_0003827), Hypoxemia (EFO_0009447), Colorectal Carcinoma (EFO_1001951), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Bronchiolitis (HP_0011950), Myocardial Ischemia (EFO_1001375), Respiratory Insufficiency (HP_0002093), Tinea Pedis (EFO_0007512), Congestive Heart Failure (EFO_0000373), Persistent Fetal Circulation Syndrome (EFO_1001103), Neuropathic Pain (EFO_0005762), Brain Ischemia (MONDO_0005299), Sudden Cardiac Arrest (EFO_0004278), Acute Respiratory Distress Syndrome (EFO_1000637), Diabetic Foot (EFO_1001459), Decubitus Ulcer (EFO_0007067), Acute Myocardial Infarction (EFO_0008583), Sinusitis (EFO_0007486), Cardiac Arrest (EFO_0009492), Respiratory System Disease (EFO_0000684), Sepsis (HP_0100806), Premature Birth (EFO_0003917), Anemia (Phenotype) (EFO_0004272), Viral Pneumonia (EFO_0007541), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Inflammation (MP_0001845), Brain Injury (MONDO_0043510), Opioid Dependence (EFO_0005611), Varicose Ulcer (EFO_1001923), Congenital Heart Disease (EFO_0005207), Dyspnea (HP_0002094), Skin Ulcer (HP_0200042), Newborn Respiratory Distress Syndrome (EFO_1000644), Ischemia Reperfusion Injury (EFO_0002687), Respiratory Failure (EFO_0009686), Cutaneous Leishmaniasis (EFO_0005046), Acute Kidney Injury (HP_0001919), Cystic Fibrosis (MONDO_0009061), Bronchopulmonary Dysplasia (MONDO_0019091), Pneumonia, Aspiration (EFO_1001399), Severe Acute Respiratory Syndrome (EFO_0000694), Hypoxia (EFO_0009444)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2617', 'drugName': 'Cholecalciferol', 'tradeNames_string': "Accrete d3, Aciferol d3, Adcal-d3, Aviticol, Bio-vitamin d3, Biolife vitamin d3, Cacit d3, Calceos, Calci-d, Calcichew d3, Calcichew d3 fte, Calcichew d3 once daily, Caldrink d3, Calfovit d3, Colecal d3, Colecalciferol, Colekal-d3, Colevit d3, Cubicole d3, D-max, D-tracetten, D-vit3, D3 lemon melts, D3-50, Dekristol, Desunin, Dihydrocholesterol, Dlux 400, E-d3, Evacal d3, Fultium daily d3, Fultium-d3, Hux d3, Invita d3, Iso d3, Kora liquid, Natecal d3, Nature's remedy vitamin d3, Neo-d, Nphd3, Osteocaps d3, Plenachol, Pro d3, Pro d3 folic, Pro d3 forte, Royalvit d3, Stexerol-d3, Stivit-d3, Sunvit-d3 1,000, Sunvit-d3 10,000, Sunvit-d3 2,000, Sunvit-d3 20,000, Sunvit-d3 3,000, Sunvit-d3 400, Sunvit-d3 5,000, Sunvit-d3 50,000, Sunvit-d3 800, Synervit-d3, Theical d-3, Thorens, Vigantol, Vigantoletten, Vigantoletten 500, Vit d3 streuli, Vita-d3, Vitamin D 3, Zymad", 'drugSynonyms_string': '7-dehydrocholesterol, activated, AK R215 COMPONENT COLECALCIFEROL, AK-R215 COMPONENT COLECALCIFEROL, Cholecalciferol, Colecalciferol, Colecalciferolum, Delsterol, Delta-d, Deparal, Ebivit, NSC-375571, Provitina, Ricketon, Vitamin d, Vitamin d (cholecalciferol), Vitamin d assay system suitability, Vitamin d-3, Vitamin d3, Vitamin d3 (as cholecalciferol)', 'linkedDiseasesDrug_string': "Autism (EFO_0003758), Psoriasis (EFO_0000676), Postmenopausal Osteoporosis (EFO_0003854), Infection (EFO_0000544), Skin Cancer (MONDO_0002898), Male Infertility (EFO_0004248), Pregnancy (EFO_0002950), Malignant Colon Neoplasm (MONDO_0021063), Osteoporosis (EFO_0003882), Polycystic Ovary Syndrome (EFO_0000660), Vitamin D Deficiency (EFO_0003762), Atopic Eczema (EFO_0000274), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Bone Fracture (EFO_0003931), Hypogonadism (MONDO_0002146), Optic Neuritis (EFO_0007405), Anemia (Phenotype) (EFO_0004272), Sickle Cell Anemia (MONDO_0011382), Hiv-1 Infection (EFO_0000180), Breast Ductal Carcinoma In Situ (EFO_0000432), Colorectal Adenocarcinoma (EFO_0000365), Burn (EFO_0009516), Respiratory Failure (EFO_0009686), Prediabetes Syndrome (EFO_1001121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Barrett'S Esophagus (EFO_0000280), X-Linked Adrenoleukodystrophy (Orphanet_43), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Inborn Error Of Immunity (MONDO_0003778), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Urticaria (EFO_0005531), Hyperparathyroidism (EFO_0008506), Acute Myeloid Leukemia (EFO_0000222), Allergic Conjunctivitis (EFO_0007141), Asthma (MONDO_0004979), Sarcopenia (EFO_1000653), Abnormal Glucose Tolerance (EFO_0002546), Actinic Keratosis (EFO_0002496), Influenza (EFO_0007328), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Metabolic Syndrome (EFO_0000195), Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Irritable Bowel Syndrome (EFO_0000555), Aids (EFO_0000765), Ovarian Cancer (MONDO_0008170), Bronchiolitis (HP_0011950), Osteopenia (HP_0000938), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Cardiovascular Disease (EFO_0000319), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Epilepsy (EFO_0000474), Tibia Fracture (EFO_0003944), Common Cold (EFO_0007214), Colorectal Adenoma (EFO_0005406), Neurofibromatosis Type 1 (MONDO_0018975), Chronic Obstructive Pulmonary Disease (EFO_0000341), Gestational Diabetes (EFO_0004593), Urinary Tract Infection (EFO_0003103), Depressive Disorder (MONDO_0002050), Papilloma (MONDO_0002363), Staphylococcus Aureus Infection (EFO_0005681), Allergic Disease (MONDO_0005271), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Tuberculosis (MONDO_0018076), Type 1 Diabetes Mellitus (MONDO_0005147), Helicobacter Pylori Infectious Disease (EFO_1000961), Type 2 Diabetes Mellitus (MONDO_0005148), Iron Deficiency Anemia (HP_0001891), Hip Fracture (EFO_0003964), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Ulcerative Colitis (EFO_0000729), Hepatitis C Virus Infection (EFO_0003047), Inflammatory Bowel Disease (EFO_0003767), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Osteitis Deformans (EFO_0004261), Disorder Of Lipid Metabolism (Orphanet_309005), In Situ Carcinoma (MONDO_0004647), Nasal Congestion (HP_0001742), Malnutrition (EFO_0008572), Cognitive Impairment (HP_0100543), Gingivitis (MONDO_0002508), Melanoma (EFO_0000756), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5208', 'drugName': 'Rosuvastatin Calcium', 'tradeNames_string': 'Crestor, Ezallor, Ezallor sprinkle, Rosuvastatin calcium', 'drugSynonyms_string': 'Fortius, NSC-747274, NSC-758930, Rostar, Rosuvastatin (as calcium), Rosuvastatin calcium, Rosuvastatin calcium salt, Rosuvastatin hemicalcium, Rozavel, S-4522, Suvikan, ZD-4522, ZD-4522 (CALCIUM SALT), ZD-4522 CALCIUM, ZD4522 (CALCIUM SALT), ZD4522 CALCIUM', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipoproteinemia Type 3 (MONDO_0018473), Hypertriglyceridemia (EFO_0004211), Coronary Artery Disease (EFO_0001645), Ischemic Stroke (HP_0002140), Hyperlipidemia (MONDO_0021187), Chronic Hepatitis B Virus Infection (EFO_0004239), Combined Hyperlipidemia (Orphanet_79211), Heart Failure (EFO_0003144), Familial Hypercholesterolemia (EFO_0004911), Hypertension (EFO_0000537), Hypercholesterolemia (HP_0003124), Acute Coronary Syndrome (EFO_0005672), Disorder Of Lipid Metabolism (Orphanet_309005), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_247', 'drugName': 'Cinacalcet', 'tradeNames_string': 'Sensipar', 'drugSynonyms_string': 'AMG 073, AMG-073, AMG073, Cinacalcet, KRN-1493, KRN1493', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Memory Impairment (EFO_0001072), Secondary Hyperparathyroidism (EFO_1001173), Hyperparathyroidism (EFO_0008506), Parathyroid Gland Carcinoma (EFO_1000456), Primary Hyperparathyroidism (EFO_0008519), Parathyroid Disease (EFO_0005754), Renal Osteodystrophy (EFO_1001152), Hypophosphatemic Rickets (MONDO_0024300), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3802', 'drugName': 'Adalimumab', 'tradeNames_string': 'Humira', 'drugSynonyms_string': 'AVT-02, Abp-501, Abrilada, Adalimumab, Adalimumab (genetical recombination), Adalimumab (humira), Adalimumab adaz, Adalimumab adbm, Adalimumab afzb, Adalimumab aqvh, Adalimumab atto, Adalimumab beta, Adalimumab biosimilar (alvotech), Adalimumab biosimilar (avt02), Adalimumab biosimilar (celltrion), Adalimumab biosimilar (ct-p17), Adalimumab biosimilar (fkb-327), Adalimumab biosimilar (zrc-3197), Adalimumab bwwd, Adalimumab-adaz, Adalimumab-adbm, Adalimumab-afzb, Adalimumab-aqvh, Adalimumab-atto, Adalimumab-bwwd, Adalimumab-fkjp, Amjevita, Avt02, BI695501, Bcd-057, Bi 695501, Bi-695501, CT-P17, Chs-1420, Cyltezo, D2E7, Exemptia, FKB-327, FKB327, GP2017, Gp-2017, HLX-03, HLX03, Hadlima, Hulio, Hyrimoz, LU-200134, LU200134, M-923, M923, MSB-11022, MSB11022, Ons-3010, Trudexa, Yusimry, ZRC-3197, ZRC3197', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Ankylosing Spondylitis (EFO_0003898), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Wet Macular Degeneration (EFO_0004683), Ulcerative Colitis (EFO_0000729), Focal Segmental Glomerulosclerosis (EFO_0004236), Inflammatory Bowel Disease (EFO_0003767), Temporal Arteritis (EFO_1001209), Uveitis (EFO_1001231), Sciatica (HP_0011868), Crohn'S Disease (EFO_0000384), Mucopolysaccharidosis Type 2 (MONDO_0010674), Juvenile Idiopathic Arthritis (EFO_0002609), Netherton Syndrome (MONDO_0009735), Osteoarthritis, Knee (EFO_0004616), Arthritis (EFO_0005856), Frozen Shoulder (EFO_1000941), Psoriatic Arthritis (EFO_0003778), Mucopolysaccharidosis Type 6 (MONDO_0009661), Immune System Disease (EFO_0000540), Dupuytren Contracture (EFO_0004229), Asthma (MONDO_0004979), Pyoderma (HP_0000999), Thyroid Cancer (MONDO_0002108), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Sarcoidosis (MONDO_0019338), Osteoarthritis (MONDO_0005178), Interstitial Cystitis (EFO_0008507), Colitis (EFO_0003872), Hidradenitis Suppurativa (EFO_1000710)", 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TNF (ENSG00000232810)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_110', 'drugName': 'Prucalopride', 'tradeNames_string': 'Resolor', 'drugSynonyms_string': 'Prucalopride, R-093877, R093877', 'linkedDiseasesDrug_string': 'Liver Disease (EFO_0001421), Dyspepsia (EFO_0008533), Paralytic Ileus (HP_0002590), Irritable Bowel Syndrome (EFO_0000555), Constipation Disorder (MONDO_0002203), Constipation (HP_0002019), Dysphagia (HP_0002015), Depressive Disorder (MONDO_0002050), Ileus (MONDO_0004567)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6297', 'drugName': 'Acalabrutinib Maleate', 'tradeNames_string': 'Calquence', 'drugSynonyms_string': 'Acalabrutinib maleate, Acalabrutinib maleate anhydrous, Calquence maleate', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Mantle Cell Lymphoma (EFO_1001469)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_147', 'drugName': 'Acetaminophen', 'tradeNames_string': "Abdine, Acephen, Acetaminophen, Alvedon, Angiers, Calpol, Calpol six plus, Calpol six plus fastmelts, Child lemsip, Cupanol, Dafalgan, Datril, Disprol, Disprol infant, Disprol jnr, Disprol paed, Fennings, Galpamol, Hedex, Infadrops, Infants' feverall, Injectapap, Junior parapaed, Mandanol, Medinol, Medinol for children, Medinol over 6, Medinol under 6, Medised plain, Miradol, Neopap, Ofirmev, Paldesic, Panadol, Panadol actifast, Panadol actifast solb, Panadol advan, Panadol jnr, Panadol oa, Panaleve, Panaleve 6 plus, Paracetamol, Paramin, Parapaed jnr, Parapaed six plus, Paravict, Perfalgan, Phenaphen, Placidex, Rimadol, Salzone, Tixymol, Tramil 500, Tylenol", 'drugSynonyms_string': 'Acetaminophen, Apap, Biocetamol, Doliprane, Efferalgan, N-acetyl-p-aminophenol, NSC-109028, NSC-3991, P-hydroxy-acetanilid, Paracetamol, Paracetamolum, Vermidon', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Nephrolithiasis (EFO_0004253), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Hypertrophy (EFO_0002460), Neuropathic Pain (EFO_0005762), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Malignant Glioma (MONDO_0100342), Neck Pain (HP_0030833), Borderline Personality Disorder (HP_0012076), Streptococcal Infection (EFO_1001476), Renal Colic (EFO_1001412), T-Lymphoblastic Lymphoma (MONDO_0044917), Extramammary Paget Disease (EFO_1000249), Diabetic Neuropathy (EFO_1000783), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Myopia (HP_0000545), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Myelodysplastic Syndrome (EFO_0000198), Headache (HP_0002315), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Morbid Obesity (EFO_0001074), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Pharyngitis (MONDO_0002258), Delirium (EFO_0009267), Influenza (EFO_0007328), Bacterial Meningitis (EFO_1000831), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Tract Infectious Disorder (MONDO_0024355), Vomiting (HP_0002013), Low Back Pain (HP_0003419), Plasmodium Falciparum Malaria (EFO_0007444), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Gastrointestinal Disease (EFO_0010282), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Rotator Cuff Tear (EFO_1001250), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Arthritis (EFO_0005856), Cardiac Arrhythmia (EFO_0004269), Patent Ductus Arteriosus (HP_0001643), Concussion (EFO_0011023), Common Cold (EFO_0007214), Neoplasm Of Mature B-Cells (EFO_0000096), Fever (HP_0001945), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Ankle Fracture (EFO_0009615), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Toothache (EFO_0010072), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Crohn'S Disease (EFO_0000384), Tooth Disease (EFO_1001216), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Sepsis (HP_0100806), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Cleft Palate (HP_0000175), Recurrent Tonsillitis (HP_0011110), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592)", 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1080', 'drugName': 'Cetuximab', 'tradeNames_string': 'Erbitux', 'drugSynonyms_string': 'ABP-494, C-225, C225, CMAB-009, CMAB009, Cetuximab, Cetuximab (genetical recombination), Cetuximab biosimilar (abp-494), IMC-225, IMC-C225, MOAB C225', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Head And Neck Carcinoma (MONDO_0002038), Complex Regional Pain Syndrome (EFO_1001998), Verrucous Carcinoma (EFO_0007535), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Adenoid Cystic Carcinoma (EFO_0000231), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Colon Carcinoma (EFO_1001950), Anal Neoplasm (EFO_0003835), Esophageal Carcinoma (EFO_0002916), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Endometrial Cancer (MONDO_0011962), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Ovarian Cancer (MONDO_0008170), Mouth Neoplasm (EFO_0003868), Colorectal Neoplasm (EFO_0004142), Gastric Adenocarcinoma (EFO_0000503), Cervical Carcinoma (EFO_0001061), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cholangiocarcinoma (EFO_0005221), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Neoplasm Of Oropharynx (MONDO_0021364), Tongue Neoplasm (EFO_0003871), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Hypopharyngeal Carcinoma (EFO_0002938), Oropharynx Cancer (EFO_1001931), Colorectal Cancer (MONDO_0005575), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Malignant Tumor Of Neck (MONDO_0021310), Peritoneum Cancer (MONDO_0002087), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Laryngeal Neoplasm (EFO_0003817), Oropharyngeal Carcinoma (MONDO_0044926), Biliary Tract Neoplasm (EFO_0003891), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Brain Cancer (MONDO_0001657), Rectum Cancer (EFO_1000657), Prolymphocytic Leukemia (MONDO_0001023), Head And Neck Malignant Neoplasia (EFO_0006859), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Urinary Bladder Cancer (MONDO_0001187), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Chordoma (MONDO_0008978), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Lung Cancer (MONDO_0008903), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Adenocarcinoma (EFO_0000228), Laryngeal Carcinoma (MONDO_0002358), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Neuralgia (EFO_0009430), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_146', 'drugName': 'Acetaminophen', 'tradeNames_string': "Abdine, Acephen, Acetaminophen, Alvedon, Angiers, Calpol, Calpol six plus, Calpol six plus fastmelts, Child lemsip, Cupanol, Dafalgan, Datril, Disprol, Disprol infant, Disprol jnr, Disprol paed, Fennings, Galpamol, Hedex, Infadrops, Infants' feverall, Injectapap, Junior parapaed, Mandanol, Medinol, Medinol for children, Medinol over 6, Medinol under 6, Medised plain, Miradol, Neopap, Ofirmev, Paldesic, Panadol, Panadol actifast, Panadol actifast solb, Panadol advan, Panadol jnr, Panadol oa, Panaleve, Panaleve 6 plus, Paracetamol, Paramin, Parapaed jnr, Parapaed six plus, Paravict, Perfalgan, Phenaphen, Placidex, Rimadol, Salzone, Tixymol, Tramil 500, Tylenol", 'drugSynonyms_string': 'Acetaminophen, Apap, Biocetamol, Doliprane, Efferalgan, N-acetyl-p-aminophenol, NSC-109028, NSC-3991, P-hydroxy-acetanilid, Paracetamol, Paracetamolum, Vermidon', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Nephrolithiasis (EFO_0004253), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Hypertrophy (EFO_0002460), Neuropathic Pain (EFO_0005762), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Malignant Glioma (MONDO_0100342), Neck Pain (HP_0030833), Borderline Personality Disorder (HP_0012076), Streptococcal Infection (EFO_1001476), Renal Colic (EFO_1001412), T-Lymphoblastic Lymphoma (MONDO_0044917), Extramammary Paget Disease (EFO_1000249), Diabetic Neuropathy (EFO_1000783), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Myopia (HP_0000545), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Myelodysplastic Syndrome (EFO_0000198), Headache (HP_0002315), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Morbid Obesity (EFO_0001074), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Pharyngitis (MONDO_0002258), Delirium (EFO_0009267), Influenza (EFO_0007328), Bacterial Meningitis (EFO_1000831), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Tract Infectious Disorder (MONDO_0024355), Vomiting (HP_0002013), Low Back Pain (HP_0003419), Plasmodium Falciparum Malaria (EFO_0007444), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Gastrointestinal Disease (EFO_0010282), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Rotator Cuff Tear (EFO_1001250), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Arthritis (EFO_0005856), Cardiac Arrhythmia (EFO_0004269), Patent Ductus Arteriosus (HP_0001643), Concussion (EFO_0011023), Common Cold (EFO_0007214), Neoplasm Of Mature B-Cells (EFO_0000096), Fever (HP_0001945), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Ankle Fracture (EFO_0009615), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Toothache (EFO_0010072), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Crohn'S Disease (EFO_0000384), Tooth Disease (EFO_1001216), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Sepsis (HP_0100806), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Cleft Palate (HP_0000175), Recurrent Tonsillitis (HP_0011110), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592)", 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_545', 'drugName': 'Tetrahydrozoline', 'tradeNames_string': '', 'drugSynonyms_string': 'Caltheon, Tetrahydrozoline, Tetryzoline, Tyzine', 'linkedDiseasesDrug_string': 'Dry Eye Syndrome (EFO_1000906), Inflammation (MP_0001845), Nasal Congestion (HP_0001742), Eye Allergy (EFO_0005751), Pterygium (EFO_0000678)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_4543', 'drugName': 'Alfacalcidol', 'tradeNames_string': 'Alfa d, Etalpha, One-alpha', 'drugSynonyms_string': '.alpha.-calcidol, 1-alpha-vitamin d, 1-hydroxycholecalciferol, 1-hydroxyvitamin d3, 1.alpha-hydroxycholecalciferol, 1.alpha.(oh)d3, 1.alpha.-hydroxycholecalciferol, 1.alpha.-hydroxyvitamin d3, Alfacalcidol, Alfarol, Alpha d3, Alphacalcidol, Alpharol, Alsiodol, Bondiol, Einsalpha, Oxydevit, Tevabone, Un alfa, Un alpha', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Polycystic Ovary Syndrome (EFO_0000660), Postmenopausal Osteoporosis (EFO_0003854), Muscular Disease (EFO_0002970), Sudden Cardiac Arrest (EFO_0004278), Kidney Failure (EFO_1002048), Scoliosis (EFO_0004273), Calcification (EFO_0003837)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_356', 'drugName': 'Ergocalciferol', 'tradeNames_string': 'Calciferol, Calciferol in arach oil, Caltrate, D-forte, Deltalin, Drisdol, Eciferol d2, Ergo-d2, Ergocalciferol, Ergoral d2, Lanes, Oleovitamin D, Osto-d2, Sterogyl, Sterogyl 15h, Sterogyl-15, Uvesterol d, Vitamin D 2, Vitamin d', 'drugSynonyms_string': 'Calciferol, Ergocalciferol, Ergocalciferolum, Ergorone, NSC-62792, Oleovitamin d, synthetic, Ostelin, Viosterol, Viosterol in oil, Vitamin d (ergocalciferol), Vitamin d2', 'linkedDiseasesDrug_string': "Postmenopausal Osteoporosis (EFO_0003854), Migraine Disorder (MONDO_0005277), Disseminated Intravascular Coagulation (HP_0005521), Pregnancy (EFO_0002950), Malignant Colon Neoplasm (MONDO_0021063), Spinal Cord Injury (EFO_1001919), Osteoporosis (EFO_0003882), Polycystic Ovary Syndrome (EFO_0000660), Vitamin D Deficiency (EFO_0003762), Neuropathic Pain (EFO_0005762), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Bone Fracture (EFO_0003931), Optic Neuritis (EFO_0007405), Abnormality Of Connective Tissue (HP_0003549), Alopecia Areata (EFO_0004192), Hypoparathyroidism (EFO_0009451), Menopause (EFO_0003922), Primary Hyperparathyroidism (EFO_0008519), Sickle Cell Anemia (MONDO_0011382), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Diabetic Neuropathy (EFO_1000783), Leukemia (EFO_0000565), Giant Cell Tumor (MONDO_0002171), Burn (EFO_0009516), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Colorectal Carcinoma (EFO_1001951), Hyperprolactinemia (EFO_0007319), Myocardial Ischemia (EFO_1001375), Sudden Cardiac Arrest (EFO_0004278), Restless Legs Syndrome (EFO_0004270), Asthma (MONDO_0004979), Insulin Resistance (EFO_0002614), Sarcopenia (EFO_1000653), Chronic Hepatitis C Virus Infection (EFO_0004220), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Colonic Neoplasm (EFO_0004288), Hypophosphatemic Rickets (MONDO_0024300), Hypocalcemia (HP_0002901), Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Cutaneous Lupus Erythematosus (EFO_0003834), Psoriasis Vulgaris (EFO_1001494), Breast Neoplasm (EFO_0003869), Osteopenia (HP_0000938), Breast Cancer (MONDO_0007254), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Premature Birth (EFO_0003917), Gestational Diabetes (EFO_0004593), Cutaneous Melanoma (EFO_0000389), Osteogenesis Imperfecta (MONDO_0019019), Heart Failure (EFO_0003144), Tuberculosis (MONDO_0018076), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), X-Linked Hypophosphatemia (Orphanet_89936), Hypophosphatemia (HP_0002148), Latent Autoimmune Diabetes In Adults (EFO_0009706), Hip Fracture (EFO_0003964), Covid-19 (MONDO_0100096), Femoral Neck Fracture (EFO_1001792), Bone Giant Cell Tumor (EFO_0007176), Endometrial Cancer (MONDO_0011962), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Inflammatory Bowel Disease (EFO_0003767), Hepatitis C Virus Infection (EFO_0003047), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Mood Disorder (EFO_0004247), Osteitis Deformans (EFO_0004261), Disorder Of Lipid Metabolism (Orphanet_309005), Malnutrition (EFO_0008572), Blood Coagulation Disease (EFO_0009314)", 'yearOfFirstApproval': 1941, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2888', 'drugName': 'Diphenhydramine Hydrochloride', 'tradeNames_string': 'Alledryl, Antitussive, Beldin, Belix, Benadryl, Benadryl preservative free, Benylin, Caladryl, Coltex, Dibenil, Diphen, Diphenhydramine hydrochloride, Diphenhydramine hydrochloride preservative free, Dreemon, Dytuss, Fedril, Gppe cough expect paed, Gppe oral soln, Histergan, Hydramine, Medinex, Nightcalm, Nytol, Nytol one-a-night, Paxidorm, Silphen, Sleepia, Syntedril, Tixylix catarrh, Vicks formula 44', 'drugSynonyms_string': 'Dimedrol, Diphenhydramine HCl, Diphenhydramine hcl, Diphenhydramine hydrochloride, NSC-33299', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Orthostatic Hypotension (EFO_0005252), Headache (HP_0002315), Chronic Lymphocytic Leukemia (EFO_0000095), Diabetic Neuropathy (EFO_1000783), Breast Cancer (MONDO_0007254), Pain (EFO_0003843), Kidney Cancer (MONDO_0002367), Skin Disease (EFO_0000701), Systemic Lupus Erythematosus (MONDO_0007915), Allergic Rhinitis (EFO_0005854), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Disease (MONDO_0005271), Lupus Nephritis (EFO_0005761)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1667', 'drugName': 'Orlistat', 'tradeNames_string': 'Alli, Beacita, Xenical', 'drugSynonyms_string': 'Lipstatin, NSC-758881, Orlipastat, Orlistat, RO 18-0647/002, RO-180647-002, RO-180647002, Tetrahydrolipstatin', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545), Obesity (EFO_0001073), Hyperlipoproteinemia Type 1 (Orphanet_411), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LIPF (ENSG00000182333), PNLIP (ENSG00000175535)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_71', 'drugName': 'Hydrocortisone Acetate', 'tradeNames_string': 'Barquinol hc, Chloromycetin hydrocort, Colifoam, Cortef acetate, Cortifoam, Cortril, Cortucid, Dricort, Epifoam, Framycort, Fucidin h, Genticin hc, Gentisone hc, Gppe ear susp, Gppe eye crm, Gppe foam aero, Hc45 hydrocort, Hemsol-hc, Hepacort plus, Hydrocal, Hydrocortisone acetate, Hydrocortone, Lanacort, Micort-hc, Neo-cortef, Orabase hca', 'drugSynonyms_string': 'Cortisol 21-acetate, Hydrocortisone 21-acetate, Hydrocortisone Acetate, Hydrocortisone acetate, Hydrocortisoni acetas, NSC-741', 'linkedDiseasesDrug_string': 'Vitiligo (EFO_0004208), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Atopic Eczema (EFO_0000274), Inflammation (MP_0001845), Skin Disease (EFO_0000701), Depressive Disorder (MONDO_0002050), Pruritus (HP_0000989)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1708', 'drugName': 'Hydrocortisone', 'tradeNames_string': 'Acetasol hc, Acticort, Aeroseb-hc, Ala-cort, Ala-scalp, Alkindi sprinkle, Alphaderm, Anflam, Anucort-Hc, Anugesic hc, Anusol hc, Anusol plus hc, Anusol soothing relief, Anusol-Hc, Balneol-hc, Beta-hc, Calmurid hc, Canesten hc, Cetacort, Cipro hc, Cobadex, Colocort, Corlan, Cort-dome, Cortef, Cortenem, Cortenema, Cortril, Daktacort, Daktacort hydrocort, Derma care hydrocort, Dermacort, Dermaspray demang, Dioderm, Dome-cort, Econacort, Efcortelan p, Eldecort, Epicort, Eurax-hc, Eurax-hydrocort, Evacort, Exe-cort, Flexicort, Germoloids hc, Glycort, Gregoderm, H-cort, Hc #1, Hc #4, Hc (hydrocortisone), Hi-cor, Hydro-rx, Hydrocort in calamine oily, Hydrocort in cetomacrogol for a, Hydrocort in wte soft paraf, Hydrocortisone, Hydrocortisone in absorbase, Hydrocortone, Hydroderm, Hydroderm hc, Hytone, Jungle for, Locoid, Medicort, Mildison lipocream, Nogenic hc, Nutracort, Nybadex, Nystaform-hc, Otoseptil, Otosporin, Penecort, Perinal, Plenadren, Proctocort, Proctocream hc, Proctofoam hc, Proctosedyl, Quinocort, Sential hc, Stie-cort, Synacort, Terra-cortril nystatin, Texacort, Timocort, Timodine, Topisone, Tri-cicatrin, Uniroid, Uniroid hc, Xyloproct, Zenoxone', 'drugSynonyms_string': 'Cor-Oticin, Cortifoam, Cortisol, FLEXICORT, Hydrocortisone, Micort-HC, NSC-10483, Neo-Cortef, Ophthocort, Terra-Cortril, U-Cort', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Hemophagocytic Syndrome (MONDO_0015540), Chronic Primary Adrenal Insufficiency (MONDO_0015129), Refractory Anemia (EFO_0003802), Acute Myelomonocytic Leukemia (EFO_0000223), Atopic Eczema (EFO_0000274), Congenital Adrenal Hyperplasia (MONDO_0018479), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Primary Adrenal Insufficiency (MONDO_0015128), Viral Pneumonia (EFO_0007541), Borderline Personality Disorder (HP_0012076), Alopecia Areata (EFO_0004192), Acute Erythroleukemia (EFO_0000218), Leukemia (EFO_0000565), Adrenocortical Insufficiency (EFO_0009491), Cancer (MONDO_0004992), Obesity (EFO_0001073), Anaplastic Large Cell Lymphoma (EFO_0003032), Hypotension (EFO_0005251), Myelodysplastic Syndrome (EFO_0000198), Aging (GO_0007568), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Memory Impairment (EFO_0001072), Asthma (MONDO_0004979), Insulin Resistance (EFO_0002614), Hemorrhoid (EFO_0009552), Influenza (EFO_0007328), Opioid Dependence (EFO_0005611), Pancreatitis (EFO_0000278), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Osteoarthritis (MONDO_0005178), Myeloproliferative Disorder (EFO_0004251), Acute Monocytic Leukemia (EFO_0000221), Dermatitis (MONDO_0002406), Mast-Cell Leukemia (EFO_0007359), Psoriasis Vulgaris (EFO_1001494), Atrial Fibrillation (EFO_0000275), Herpes Labialis (EFO_1001347), Lymphoma (EFO_0000574), Fibromyalgia (EFO_0005687), Acute Megakaryoblastic Leukaemia (EFO_0003025), Central Nervous System Neoplasm (EFO_1000158), Myocardial Infarction (EFO_0000612), Alcohol Dependence (MONDO_0007079), Eczema (HP_0000964), Opioid Use Disorder (EFO_0010702), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147), Phobic Disorder (EFO_1001908), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Otitis Externa (EFO_0009560), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Eye Inflammation (EFO_0005752), Chronic Myelomonocytic Leukemia (EFO_1001779), Cardiac Arrest (EFO_0009492), Refractory Anemia With Excess Blasts (EFO_0003811), Sepsis (HP_0100806), Lymphoblastic Lymphoma (MONDO_0000873), Inflammation (MP_0001845), Nasal Congestion (HP_0001742), Adrenal Cortex Carcinoma (EFO_1000796), Melanoma (EFO_0000756), Bronchopulmonary Dysplasia (MONDO_0019091), Oral Submucous Fibrosis (EFO_1001818), Hypoxia (EFO_0009444), Cirrhosis Of Liver (EFO_0001422)", 'yearOfFirstApproval': 1952, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1615', 'drugName': 'Albiglutide', 'tradeNames_string': 'Eperzan', 'drugSynonyms_string': 'Albiglutide, Albiglutide (genetical recombination), GSK-716155, GSK716155, Tanzeum', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Congestive Heart Failure (EFO_0000373), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5149', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_879', 'drugName': 'Mogamulizumab', 'tradeNames_string': 'Poteligeo', 'drugSynonyms_string': 'AMG-761, KM-8761, KM8761, KW-0761, Mogamulizumab, Mogamulizumab (genetical recombination), Mogamulizumab kpkc, Mogamulizumab-kpkc', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Hepatocellular Carcinoma (EFO_0000182), Asthma (MONDO_0004979), Neoplasm (EFO_0000616), Tropical Spastic Paraparesis (EFO_0007527), Non-Small Cell Lung Carcinoma (EFO_0003060), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Mycosis Fungoides (EFO_1001051), Carcinoma (EFO_0000313), Cutaneous T-Cell Lymphoma (EFO_0002913), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CCR4 (ENSG00000183813)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6174', 'drugName': 'Verapamil', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-16,533-1, CP-16533-1, CP-165331, Calan, Covera-HS, D-365, Iproveratril, Isoptin, NSC-272306NA, Tarka, Verapamil, Verapamil slow release, Verelan', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Hemorrhage (MP_0001914), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Atrial Fibrillation (EFO_0000275), Crohn'S Disease (EFO_0000384), Ischemic Stroke (HP_0002140), Dravet Syndrome (Orphanet_33069), Hypertension (EFO_0000537), Osteoarthritis, Knee (EFO_0004616), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Drug Dependence (EFO_0003890), Respiratory Syncytial Virus Infection (EFO_1001413), Ventricular Arrhythmia (HP_0004308), Bipolar Disorder (MONDO_0004985), Hodgkins Lymphoma (EFO_0000183), Heart Failure (EFO_0003144), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)", 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6195', 'drugName': 'Calcifediol', 'tradeNames_string': 'Calderol, Rayaldee', 'drugSynonyms_string': 'CTAP101, Calcidiol, Calcifediol, Calcifediol hydrate, Ctap-101, Didrogyl, Hidroferol, Rayaldy, U-32,070E, U-32070E', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Vitamin D Deficiency (EFO_0003762), Parathyroid Disease (EFO_0005754), Covid-19 (MONDO_0100096), Myocardial Infarction (EFO_0000612), Acute Kidney Injury (HP_0001919), Obstructive Sleep Apnea (EFO_0003918)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1617', 'drugName': 'Ranitidine Hydrochloride', 'tradeNames_string': 'Azantac, Dumoran, Gavilast, Gavilast-p, Histac, Raciran 150, Raciran 300, Ranicalm, Raniplex, Ranitic, Ranitidine hydrochloride, Ranitil, Rantec, Ranzac, Vivatak, Zaedoc 150, Zaedoc 300, Zantac, Zantac 150, Zantac 25, Zantac 300, Zantac 75, Zantac 75 dissolve, Zantac 75 relief, Zantac 75 relief dissolve', 'drugSynonyms_string': 'AH 19065, AH-19065, Ranitidine hcl, Ranitidine hydrochloride, Taladine', 'linkedDiseasesDrug_string': 'Ulcer Disease (MONDO_0043839), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4905', 'drugName': 'Clomipramine', 'tradeNames_string': '', 'drugSynonyms_string': '3-chloro-iminodibenzyl, Anafranil, Anapramine, Chlorimipramine, Clomicalm, Clomipramine, NSC-169865', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Obsessive-Compulsive Disorder (EFO_0004242), Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5049', 'drugName': 'Calcipotriene', 'tradeNames_string': 'Calcipotriene, Dovobet, Dovonex, Enstilar, Sorilux, Xamiol', 'drugSynonyms_string': 'Calcipotriene, Calcipotriene hydrate, Calcipotriene monohydrate, Calcipotriol, Calcipotriol anhydrous, Calcipotriol hydrate, Calcipotriol monohydrate, Calciptriol, MC 903, MC-903, PRI-2201', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Localised Scleroderma (EFO_1001361), Vitiligo (EFO_0004208), Psoriasis (EFO_0000676), Squamous Cell Carcinoma (EFO_0000707), Radiodermatitis (MONDO_0043771), Atopic Eczema (EFO_0000274), Actinic Keratosis (EFO_0002496), Skin Disease (EFO_0000701), Acne (EFO_0003894), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2718', 'drugName': 'Bicalutamide', 'tradeNames_string': 'Bicalutamide, Calutide, Casodex, Cosudex, Kalumid', 'drugSynonyms_string': 'Bicalutamide, Casodex, ICI 176,334, ICI-176334, ICI176,334-1, NSC-759816', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Fallopian Tube Cancer (MONDO_0002158), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Gynecomastia (HP_0000771), Covid-19 (MONDO_0100096), Metastatic Prostate Cancer (EFO_0000196), Peritoneum Cancer (MONDO_0002087), Salivary Gland Cancer (MONDO_0004669), Carcinoma (EFO_0000313), Precocious Puberty (MONDO_0000088), Severe Acute Respiratory Syndrome (EFO_0000694), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5140', 'drugName': 'Vincristine', 'tradeNames_string': '', 'drugSynonyms_string': '22-oxovincaleukoblastine, Leucristine, Leurocristine, Oncotcs, Tecnocris, Vincaleukoblastine, 22-oxo-, Vincristin, Vincristine, Vinkristin', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Lymphoplasmacytic Lymphoma (MONDO_0000432), Hemophagocytic Syndrome (MONDO_0015540), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Retinoblastoma (MONDO_0008380), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Hemangioma (EFO_1000635), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Castleman Disease (MONDO_0015564), Carcinoma (EFO_0000313), T-Lymphoblastic Lymphoma (MONDO_0044917), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Follicular Lymphoma (MONDO_0018906), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Lymphoma, Aids-Related (EFO_1001365), Classic Hodgkin Lymphoma (MONDO_0009348), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Anaplastic Large Cell Lymphoma (EFO_0003032), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Mantle Cell Lymphoma (EFO_1001469), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Small Cell Lung Carcinoma (EFO_0000702), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Langerhans Cell Histiocytosis (EFO_1000318), Gestational Trophoblastic Neoplasm (MONDO_0018944), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Aids (EFO_0000765), Hepatoblastoma (EFO_1000292), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Anaplastic Astrocytoma (EFO_0002499), Embryonal Rhabdomyosarcoma (EFO_0000437), Anaplastic Ependymoma (MONDO_0016700), Lymphoma (EFO_0000574), Wilms Tumor (MONDO_0006058), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Neurofibromatosis Type 1 (MONDO_0018975), Ganglioneuroblastoma (EFO_0000502), Mesothelioma (EFO_0000588), Waldenstrom Macroglobulinemia (EFO_0009441), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Kidney Wilms Tumor (MONDO_0019004), Childhood Ependymoma (MONDO_0003478), Medulloblastoma (EFO_0002939), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), B-Cell Neoplasm (MONDO_0004095), Astrocytoma (EFO_0000272), Lymphoblastic Lymphoma (MONDO_0000873), Alveolar Rhabdomyosarcoma (EFO_0000248), Lymphoid Leukemia (EFO_0004289), Optic Nerve Glioblastoma (EFO_0009254), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Mesenchymoma (EFO_1001042), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Primitive Neuroectodermal Tumor (EFO_0005235), Choroid Plexus Neoplasm (MONDO_0016717)", 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_2779', 'drugName': 'Paricalcitol', 'tradeNames_string': 'Paricalcitol, Zemplar', 'drugSynonyms_string': 'COMPOUND 49510, COMPOUND-49510, Paricalcitol', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Secondary Hyperparathyroidism (EFO_1001173), Iga Glomerulonephritis (EFO_0004194), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Left Ventricular Hypertrophy (EFO_0003896), Hyperparathyroidism (EFO_0008506), Parathyroid Disease (EFO_0005754), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Pancreatic Carcinoma (EFO_0002618), Proteinuria (HP_0000093), Albuminuria (EFO_0004285), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Neoplasm (EFO_0000616), Diabetic Nephropathy (EFO_0000401), Kidney Disease (EFO_0003086), Type 2 Diabetes Mellitus (MONDO_0005148), Hypocalcemia (HP_0002901)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_927', 'drugName': 'Diltiazem Hydrochloride', 'tradeNames_string': 'Adizem-60, Adizem-sr, Adizem-xl, Angiozem 60, Angiozem cr 120, Angiozem cr 90, Angitil sr 120, Angitil sr 180, Angitil sr 90, Angitil xl 240, Angitil xl 300, Anoheal, Bi-carzem sr, Bi-carzem xl, Britiazim, Calazem, Calcicard, Calcicard cr, Cardizem, Cardizem cd, Cardizem la, Cardizem sr, Cartia xt, Dilacor, Dilacor xr, Dilcardia sr, Dilcardia xl, Dilt-cd, Diltiazem hydrochloride, Diltiazem hydrochloride in dextrose 5%, Diltzac, Dilzem sr 120, Dilzem sr 60, Dilzem sr 90, Dilzem xl 120, Dilzem xl 180, Dilzem xl 240, Disogram sr, Horizem sr 120, Horizem sr 60, Horizem sr 90, Kentiazem, Kenzem sr, Optil, Optil sr 120, Optil sr 180, Optil sr 90, Optil xl 240, Optil xl 300, Retalzem 60, Slozem, Slozem 120, Slozem 180, Slozem 240, Taztia xt, Tiamex, Tiazac, Tildiem, Tildiem la 200, Tildiem la 300, Tildiem ret 120, Tildiem ret 90, Uard 120xl, Uard 180xl, Uard 240xl, Uard 300xl, Viazem xl, Zemret 180 xl, Zemret 240 xl, Zemret 300 xl, Zemtard 120 xl, Zemtard 180 xl, Zemtard 240 xl, Zemtard 300 xl, Zildil sr', 'drugSynonyms_string': 'Adizem, Altiazem, CRD-401, Cartia, Deltazen, Diladel, Dilpral, Dilrene, Diltiazem hcl, Diltiazem hydrochloride, Dilzem, Dilzene, Masdil, NSC-759576, RG 83606, RG-83606, Taztia, Zilden', 'linkedDiseasesDrug_string': 'Coronary Vasospasm (EFO_0004225), Hiv Infection (EFO_0000764), Angina Pectoris (EFO_0003913), Anal Fissure (HP_0012390), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Constipation (HP_0002019), Skin Disease (EFO_0000701), Colorectal Carcinoma (EFO_1001951), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4241', 'drugName': 'Doxercalciferol', 'tradeNames_string': 'Doxercalciferol, Hectorol', 'drugSynonyms_string': '1-.alpha.-hydroxyergocalciferol, 1-alpha-hydroxyergocalciferol, 1-hydroxyergocalciferol, 1.alpha.-hydroxyergocalciferol, 1.alpha.-hydroxyvitamin d2, Doxercalciferol, GZ427397, TSA-840', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Chronic Kidney Disease (EFO_0003884), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Secondary Hyperparathyroidism (EFO_1001173), Parathyroid Disease (EFO_0005754)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2584', 'drugName': 'Amlodipine Besylate', 'tradeNames_string': 'Amlodipine besylate, Norliqva, Norvasc', 'drugSynonyms_string': 'Amlodipine (as besilate), Amlodipine benzenesulfonate, Amlodipine besilate, Amlodipine besylate, Amlor, Antacal, Lodipressin, Monopina, NSC-758922, Norliqva, UK-48,340-26, UK-48340-26', 'linkedDiseasesDrug_string': "Hyperlipidemia (MONDO_0021187), Congestive Heart Failure (EFO_0000373), Coronary Artery Disease (EFO_0001645), Angina Pectoris (EFO_0003913), Familial Hypercholesterolemia (EFO_0004911), Prinzmetal'S Angina (EFO_1000013), Hypertension (EFO_0000537), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Fish-Eye Disease (Orphanet_79292), Hypercholesterolemia (HP_0003124), Proteinuria (HP_0000093), Essential Hypertension (MONDO_0001134)", 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_841', 'drugName': 'Cinacalcet Hydrochloride', 'tradeNames_string': 'Mimpara, Sensipar', 'drugSynonyms_string': 'AMG-073, AMG-073 HCL, AMG073 HCL, AMG073 HYDROCHLORIDE, Cinacalcet hcl, Cinacalcet hydrochloride', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Parathyroid Gland Carcinoma (EFO_1000456), Carcinoma (EFO_0000313), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5017', 'drugName': 'Isradipine', 'tradeNames_string': 'Dynacirc, Dynacirc cr, Isradipine, Prescal', 'drugSynonyms_string': 'Isradipine, Isrodipine, NSC-759892, PN 200-110, PN-200-110', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Drug Dependence (EFO_0003890), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Parkinson Disease (MONDO_0005180), Bipolar Disorder (MONDO_0004985), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_763', 'drugName': 'Pitavastatin Calcium', 'tradeNames_string': 'Livalo, Pitavastatin calcium', 'drugSynonyms_string': 'Itavastatin calcium, NK-104, Pitavastatin Calcium, Pitavastatin calcium, Pitavastatin calcium salt', 'linkedDiseasesDrug_string': 'Abnormal Circulating Lipid Concentration (HP_0003119), Hyperlipidemia (MONDO_0021187), Disorder Of Lipid Metabolism (Orphanet_309005), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3863', 'drugName': 'Obeticholic Acid', 'tradeNames_string': 'Ocaliva', 'drugSynonyms_string': '6-ecdca, 6-ethylchenodeoxycholic acid, DSP-1747, INT-747, Obeticholic acid', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Hepatitis, Alcoholic (EFO_1001345), Diarrhea (HP_0002014), Cholangitis (HP_0030151), Liver Disease (EFO_0001421), Biliary Liver Cirrhosis (EFO_0004267), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Cholestasis (MONDO_0001751), Barrett'S Esophagus (EFO_0000280), Sclerosing Cholangitis (EFO_0004268), Pruritus (HP_0000989), Primary Biliary Cirrhosis (EFO_1001486), Familial Partial Lipodystrophy (MONDO_0020088)", 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR1H4 (ENSG00000012504)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_593', 'drugName': 'Acalabrutinib', 'tradeNames_string': 'Calquence', 'drugSynonyms_string': 'ACP-196, Acalabrutinib, Acp-196', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Infectious Disease (EFO_0005741), Food Allergy (EFO_1001890), Ovarian Cancer (MONDO_0008170), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Rheumatoid Arthritis (EFO_0000685), Prolymphocytic Leukemia (MONDO_0001023), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BTK (ENSG00000010671)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4270', 'drugName': 'Deflazacort', 'tradeNames_string': 'Calcort, Emflaza, Zamene', 'drugSynonyms_string': 'Deflazacort, MDL 458, MDL-458, MDL458', 'linkedDiseasesDrug_string': 'Allergic Bronchopulmonary Aspergillosis (EFO_0007140), Liver Disease (EFO_0001421), Duchenne Muscular Dystrophy (MONDO_0010679), Kidney Disease (EFO_0003086), Limb-Girdle Muscular Dystrophy (MONDO_0016971), Muscular Dystrophy (MONDO_0020121)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_148', 'drugName': 'Acetaminophen', 'tradeNames_string': "Abdine, Acephen, Acetaminophen, Alvedon, Angiers, Calpol, Calpol six plus, Calpol six plus fastmelts, Child lemsip, Cupanol, Dafalgan, Datril, Disprol, Disprol infant, Disprol jnr, Disprol paed, Fennings, Galpamol, Hedex, Infadrops, Infants' feverall, Injectapap, Junior parapaed, Mandanol, Medinol, Medinol for children, Medinol over 6, Medinol under 6, Medised plain, Miradol, Neopap, Ofirmev, Paldesic, Panadol, Panadol actifast, Panadol actifast solb, Panadol advan, Panadol jnr, Panadol oa, Panaleve, Panaleve 6 plus, Paracetamol, Paramin, Parapaed jnr, Parapaed six plus, Paravict, Perfalgan, Phenaphen, Placidex, Rimadol, Salzone, Tixymol, Tramil 500, Tylenol", 'drugSynonyms_string': 'Acetaminophen, Apap, Biocetamol, Doliprane, Efferalgan, N-acetyl-p-aminophenol, NSC-109028, NSC-3991, P-hydroxy-acetanilid, Paracetamol, Paracetamolum, Vermidon', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Nephrolithiasis (EFO_0004253), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Hypertrophy (EFO_0002460), Neuropathic Pain (EFO_0005762), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Malignant Glioma (MONDO_0100342), Neck Pain (HP_0030833), Borderline Personality Disorder (HP_0012076), Streptococcal Infection (EFO_1001476), Renal Colic (EFO_1001412), T-Lymphoblastic Lymphoma (MONDO_0044917), Extramammary Paget Disease (EFO_1000249), Diabetic Neuropathy (EFO_1000783), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Myopia (HP_0000545), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Myelodysplastic Syndrome (EFO_0000198), Headache (HP_0002315), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Morbid Obesity (EFO_0001074), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Pharyngitis (MONDO_0002258), Delirium (EFO_0009267), Influenza (EFO_0007328), Bacterial Meningitis (EFO_1000831), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Tract Infectious Disorder (MONDO_0024355), Vomiting (HP_0002013), Low Back Pain (HP_0003419), Plasmodium Falciparum Malaria (EFO_0007444), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Gastrointestinal Disease (EFO_0010282), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Rotator Cuff Tear (EFO_1001250), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Arthritis (EFO_0005856), Cardiac Arrhythmia (EFO_0004269), Patent Ductus Arteriosus (HP_0001643), Concussion (EFO_0011023), Common Cold (EFO_0007214), Neoplasm Of Mature B-Cells (EFO_0000096), Fever (HP_0001945), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Ankle Fracture (EFO_0009615), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Toothache (EFO_0010072), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Crohn'S Disease (EFO_0000384), Tooth Disease (EFO_1001216), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Sepsis (HP_0100806), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Cleft Palate (HP_0000175), Recurrent Tonsillitis (HP_0011110), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592)", 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2465', 'drugName': 'Prucalopride Succinate', 'tradeNames_string': 'Motegrity, Resolor', 'drugSynonyms_string': 'Prucalopride (as succinate), Prucalopride succinate, R-108512', 'linkedDiseasesDrug_string': 'Constipation (HP_0002019), Constipation Disorder (MONDO_0002203)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2157', 'drugName': 'Calcifediol', 'tradeNames_string': '', 'drugSynonyms_string': 'Calcifediol', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Vitamin D Deficiency (EFO_0003762), Parathyroid Disease (EFO_0005754), Covid-19 (MONDO_0100096), Myocardial Infarction (EFO_0000612), Acute Kidney Injury (HP_0001919), Obstructive Sleep Apnea (EFO_0003918)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4515', 'drugName': 'Felodipine', 'tradeNames_string': 'Cabren, Cardioplen xl, Felodipine, Felogen xl, Felotens xl, Folpik xl, Keloc sr, Neofel xl, Parmid xl, Pinefeld xl, Plendil, Preslow, Vascalpha', 'drugSynonyms_string': 'C08CA02, Felodipine, H 154/82, H-154/82, NSC-760343', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4676', 'drugName': 'Interferon Alfa-2A', 'tradeNames_string': 'Roferon-a', 'drugSynonyms_string': 'INTERFERON ALFA-2A, Interferon alfa-2a, Interferon alfa-2a (genetical recombination), RO 22-8181, RO-22-8181, RO-228181', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Psoriasis (EFO_0000676), Retinal Vasculitis (EFO_1001156), Multiple Myeloma (EFO_0001378), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Behcet'S Syndrome (EFO_0003780), Kidney Cancer (MONDO_0002367), Acute Lymphoblastic Leukemia (EFO_0000220), Renal Cell Carcinoma (EFO_0000681), Melanoma (EFO_0000756), Lymphoma (EFO_0000574), Chronic Hepatitis C Virus Infection (EFO_0004220), Metastatic Melanoma (EFO_0002617), Hairy Cell Leukemia (EFO_1000956), Hepatitis C Virus Infection (EFO_0003047)", 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3638', 'drugName': 'Abatacept', 'tradeNames_string': 'Orencia, Orencia clickject', 'drugSynonyms_string': 'Abatacept, Abatacept (genetical recombination), Abatacept recombinant, BMS-188667, CTLA4-IGG4M, RG-1046, RG-2077', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Multiple Sclerosis (MONDO_0005301), Sjogren Syndrome (EFO_0000699), Ankylosing Spondylitis (EFO_0003898), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Graft Versus Host Disease (MONDO_0013730), Systemic Lupus Erythematosus (MONDO_0007915), Myasthenia Gravis (EFO_0004991), Ulcerative Colitis (EFO_0000729), Psoriasis Vulgaris (EFO_1001494), Diffuse Scleroderma (EFO_0000404), Nephrotic Syndrome (EFO_0004255), Uveitis (EFO_1001231), Temporal Arteritis (EFO_1001209), Crohn'S Disease (EFO_0000384), Thalassemia (EFO_1001996), Juvenile Idiopathic Arthritis (EFO_0002609), Hypertension (EFO_0000537), Psoriatic Arthritis (EFO_0003778), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acute Graft Vs. Host Disease (EFO_0004599), Granulomatosis With Polyangiitis (EFO_0005297), Polymyalgia Rheumatica (EFO_0008518), Relapsing Polychondritis (EFO_1001148), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540), Peanut Allergic Reaction (EFO_0007425), Vitiligo (EFO_0004208), Alopecia Areata (EFO_0004192), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Sarcoidosis (MONDO_0019338), Takayasu Arteritis (EFO_1001857), Type 1 Diabetes Mellitus (MONDO_0005147), Myocarditis (EFO_0009609), Lupus Nephritis (EFO_0005761), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD80 (ENSG00000121594), CD86 (ENSG00000114013)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3639', 'drugName': 'Abatacept', 'tradeNames_string': 'Orencia, Orencia clickject', 'drugSynonyms_string': 'Abatacept, Abatacept (genetical recombination), Abatacept recombinant, BMS-188667, CTLA4-IGG4M, RG-1046, RG-2077', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Multiple Sclerosis (MONDO_0005301), Sjogren Syndrome (EFO_0000699), Ankylosing Spondylitis (EFO_0003898), Behcet'S Syndrome (EFO_0003780), Covid-19 (MONDO_0100096), Graft Versus Host Disease (MONDO_0013730), Systemic Lupus Erythematosus (MONDO_0007915), Myasthenia Gravis (EFO_0004991), Ulcerative Colitis (EFO_0000729), Psoriasis Vulgaris (EFO_1001494), Diffuse Scleroderma (EFO_0000404), Nephrotic Syndrome (EFO_0004255), Uveitis (EFO_1001231), Temporal Arteritis (EFO_1001209), Crohn'S Disease (EFO_0000384), Thalassemia (EFO_1001996), Juvenile Idiopathic Arthritis (EFO_0002609), Hypertension (EFO_0000537), Psoriatic Arthritis (EFO_0003778), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acute Graft Vs. Host Disease (EFO_0004599), Granulomatosis With Polyangiitis (EFO_0005297), Polymyalgia Rheumatica (EFO_0008518), Relapsing Polychondritis (EFO_1001148), Dermatomyositis (EFO_0000398), Immune System Disease (EFO_0000540), Peanut Allergic Reaction (EFO_0007425), Vitiligo (EFO_0004208), Alopecia Areata (EFO_0004192), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Sarcoidosis (MONDO_0019338), Takayasu Arteritis (EFO_1001857), Type 1 Diabetes Mellitus (MONDO_0005147), Myocarditis (EFO_0009609), Lupus Nephritis (EFO_0005761), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD80 (ENSG00000121594), CD86 (ENSG00000114013)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5152', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_998', 'drugName': 'Aflibercept', 'tradeNames_string': 'Eylea, Zaltrap', 'drugSynonyms_string': 'ABP-938, AVE-0005, AVE0005, Aflibercept, Aflibercept (genetical recombination), Aflibercept beta, Aflibercept biosimilar (amgen), Aflibercept recombinant, BAY-86-5321, BAY-865321, BAY86-5321, VEGF TRAP, Vegf trap-eye, Ziv-aflibercept', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Macular Degeneration (EFO_0009606), Non-Hodgkins Lymphoma (EFO_0005952), Retinal Vein Occlusion (EFO_1001157), Mixed Glioma (MONDO_0003268), Wet Macular Degeneration (EFO_0004683), Metastatic Melanoma (EFO_0002617), Glaucoma (MONDO_0005041), Colorectal Carcinoma (EFO_1001951), Retinopathy (EFO_0003839), Telangiectasis (MONDO_0001576), Malignant Colon Neoplasm (MONDO_0021063), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Graves Ophthalmopathy (EFO_1001466), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Diabetic Retinopathy (EFO_0003770), Lymphoma (EFO_0000574), Histoplasmosis (EFO_0007310), Ocular Vascular Disease (EFO_0005753), Urethra Cancer (MONDO_0004192), Vitreous Hemorrhage (EFO_0008626), Retinopathy Of Prematurity (EFO_1001158), Endometrial Carcinoma (EFO_1001512), Anaplastic Oligodendroglioma (EFO_0002501), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Central Serous Retinopathy (EFO_0009784), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Neovascular Glaucoma (EFO_1001060), Cutaneous Melanoma (EFO_0000389), Age-Related Macular Degeneration (EFO_0001365), Macular Retinal Edema (MONDO_0003005), Rectum Cancer (EFO_1000657), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Pseudoxanthoma Elasticum (Orphanet_758), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pathological Myopia (EFO_0004207)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VEGFA (ENSG00000112715), PGF (ENSG00000119630)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5151', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5150', 'drugName': 'Doxycycline Calcium', 'tradeNames_string': 'Vibramycin', 'drugSynonyms_string': 'Doxycycline calcium', 'linkedDiseasesDrug_string': 'Osteomyelitis (EFO_0003102)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MMP1 (ENSG00000196611), MMP13 (ENSG00000137745), MMP7 (ENSG00000137673), MMP8 (ENSG00000118113)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4126', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_string': 'Akten, Alphacaine hydrochloride, Anestacon, Anodesyn, Bismodyne, Bradosol plus, Calgel, Co-phenylcaine fte, Denela, Dequaspray, Emla, Germoloids, Germoloids complete, Glydo, Hemocane, Iglu, Instillagel, Laryng-o-jet kit, Laryngojet, Laryngotracheal anesthesia kit, Lido hcl, Lidocaine hydrochloride, Lidocaine hydrochloride preservative free, Lidocaine hydrochloride viscous, Lidocaine viscous, Lidocaton, Lidopen, Lignokent, Lignospan special, Lignostab, Lignostab a 100, Lignostab n, Lignostab-a, Lta ii kit, Medijel, Oragard, Pediatric lta kit, Preparation h, Rexocaine, Versatis, Xylocaine, Xylocaine dental, Xylocaine preservative free, Xylocaine viscous, Xylotox e80, Zingo', 'drugSynonyms_string': 'Anhydrous lidocaine hydrochloride, Lidocaine hcl, Lidocaine hydrochloride, Lidocaine hydrochloride anhydrous, Lidocaine hydrochloride monohydrate, Lidocaine hydrochloride usp, Lidocaini hydrochloridum, Lignocaine (as hydrochloride), Lignocaine hydrochloride, NSC-757420, Xylocaine hydrochloride', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Injury (EFO_0000546), Pregnancy (EFO_0002950), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Rotator Cuff Tear (EFO_1001250), Thalassemia (EFO_1001996), Hypertension (EFO_0000537), Pruritus (HP_0000989), Pancreatic Carcinoma (EFO_0002618), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Back Pain (HP_0003418), Liver Cancer (MONDO_0002691), Chronic Pain (HP_0012532), Mucositis (EFO_1001898)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3358', 'drugName': 'Amitriptyline Hydrochloride', 'tradeNames_string': 'Amitid, Amitril, Amitriptyline hydrochloride, Cytriptyline, Domical, Elavil, Endep, Lentizol, Limbitrol 5, Saroten, Saroten retard, Triptafen, Triptafen-m, Tryptizol, Tryptizol-75', 'drugSynonyms_string': 'Amitriptyline hcl, Amitriptyline hydrochloride, Amitriptylini hydrochloridum, Etravil, NIH 10794, NSC-104210, Novoprotect, Syneudon', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Pruritus (HP_0000989), Peripheral Nervous System Disease (EFO_0009387)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3209', 'drugName': 'Ibuprofen', 'tradeNames_string': "Aches-n-pain, Advil, Advil liqui-gels, Advil migraine liqui-gels, Anadin joint pain, Anadin liquifast, Anadin period pain relief, Anadin ultra, Apsifen, Apsifen-f, Arthrofen 200, Arthrofen 400, Arthrofen 600, Brufen ret, Caldolor, Cap-profen, Children's advil, Children's advil-flavored, Children's elixsure, Children's ibuprofen, Children's motrin, Co-op, Codafen continus, Cuprofen for child, Cuprofen plus, Deep relief, Ebufac, Femafen, Fenbid, Fenbid fte, Fenpaed, Feverfen, Fleximex, Ibu-slo, Ibu-tab, Ibu-tab 200, Ibucalm, Ibuderm, Ibufac, Ibugel, Ibugel fte, Ibular, Ibuleve, Ibumed, Ibumetin, Ibumousse, Ibuprin, Ibuprofen, Ibuprohm, Ibuspray, Ibutime, Inabrin, Infant's advil, Inoven, Isisfen, Junifen, Junior strength advil, Junior strength ibuprofen, Junior strength motrin, Lidifen, Lidifen-f, Lobufen, Mandafen, Manorfen, Maxa-gesic, Medipren, Midol, Midol liquid gels, Migrafen, Motrin, Motrin ib, Motrin migraine pain, Novaprin, Nuprin, Nurofen 400, Nurofen back pain sr, Nurofen child, Nurofen for child, Nurofen plus, Nurofen recovery, Nurofen sinus, Nurofen solb, Orbifen, Pacifene, Paxofen, Pedea, Pediatric advil, Phensic, Phor pain, Phorpain, Phorpain max strgh, Profen, Proflex, Proflex sr, Relcofen, Rimafen, Rufen, Seclodin, Suspren, Tab-profen", 'drugSynonyms_string': 'Burana, IB-100, IP-82, Ibuprofen, Ibuprofenum, M01AE01, NSC-256857, RD 13621, U-18,573, U-18573', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Migraine Disorder (MONDO_0005277), Vasculitis (EFO_0006803), Allergic Rhinitis (EFO_0005854), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Causalgia (EFO_1000854), Malignant Glioma (MONDO_0100342), Retinopathy Of Prematurity (EFO_1001158), Neck Pain (HP_0030833), Myalgia (HP_0003326), Arthralgia (HP_0002829), Burn (EFO_0009516), Orthostatic Hypotension (EFO_0005252), Brachial Plexus Neuritis (EFO_1000843), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Dysmenorrhea (HP_0100607), Headache (HP_0002315), Acute Respiratory Distress Syndrome (EFO_1000637), Chronic Granulomatous Disease (MONDO_0018305), Peptic Ulcer (HP_0004398), Sinusitis (EFO_0007486), Cervical Spondylosis (EFO_0009610), Pharyngitis (MONDO_0002258), Duchenne Muscular Dystrophy (MONDO_0010679), Influenza (EFO_0007328), Obstructive Sleep Apnea (EFO_0003918), Hiv Infection (EFO_0000764), Pulpitis (EFO_1001139), Osteoarthritis (MONDO_0005178), Low Back Pain (HP_0003419), Alzheimer Disease (MONDO_0004975), Spondyloarthropathy (EFO_0000706), Breast Neoplasm (EFO_0003869), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Aphthous Ulcer (EFO_0003938), Osteoarthritis, Knee (EFO_0004616), Arthritis (EFO_0005856), Cardiovascular Disease (EFO_0000319), Partial Epilepsy (EFO_0004263), Periodontitis (EFO_0000649), Tibia Fracture (EFO_0003944), Patent Ductus Arteriosus (HP_0001643), Sunburn (EFO_0003958), Premature Birth (EFO_0003917), Common Cold (EFO_0007214), Fever (HP_0001945), Sprain (EFO_0009582), Ankle Fracture (EFO_0009615), Chronic Pain (HP_0012532), Tuberculosis (MONDO_0018076), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Toothache (EFO_0010072), Rheumatic Disease (EFO_0005755), Cerebral Palsy (EFO_1000632), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Malaria (EFO_0001068), Tooth Disease (EFO_1001216), Muscular Disease (EFO_0002970), Septic Shock (EFO_0006834), Emphysema (EFO_0000464), Acute Pancreatitis (EFO_1000652), Vaginal Inflammation (EFO_0005757), Enuresis (MONDO_0024290), Back Pain (HP_0003418), Rheumatoid Arthritis (EFO_0000685), Altitude Sickness (EFO_1000782), Temporomandibular Joint Disorder (EFO_0005279), Cognitive Impairment (HP_0100543), Bronchopulmonary Dysplasia (MONDO_0019091)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3093', 'drugName': 'Fenoprofen Calcium', 'tradeNames_string': 'Fenoprofen calcium, Nalfon', 'drugSynonyms_string': '69323, Fenoprofen calcium, Fenoprofen calcium salt dihydrate, Fenopron, Fepron, Feprona, Nalgesic', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4457', 'drugName': 'Pindolol', 'tradeNames_string': 'Betadren, Pindolol, Visken', 'drugSynonyms_string': '(rs)-pindolol, Apo-pindol, Betapindol, Blocklin-l, Calvisken, Carvisken, Decreten, Dl-lb-46, Dl-pindolol, Durapindol, Glauco-visken, LB-46, NSC-757276, Pectobloc, Pinbetol, Pindolol, Prinodolol, Pynastin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4458', 'drugName': 'Pindolol', 'tradeNames_string': 'Betadren, Pindolol, Visken', 'drugSynonyms_string': '(rs)-pindolol, Apo-pindol, Betapindol, Blocklin-l, Calvisken, Carvisken, Decreten, Dl-lb-46, Dl-pindolol, Durapindol, Glauco-visken, LB-46, NSC-757276, Pectobloc, Pinbetol, Pindolol, Prinodolol, Pynastin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_934', 'drugName': 'Glyburide', 'tradeNames_string': 'Calabren, Daonil, Diabeta, Diabetamide 2.5, Diabetamide 5, Euglucon, Gliken, Glyburide, Glyburide (micronized), Glynase, Glynase Prestab, Lederglib, Libanil, Malix, Micronase, Semi-daonil', 'drugSynonyms_string': 'Cirara, Glibenclamide, Glibenclamidum, Glybenclamide, Glyburide, HB 419, HB-419, NSC-759618, U-26,45, U-26,452, U-26452', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Ischemic Stroke (HP_0002140), Angina Pectoris (EFO_0003913), Stroke (EFO_0000712), Gestational Diabetes (EFO_0004593), Brain Injury (MONDO_0043510), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1666', 'drugName': 'Orlistat', 'tradeNames_string': 'Alli, Beacita, Xenical', 'drugSynonyms_string': 'Lipstatin, NSC-758881, Orlipastat, Orlistat, RO 18-0647/002, RO-180647-002, RO-180647002, Tetrahydrolipstatin', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Infertility (EFO_0000545), Obesity (EFO_0001073), Hyperlipoproteinemia Type 1 (Orphanet_411), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LIPF (ENSG00000182333), PNLIP (ENSG00000175535)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2915', 'drugName': 'Ketamine', 'tradeNames_string': 'Ketalar', 'drugSynonyms_string': 'Anaket v, Calypsol, Clorketam 1000, Dl-ketamine, Imalgene 1000, Ketamine, Ketasol 100, NSC-70151, Narketan, PMI-150, Tekam, Ursotamin, Vetaket', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Status Asthmaticus (EFO_0008590), Complex Regional Pain Syndrome (EFO_1001998), Head And Neck Carcinoma (MONDO_0002038), Bipolar I Disorder (EFO_0009963), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Agitation (HP_0000713), Cannabis Dependence (EFO_0007191), Injury (EFO_0000546), Appendicitis (EFO_0007149), Status Epilepticus (EFO_0008526), Anorexia Nervosa (MONDO_0005351), Coronavirus Infectious Disease (EFO_0007224), Reproductive System Disease (EFO_0000512), Radius Fracture (EFO_0003957), Post-Traumatic Stress Disorder (EFO_0001358), Headache (HP_0002315), Postpartum Depression (EFO_0007453), Ischemic Stroke (HP_0002140), Bronchospasm (HP_0025428), Breast Cancer (MONDO_0007254), Nicotine Dependence (EFO_0003768), Cataract (MONDO_0005129), Septic Shock (EFO_0006834), Neuropathic Pain (EFO_0005762), Hypertrophy (EFO_0002460), Persian Gulf Syndrome (EFO_0007430), Acute Respiratory Distress Syndrome (EFO_1000637), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Morbid Obesity (EFO_0001074), Autism Spectrum Disorder (EFO_0003756), Bone Fracture (EFO_0003931), Rib Fracture (EFO_0009620), Pruritus (HP_0000989), Suicidal Ideation (EFO_0004320), Treatment Resistant Depression (EFO_0009854), Cardiac Arrest (EFO_0009492), Aggressive Behavior (EFO_0003015), Pharyngitis (MONDO_0002258), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Mental Or Behavioural Disorder (EFO_0000677), Sepsis (HP_0100806), Borderline Personality Disorder (HP_0012076), Stroke (EFO_0000712), Hemorrhoid (EFO_0009552), Renal Colic (EFO_1001412), Sickle Cell Anemia (MONDO_0011382), Delirium (EFO_0009267), Ventricular Septal Defect (MONDO_0002070), Subarachnoid Hemorrhage (EFO_0000713), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Brain Injury (MONDO_0043510), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Temporomandibular Joint Disorder (EFO_0005279), Unipolar Depression (EFO_0003761), Strabismus (HP_0000486), Lung Cancer (MONDO_0008903), Cognitive Impairment (HP_0100543), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Respiratory Failure (EFO_0009686), Mucositis (EFO_1001898), Tinnitus (HP_0000360), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Multiple Bone Fractures (EFO_0009513), Schizophrenia (MONDO_0005090), Severe Acute Respiratory Syndrome (EFO_0000694), Perceptual Disorders (MONDO_0024417)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_5721', 'drugName': 'Menthol', 'tradeNames_string': "Aqua-cool, Aquasoothe, Arjun, Catarrh, Dermacool, Fisherman's friend lozenges, Halls, Karvol, Lockets, Meggezones, Muirs, Therapeutic mineral ice, Tixylix decongestant inh, Vocalzone", 'drugSynonyms_string': 'Dl-menthol, FEMA NO. 2665, Meggezone, Menthol, Menthol racemate, Menthol, cis-1,3,trans-1,4-, Menthol, dl-, NSC-2603, Rac-menthol, Racementhol', 'linkedDiseasesDrug_string': 'Tendinopathy (EFO_1001434), Pain (EFO_0003843), Cough (HP_0012735), Muscle Spasm (HP_0003394), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Bronchitis (EFO_0009661), Gastric Cancer (MONDO_0001056), Headache (HP_0002315), Herpes Labialis (EFO_1001347), Nicotine Dependence (EFO_0003768), Bursitis (MONDO_0002471), Hypertension (EFO_0000537), Arthritis (EFO_0005856), Oral Ulcer (HP_0000155), Frozen Shoulder (EFO_1000941), Tendinitis (MONDO_0004857), Sunburn (EFO_0003958), Pruritus (HP_0000989), Asthma (MONDO_0004979), Pharyngitis (MONDO_0002258), Common Cold (EFO_0007214), Hemorrhoid (EFO_0009552), Back Pain (HP_0003418), Sprain (EFO_0009582), Nasal Congestion (HP_0001742), Myalgia (HP_0003326), Skin Infection (MONDO_0021201), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Diabetic Neuropathy (EFO_1000783), Burn (EFO_0009516), Dysphagia (HP_0002015)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPA1 (ENSG00000104321), TRPM8 (ENSG00000144481)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5722', 'drugName': 'Menthol', 'tradeNames_string': "Aqua-cool, Aquasoothe, Arjun, Catarrh, Dermacool, Fisherman's friend lozenges, Halls, Karvol, Lockets, Meggezones, Muirs, Therapeutic mineral ice, Tixylix decongestant inh, Vocalzone", 'drugSynonyms_string': 'Dl-menthol, FEMA NO. 2665, Meggezone, Menthol, Menthol racemate, Menthol, cis-1,3,trans-1,4-, Menthol, dl-, NSC-2603, Rac-menthol, Racementhol', 'linkedDiseasesDrug_string': 'Tendinopathy (EFO_1001434), Pain (EFO_0003843), Cough (HP_0012735), Muscle Spasm (HP_0003394), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Bronchitis (EFO_0009661), Gastric Cancer (MONDO_0001056), Headache (HP_0002315), Herpes Labialis (EFO_1001347), Nicotine Dependence (EFO_0003768), Bursitis (MONDO_0002471), Hypertension (EFO_0000537), Arthritis (EFO_0005856), Oral Ulcer (HP_0000155), Frozen Shoulder (EFO_1000941), Tendinitis (MONDO_0004857), Sunburn (EFO_0003958), Pruritus (HP_0000989), Asthma (MONDO_0004979), Pharyngitis (MONDO_0002258), Common Cold (EFO_0007214), Hemorrhoid (EFO_0009552), Back Pain (HP_0003418), Sprain (EFO_0009582), Nasal Congestion (HP_0001742), Myalgia (HP_0003326), Skin Infection (MONDO_0021201), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Diabetic Neuropathy (EFO_1000783), Burn (EFO_0009516), Dysphagia (HP_0002015)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPA1 (ENSG00000104321), TRPM8 (ENSG00000144481)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5956', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5957', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2097', 'drugName': 'Calcium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Calcium oxybate, Oxybate calcium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3759', 'drugName': 'Norethindrone', 'tradeNames_string': 'Aygestin, Camila, Errin, Heather, Incassia, Jencycla, Menzol, Micronor, Micronor hrt, Nor-qd, Norethidrone, Norethindrone, Noriday, Norlutin, Primolut n, Utovlan', 'drugSynonyms_string': 'Activella, Anovule, Aygestin, Calluna vulgaris, Calluna vulgaris whole, Combipatch, Femhrt, Gestest, Heather whole, NSC-9564, Norethindrone, Norethisteron, Norethisterone, Norethisteronum, Norlutate, SC-4640, Triella', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Ischemia Reperfusion Injury (EFO_0002687), Neoplasm (EFO_0000616), Secondary Progressive Multiple Sclerosis (EFO_0008522), Menopause (EFO_0003922), Pain (EFO_0003843), Dysmenorrhea (HP_0100607), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Endometriosis (EFO_0001065), Hyperandrogenism (EFO_0009006), Sexual Dysfunction (EFO_0004714), Primary Progressive Multiple Sclerosis (EFO_0008520), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2660', 'drugName': 'Abciximab', 'tradeNames_string': 'Reopro', 'drugSynonyms_string': 'Abciximab, Abciximab (genetical recombination), C7E3', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Angina Pectoris (EFO_0003913), Internal Carotid Artery Stenosis (EFO_0002615), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Acute Myocardial Infarction (EFO_0008583), Brain Ischemia (MONDO_0005299), St Elevation Myocardial Infarction (EFO_0008585), Intermediate Coronary Syndrome (EFO_1000985)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961), ITGAV (ENSG00000138448)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6261', 'drugName': 'Vinblastine Sulfate', 'tradeNames_string': 'Velban, Velbe, Vinblast,lederle, Vinblastine sulfate', 'drugSynonyms_string': '29060-LE, 29060LE, Alkaban-aq, NSC-49842, Vinblastine sulfate, Vinblastine sulphate, Vinblastini sulfas, Vincaleukoblastine sulfate, Vlb monosulfate', 'linkedDiseasesDrug_string': 'Childhood Germ Cell Tumor (MONDO_0003751), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642), Prostate Cancer (MONDO_0008315), Lymphoma (EFO_0000574), Urethra Cancer (MONDO_0004192), Testicular Neoplasm (EFO_0004281), Fungal Infectious Disease (MONDO_0002041), Urinary Bladder Carcinoma (MONDO_0004986), Mesothelioma (EFO_0000588), Cutaneous Melanoma (EFO_0000389), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Urinary Bladder Cancer (MONDO_0001187), Classic Hodgkin Lymphoma (MONDO_0009348), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Desmoid-Type Fibromatosis (EFO_0009907)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_733', 'drugName': 'Fentanyl Citrate', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugSynonyms_string': 'Fentanyl buccal, Fentanyl citrate, Fentanyl citrate cii, Instanyl, Kw-2246, Leptanal, MCN-JR-4263-49, R-4263', 'linkedDiseasesDrug_string': 'Shortness Of Breath (EFO_0009727), Cancer (MONDO_0004992), Dyspnea (HP_0002094), Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Interstitial Lung Disease (EFO_0004244), Low Back Pain (HP_0003419), Injury (EFO_0000546)', 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4232', 'drugName': 'Calcitriol', 'tradeNames_string': 'Calcijex, Calcitriol, Dihydroxycholecalciferol, Dihydroxyvitamin D 3, Rocaltrol, Silkis, Topitriol, Vectical', 'drugSynonyms_string': '1,25-dihydroxyvitamin d3, 1,25-hydroxylated vitamin d, 1alpha,25-dihydroxycholecalciferol, 1alpha,25-dihydroxyvitamin d3, Calcitriol, RO 21-5535, RO-21-5535, RO-215535', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Psoriasis (EFO_0000676), Postmenopausal Osteoporosis (EFO_0003854), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Klinefelter'S Syndrome (EFO_1001006), Myelodysplastic Syndrome (EFO_0000198), Mouth Neoplasm (EFO_0003868), Psoriasis Vulgaris (EFO_1001494), Prostate Adenocarcinoma (EFO_0000673), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Breast Cancer (MONDO_0007254), Hypertension (EFO_0000537), Renal Osteodystrophy (EFO_1001152), Attention Deficit Hyperactivity Disorder (EFO_0003888), Basal Cell Carcinoma (EFO_0004193), Cholangiocarcinoma (EFO_0005221), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Sepsis (HP_0100806), Hypoparathyroidism (EFO_0009451), Fibroma (EFO_0002424), Chronic Kidney Disease (EFO_0003884), Diabetic Nephropathy (EFO_0000401), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Hypophosphatemic Rickets (MONDO_0024300), Prediabetes Syndrome (EFO_1001121), Acute Kidney Injury (HP_0001919), Type 1 Diabetes Mellitus (MONDO_0005147), Hypocalcemia (HP_0002901), X-Linked Hypophosphatemia (Orphanet_89936), Osteopetrosis (MONDO_0017198)", 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5360', 'drugName': 'Tretinoin', 'tradeNames_string': 'Acticin, Altreno, Atralin, Avita, Renova, Retin-a, Retin-a micro, Retin-a-micro, Tretin-X, Tretinoin, Vesanoid', 'drugSynonyms_string': 'Aberel, All-trans retinoic acid, All-trans-retinoic acid, Eudyna, Kerlocal, NSC-122758, Oristar rna, Retin a, Retinoic acid, Tretinoin', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Rosacea (EFO_1000760), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Adenoid Cystic Carcinoma (EFO_0000231), Myelodysplastic Syndrome (EFO_0000198), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Freckles (EFO_0003963), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Basal Cell Carcinoma (EFO_0004193), Acne (EFO_0003894), Emphysema (EFO_0000464), Pancreatic Carcinoma (EFO_0002618), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Small Cell Lung Carcinoma (EFO_0000702), Actinic Keratosis (EFO_0002496), Hypercholesterolemia (HP_0003124), Anemia (MONDO_0002280), Cutaneous Melanoma (EFO_0000389), Autoimmune Thrombocytopenia (MONDO_0019098), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Amyotrophic Lateral Sclerosis (MONDO_0004976), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Myeloproliferative Disorder (EFO_0004251), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Sclerosing Cholangitis (EFO_0004268), Lentigo (MONDO_0021582), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Striae Distensae (HP_0001065)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_757', 'drugName': 'Pentobarbital Sodium', 'tradeNames_string': 'Beuthanasia, Euthanase, Euthatal, Nembutal, Nembutal sodium, Pentobarbital sodium, Pentobarbitone Sodium, Sagatal, Sodium pentobarbital', 'drugSynonyms_string': 'Auropan, Barpental, Biosedan, Diabutal, Embutal, Entobar, Etaminal sodium, Ethaminal sodium, Euthanyl, Euthatal, Isobarb, Mebubarbital sodium, Mebumal sodium, NSC-10816, Napental, Narcoren, Pacifan, Pental, Pentobarbital sodium, Pentobarbital sodium salt, Pentobarbitone sodium, Pentonal, Pentone, Praecicalm, Rs-pentobarbital sodium, Sagatal, Sodium ethaminal, Sodium nembutal, Sodium pental, Sodium pentobarbitone, Sodium pentobarbiturate, Sodium-pent, Soluble pentobarbital, Somnopentyl, Somnotol, Sopental, Sotyl, V-pento, Vetbutal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_2327', 'drugName': 'Pentobarbital', 'tradeNames_string': 'Nembutal', 'drugSynonyms_string': 'Mebubarbital, Mebumal, NSC-28708, Pentobarbital, Pentobarbital calcium, Pentobarbital cii, Pentobarbitone', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Drug Dependence (EFO_0003890), Brain Injury (MONDO_0043510), Insomnia (EFO_0004698), Status Epilepticus (EFO_0008526)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_5343', 'drugName': 'Procainamide', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-27461, Novocainamide, Procainamide, Procan, Procanbid, Procapan, Pronestyl, Pronestyl-SR, Sp 100 (pharmaceutical)', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Ventricular Fibrillation (EFO_0004287), Myocardial Infarction (EFO_0000612), Sudden Cardiac Arrest (EFO_0004278), Cardiac Arrhythmia (EFO_0004269), Ventricular Arrhythmia (HP_0004308), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4516', 'drugName': 'Felodipine', 'tradeNames_string': 'Cabren, Cardioplen xl, Felodipine, Felogen xl, Felotens xl, Folpik xl, Keloc sr, Neofel xl, Parmid xl, Pinefeld xl, Plendil, Preslow, Vascalpha', 'drugSynonyms_string': 'C08CA02, Felodipine, H 154/82, H-154/82, NSC-760343', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3465', 'drugName': 'Nifedipine', 'tradeNames_string': 'Adalat, Adalat a.r., Adalat cc, Adalat ic, Adalat la 20, Adalat la 30, Adalat la 60, Adalat ret, Adalate lp, Adanif xl, Adipine mr 10, Adipine mr 20, Adipine xl, Afeditab cr, Angiopine 10, Angiopine 40 la, Angiopine 5, Angiopine mr 10, Angiopine mr 20, Calanif, Calchan mr 10, Calchan mr 20, Calcilat, Cardilate mr, Coracten sr, Coracten xl, Coroday mr, Fortipine la40, Genalat 10 ret, Genalat 20 ret, Hypolar ret 10, Hypolar ret 20, Hypolar xl 30, Kentipine, Kentipine mr 10, Kentipine mr 20, Neozipine xl, Nife-wolff, Nifedipine, Nifedipress mr 10, Nifedipress mr 20, Nifedotard 20 mr, Nifelease, Nifensar xl, Nifopress mr, Nifopress ret, Nimodrel mr 10, Nimodrel mr 20, Nimodrel xl, Nivaten ret, Procardia, Procardia xl, Slofedipine xl 30, Slofedipine xl 60, Tensipine mr 10, Tensipine mr 20, Unipine xl, Valni 20 ret, Valni xl, Vasad', 'drugSynonyms_string': 'BAY A 1040, BAY-A-1040, Coracten, NSC-757242, Nifedipine, Nifedipine hydrochloride, Nifedipine slow release, Nifedipinum', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Preeclampsia (EFO_0000668), Premature Birth (EFO_0003917), Drug Dependence (EFO_0003890), Diabetic Nephropathy (EFO_0000401), Anal Fissure (HP_0012390), Pulmonary Hypertension (MONDO_0005149), Coronary Vasospasm (EFO_0004225), Congenital Adrenal Hyperplasia (MONDO_0018479), Raynaud Disease (EFO_1001145), Cardiovascular Disease (EFO_0000319), Hypertension (EFO_0000537), Proteinuria (HP_0000093), Partial Epilepsy (EFO_0004263), Placenta Praevia (EFO_0007442), Anus Disease (EFO_0009660), Nephrolithiasis (EFO_0004253), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_575', 'drugName': 'Lacidipine', 'tradeNames_string': 'Caldine, Molap, Motens', 'drugSynonyms_string': "3,3'-iminobispropylamine, 3,3'-iminodipropylamine, 4-azaheptamethylenediamine, Dipropylamine, 3,3'-diamino-, Dipropylenetriamine, GR 43659X, GR-43659X, Lacidipine, NSC-7773", 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Angina Pectoris (EFO_0003913), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3742', 'drugName': 'Idelalisib', 'tradeNames_string': 'Zydelig', 'drugSynonyms_string': 'CAL-101, GS-1101, GS-11CAL-101, Idelalisib', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Lymphoplasmacytic Lymphoma (MONDO_0000432), Allergic Rhinitis (EFO_0005854), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Hodgkins Lymphoma (EFO_0000183), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_843', 'drugName': 'Heparin Calcium', 'tradeNames_string': 'Calciparine, Uniparin ca', 'drugSynonyms_string': 'Ecasolv, Heparin calcium, Heparin calcium salt, Heparinum calcicum', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Henoch-Schoenlein Purpura (EFO_1000965), Eye Disease (EFO_0003966), Habitual Abortion (EFO_1000954), Varicose Veins (HP_0002619)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6208', 'drugName': 'Tulobuterol', 'tradeNames_string': 'Brelomax, Respacal', 'drugSynonyms_string': 'Atenos, Berachin, Bremax, Chlibamol, Hokunalin, Lobuterol, NSC-758643, Tulobuterol, Tulobuterol hcl, Tulobuterol hydrochloride', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_997', 'drugName': 'Aflibercept', 'tradeNames_string': 'Eylea, Zaltrap', 'drugSynonyms_string': 'ABP-938, AVE-0005, AVE0005, Aflibercept, Aflibercept (genetical recombination), Aflibercept beta, Aflibercept biosimilar (amgen), Aflibercept recombinant, BAY-86-5321, BAY-865321, BAY86-5321, VEGF TRAP, Vegf trap-eye, Ziv-aflibercept', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Macular Degeneration (EFO_0009606), Non-Hodgkins Lymphoma (EFO_0005952), Retinal Vein Occlusion (EFO_1001157), Mixed Glioma (MONDO_0003268), Wet Macular Degeneration (EFO_0004683), Metastatic Melanoma (EFO_0002617), Glaucoma (MONDO_0005041), Colorectal Carcinoma (EFO_1001951), Retinopathy (EFO_0003839), Telangiectasis (MONDO_0001576), Malignant Colon Neoplasm (MONDO_0021063), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Graves Ophthalmopathy (EFO_1001466), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Diabetic Retinopathy (EFO_0003770), Lymphoma (EFO_0000574), Histoplasmosis (EFO_0007310), Ocular Vascular Disease (EFO_0005753), Urethra Cancer (MONDO_0004192), Vitreous Hemorrhage (EFO_0008626), Retinopathy Of Prematurity (EFO_1001158), Endometrial Carcinoma (EFO_1001512), Anaplastic Oligodendroglioma (EFO_0002501), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Central Serous Retinopathy (EFO_0009784), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Neovascular Glaucoma (EFO_1001060), Cutaneous Melanoma (EFO_0000389), Age-Related Macular Degeneration (EFO_0001365), Macular Retinal Edema (MONDO_0003005), Rectum Cancer (EFO_1000657), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Pseudoxanthoma Elasticum (Orphanet_758), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Corneal Neovascularization (EFO_1000880), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pathological Myopia (EFO_0004207)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VEGFA (ENSG00000112715), PGF (ENSG00000119630)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3681', 'drugName': 'Rilonacept', 'tradeNames_string': 'Arcalyst', 'drugSynonyms_string': 'IL-1 TRAP, IL-1-TRAP, INTERLEUKIN-1 TRAP, KPL-914, Kpl-914, Rilonacept', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Hepatitis, Alcoholic (EFO_1001345), Muckle-Wells Syndrome (MONDO_0008633), Juvenile Idiopathic Arthritis (EFO_0002609), Pericarditis (EFO_0007427), Hearing Loss (EFO_0004238), Cryopyrin-Associated Periodic Syndrome (MONDO_0016168), Type 1 Diabetes Mellitus (MONDO_0005147), Immune System Disease (EFO_0000540), Familial Mediterranean Fever (MONDO_0018088), Familial Cold Urticaria (Orphanet_47045), Diffuse Scleroderma (EFO_0000404)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL1B (ENSG00000125538)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4356', 'drugName': 'Verapamil Hydrochloride', 'tradeNames_string': 'Berkatens, Calan, Calan sr, Cordilox, Cordilox i.v., Cordilox mr 240, Covera, Covera-hs, Ethimil mr 240, Geangin, Half securon sr, Isoptin, Isoptin Sr, Manidon sr, Ranvera mr, Securon, Securon iv, Securon mid, Securon sr, Univer, Vera-til sr, Verapamil hydrochloride, Verapress mr 240, Verelan, Verelan pm, Vertab sr 240, Zolvera', 'drugSynonyms_string': 'CP-16533-1, LU-20175, NSC-272366, NSC-657799, Verapamil hcl, Verapamil hydrochloride, Verapamili hydrochloridum', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Hodgkins Lymphoma (EFO_0000183), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2954', 'drugName': 'Alteplase', 'tradeNames_string': 'Actilyse, Actilyse cathflo, Activase, Cathflo activase', 'drugSynonyms_string': 'Alteplase, Alteplase (genetical recombination), Alteplase for injection, Alteplase, recombinant, Alteplase,recombinant, Ec 3.4.21.68, RT-PA, Tissue plasminogen activator alteplase', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Retinal Vein Occlusion (EFO_1001157), Cerebral Infarction (MONDO_0002679), Nervous System Disease (EFO_0000618), Eye Disease (EFO_0003966), Covid-19 (MONDO_0100096), Hemorrhage (MP_0001914), Pulmonary Embolism (EFO_0003827), Pleural Empyema (EFO_0009680), Bronchitis (EFO_0009661), Myocardial Ischemia (EFO_1001375), Recurrent Thrombophlebitis (HP_0004419), Congestive Heart Failure (EFO_0000373), Ischemic Stroke (HP_0002140), Angina Pectoris (EFO_0003913), Intracerebral Hemorrhage (EFO_0005669), Empyema (EFO_0003097), Brain Ischemia (MONDO_0005299), Acute Respiratory Distress Syndrome (EFO_1000637), Thrombotic Disease (MONDO_0000831), Urinary Retention (HP_0000016), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Subarachnoid Hemorrhage (EFO_0000713), Thrombophlebitis (HP_0004418), Abdominal Abscess (EFO_1001753), Neoplasm (EFO_0000616), Deep Vein Thrombosis (EFO_0003907), Heart Failure (EFO_0003144), Retinal Artery Occlusion (EFO_1001154), Abscess (EFO_0003030), Severe Acute Respiratory Syndrome (EFO_0000694)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PLG (ENSG00000122194)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6001', 'drugName': 'Belimumab', 'tradeNames_string': 'Benlysta, Lymphostat-b, Lymphostat-b benlysta', 'drugSynonyms_string': 'BEL-114333, BEL114333, Belimumab, Belimumab (genetical recombination), GSK-1550188, GSK1550188, HGS-1006, HGS1006', 'linkedDiseasesDrug_string': 'Nephrotic Syndrome (EFO_0004255), Lymphopenia (MONDO_0003783), Chronic Lymphocytic Leukemia (EFO_0000095), Immune System Disease (EFO_0000540), Systemic Scleroderma (EFO_0000717), Multiple Sclerosis (MONDO_0005301), Sjogren Syndrome (EFO_0000699), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Graft Versus Host Disease (MONDO_0013730), Neuromyelitis Optica (EFO_0004256), Emphysema (EFO_0000464), Vasculitis (EFO_0006803), Systemic Lupus Erythematosus (MONDO_0007915), Myositis (EFO_0000783), Rheumatoid Arthritis (EFO_0000685), Antiphospholipid Syndrome (EFO_0002689), Lupus Nephritis (EFO_0005761), Membranous Glomerulonephritis (EFO_0004254)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TNFSF13B (ENSG00000102524)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3935', 'drugName': 'Velcalcetide', 'tradeNames_string': 'Parsabiv', 'drugSynonyms_string': 'AMG-416, Amg416, Etelcalcetide, KAI-4169, ONO-5163, Telcalcetide, Velcalcetide', 'linkedDiseasesDrug_string': 'Parathyroid Disease (EFO_0005754), Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CASR (ENSG00000036828)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.954 | Q17 | What gene does the drug Rapacuronium target? | The drug Rapacuronium targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rapacuronium%" OR LOWER(tradeNames_string) LIKE "%rapacuronium%" OR LOWER(drugSynonyms_string) LIKE "%rapacuronium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5014', 'drugName': 'Rapacuronium', 'tradeNames_string': '', 'drugSynonyms_string': 'Rapacuronium, Rapacuronium cation, Rapacuronium ion', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5464', 'drugName': 'Rapacuronium Bromide', 'tradeNames_string': 'Raplon', 'drugSynonyms_string': 'ORG 9487, ORG-9487, Rapacuronium bromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.172 | Q17 | What gene does the drug Betamethasone Valerate target? | The drug Betamethasone Valerate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betamethasone valerate%" OR LOWER(tradeNames_string) LIKE "%betamethasone valerate%" OR LOWER(drugSynonyms_string) LIKE "%betamethasone valerate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5710', 'drugName': 'Betamethasone Valerate', 'tradeNames_string': 'Audavate, Audavate rd, Beta-val, Betacap, Betaderm, Betameth val in coal tar, Betamethasone valerate, Betatrex, Betesil, Betnovate rd, Betnovate-c, Betnovate-n, Bettamousse, Bextasol, Dermabet, Fucibet, Luxiq, Valisone, Valnac, Xemacort', 'drugSynonyms_string': 'Betamethasone (as valerate), Betamethasone 17-valerate, Betamethasone valerate, Betamethasoni valeras, NSC-755912, Rinderon v, Stanoval, Tokuderm', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Atopic Eczema (EFO_0000274), Airway Obstruction (HP_0006536), Skin Disease (EFO_0000701), Oral Submucous Fibrosis (EFO_1001818), Nasal Congestion (HP_0001742), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1406 | Q17 | What gene does the drug Triciribine Phosphate target? | The drug Triciribine Phosphate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: AKT2, AKT1 and AKT3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triciribine phosphate%" OR LOWER(tradeNames_string) LIKE "%triciribine phosphate%" OR LOWER(drugSynonyms_string) LIKE "%triciribine phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_511', 'drugName': 'Triciribine Phosphate', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-154020, NSC-280594, Phosphate salt of tricyclic nucleoside, Triciribine, Triciribine phosphate, Vqd-002', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Ovarian Cancer (MONDO_0008170), Leukemia (EFO_0000565)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'AKT2 (ENSG00000105221), AKT3 (ENSG00000117020), AKT1 (ENSG00000142208)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1207 | Q17 | What gene does the drug Lisinopril target? | The drug Lisinopril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lisinopril%" OR LOWER(tradeNames_string) LIKE "%lisinopril%" OR LOWER(drugSynonyms_string) LIKE "%lisinopril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1473', 'drugName': 'Lisinopril', 'tradeNames_string': 'Prinivil, Zestril', 'drugSynonyms_string': 'Lisinopril, MK-521, NSC-751176, NSC-758151', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Essential Hypertension (MONDO_0001134), Glomerulonephritis (MONDO_0002462), Azoospermia (EFO_0000279), Systemic Lupus Erythematosus (MONDO_0007915), Gastroparesis (EFO_1000948), Focal Segmental Glomerulosclerosis (EFO_0004236), Myocardial Ischemia (EFO_1001375), Hepatocellular Carcinoma (EFO_0000182), Congestive Heart Failure (EFO_0000373), Breast Cancer (MONDO_0007254), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Fish-Eye Disease (Orphanet_79292), Non-Alcoholic Steatohepatitis (EFO_1001249), Stroke (EFO_0000712), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Primary Hyperoxaluria (MONDO_0002474), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Polycystic Kidney Disease (EFO_0008620), Vascular Disease (EFO_0004264), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_656', 'drugName': 'Lisinopril', 'tradeNames_string': 'Acemin, Carace, Lisinopril, Lisopress, Prinivil, Qbrelis, Zestril', 'drugSynonyms_string': 'Lisinopril, Lisinopril dihydrate, Lisinopril hydrate, MK-521, Ranolip', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Congestive Heart Failure (EFO_0000373), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1263 | Q17 | What gene does the drug Nusinersen target? | The drug Nusinersen targets the gene SMN2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nusinersen%" OR LOWER(tradeNames_string) LIKE "%nusinersen%" OR LOWER(drugSynonyms_string) LIKE "%nusinersen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2674', 'drugName': 'Nusinersen', 'tradeNames_string': '', 'drugSynonyms_string': 'BIIB-058, BIIB058, ISIS 396443, ISIS-396443, Nusinersen', 'linkedDiseasesDrug_string': 'Spinal Muscular Atrophy (EFO_0008525)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMN2 (ENSG00000205571)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6328', 'drugName': 'Nusinersen Sodium', 'tradeNames_string': 'Spinraza', 'drugSynonyms_string': 'Nusinersen sodium', 'linkedDiseasesDrug_string': 'Spinal Muscular Atrophy (EFO_0008525)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMN2 (ENSG00000205571)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1400 | Q17 | What gene does the drug Caplacizumab target? | The drug Caplacizumab targets the gene VWF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%caplacizumab%" OR LOWER(tradeNames_string) LIKE "%caplacizumab%" OR LOWER(drugSynonyms_string) LIKE "%caplacizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5507', 'drugName': 'Caplacizumab', 'tradeNames_string': 'Cablivi', 'drugSynonyms_string': 'ALX-0081, Caplacizumab, Caplacizumab yhdp, Caplacizumab-yhdp', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Acquired Thrombotic Thrombocytopenic Purpura (MONDO_0019740)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VWF (ENSG00000110799)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.920 | Q17 | What gene does the drug Efaproxiral target? | The drug Efaproxiral is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: HBB, HBA2 and HBA1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%efaproxiral%" OR LOWER(tradeNames_string) LIKE "%efaproxiral%" OR LOWER(drugSynonyms_string) LIKE "%efaproxiral%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5816', 'drugName': 'Efaproxiral', 'tradeNames_string': '', 'drugSynonyms_string': 'Efaproxiral, RSR-13, RSR13', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Breast Cancer (MONDO_0007254), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HBA1 (ENSG00000206172), HBA2 (ENSG00000188536), HBB (ENSG00000244734)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.497 | Q17 | What gene does the drug Acrivastine target? | The drug Acrivastine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acrivastine%" OR LOWER(tradeNames_string) LIKE "%acrivastine%" OR LOWER(drugSynonyms_string) LIKE "%acrivastine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2524', 'drugName': 'Acrivastine', 'tradeNames_string': 'Benadryl allgy relief plus decongest, Semprex', 'drugSynonyms_string': 'Acrivastine, BW 825C, BW-825C', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.962 | Q17 | What gene does the drug Dexketoprofen target? | The drug Dexketoprofen targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexketoprofen%" OR LOWER(tradeNames_string) LIKE "%dexketoprofen%" OR LOWER(drugSynonyms_string) LIKE "%dexketoprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5314', 'drugName': 'Dexketoprofen', 'tradeNames_string': 'Keral', 'drugSynonyms_string': '(s)-ketoprofen, Arveles, Dexketoprofen, Ketoprofen, (s)-', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755), Arthralgia (HP_0002829), Pain (EFO_0003843), Low Back Pain (HP_0003419), Myalgia (HP_0003326)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1106 | Q17 | What gene does the drug Dipyridamole target? | The drug Dipyridamole targets 24 genes: PDE6D, PDE9A, PDE6H, PDE4D, PDE4B, PDE1B, PDE6B, PDE6A, PDE5A, PDE10A, PDE1A, PDE8A, PDE2A, PDE6G, PDE4C, PDE7A, PDE3A, PDE7B, PDE1C, SLC29A1, PDE3B, PDE4A, PDE6C and PDE8B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dipyridamole%" OR LOWER(tradeNames_string) LIKE "%dipyridamole%" OR LOWER(drugSynonyms_string) LIKE "%dipyridamole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6106', 'drugName': 'Dipyridamole', 'tradeNames_string': 'Attia, Cerebrovase 100, Cerebrovase 25, Dipyridamole, Iv persantine, Modaplate, Ofcram pr, Persantin, Persantin ret, Persantine, Pyridantin, Vasyrol', 'drugSynonyms_string': 'B01AC07, Dipyridamole, NSC-515776, RA-8', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Recurrent Thrombophlebitis (HP_0004419), Takotsubo Cardiomyopathy (EFO_1002000), Heart Disease (EFO_0003777), Coronary Artery Disease (EFO_0001645), Hiv Infection (EFO_0000764), Angina Pectoris (EFO_0003913), Henoch-Schoenlein Purpura (EFO_1000965), Internal Carotid Artery Stenosis (EFO_0002615), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Sickle Cell Anemia (MONDO_0011382), Hypertension (EFO_0000537), Rheumatoid Arthritis (EFO_0000685), Ovarian Cancer (MONDO_0008170), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'numberLinkedTargets': 24}, {'UUID': 'DrugGeneTargets_v2_6107', 'drugName': 'Dipyridamole', 'tradeNames_string': 'Attia, Cerebrovase 100, Cerebrovase 25, Dipyridamole, Iv persantine, Modaplate, Ofcram pr, Persantin, Persantin ret, Persantine, Pyridantin, Vasyrol', 'drugSynonyms_string': 'B01AC07, Dipyridamole, NSC-515776, RA-8', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Recurrent Thrombophlebitis (HP_0004419), Takotsubo Cardiomyopathy (EFO_1002000), Heart Disease (EFO_0003777), Coronary Artery Disease (EFO_0001645), Hiv Infection (EFO_0000764), Angina Pectoris (EFO_0003913), Henoch-Schoenlein Purpura (EFO_1000965), Internal Carotid Artery Stenosis (EFO_0002615), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Sickle Cell Anemia (MONDO_0011382), Hypertension (EFO_0000537), Rheumatoid Arthritis (EFO_0000685), Ovarian Cancer (MONDO_0008170), Myocardial Ischemia (EFO_1001375)', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE5A (ENSG00000138735), PDE4A (ENSG00000065989), PDE3A (ENSG00000172572), PDE6H (ENSG00000139053), PDE6G (ENSG00000185527), PDE2A (ENSG00000186642), PDE7A (ENSG00000205268), PDE1A (ENSG00000115252), PDE9A (ENSG00000160191), PDE6B (ENSG00000133256), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE6D (ENSG00000156973), PDE6A (ENSG00000132915), PDE3B (ENSG00000152270), PDE6C (ENSG00000095464), PDE8B (ENSG00000113231), PDE10A (ENSG00000112541), PDE1B (ENSG00000123360), PDE4C (ENSG00000105650), PDE1C (ENSG00000154678), PDE8A (ENSG00000073417), PDE7B (ENSG00000171408), SLC29A1 (ENSG00000112759)', 'numberLinkedTargets': 24}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1041 | Q17 | What gene does the drug Elexacaftor target? | The drug Elexacaftor targets the gene CFTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%elexacaftor%" OR LOWER(tradeNames_string) LIKE "%elexacaftor%" OR LOWER(drugSynonyms_string) LIKE "%elexacaftor%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_133', 'drugName': 'Elexacaftor', 'tradeNames_string': '', 'drugSynonyms_string': '3-PYRIDINECARBOXAMIDE, N-((1,3-DIMETHYL-1H-PYRAZOL-4-YL)SULFONYL)-6-(3-(3,3,3-TRIFLUORO-2,2-DIMETHYLPROPOXY)-1H-PYRAZOL-1-YL)-2-((4S)-2,2,4-TRIMETHYL-1-PYRROLIDINYL)-, Elexacaftor, VX-445, Vx-445', 'linkedDiseasesDrug_string': 'Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CFTR (ENSG00000001626)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.594 | Q17 | What gene does the drug Indoprofen target? | The drug Indoprofen targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%indoprofen%" OR LOWER(tradeNames_string) LIKE "%indoprofen%" OR LOWER(drugSynonyms_string) LIKE "%indoprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4357', 'drugName': 'Indoprofen', 'tradeNames_string': '', 'drugSynonyms_string': 'Bor-ind, Flosin, Flosint, Indoprofen, Isindone, K 4277, K-4277, NSC-757065, Praxis, Reumofene', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.757 | Q17 | What gene does the drug Lidocaine target? | The drug Lidocaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lidocaine%" OR LOWER(tradeNames_string) LIKE "%lidocaine%" OR LOWER(drugSynonyms_string) LIKE "%lidocaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5933', 'drugName': 'Lidocaine', 'tradeNames_string': 'Alphacaine, Anestacon, Dentipatch, Lidocaine, Lidoderm, Lignocaine Hcl, Lignostab, Lmx 4, Oraqix, Vagisil, Xylocaine, Xylodase, Xylotox, Ztlido', 'drugSynonyms_string': 'ALGRX 3268, ALGRX-3268, Anestacon, Embolex, Iontocaine, Lidocaine, Lidocainum, Lidocaton, Lidopen, Lignocaine, NSC-40030, Octocaine, Solarcaine, Xylestesin', 'linkedDiseasesDrug_string': 'Postmenopausal Osteoporosis (EFO_0003854), Migraine Disorder (MONDO_0005277), Pregnancy (EFO_0002950), Scleroderma (EFO_1001993), Neuroma (EFO_0009619), Hypertension (EFO_0000537), Neuropathic Pain (EFO_0005762), Renal Colic (EFO_1001412), Brain Neoplasm (EFO_0003833), Anus Disease (EFO_0009660), Carcinoma (EFO_0000313), Humerus Fracture (EFO_0003943), Liver Cancer (MONDO_0002691), Extramammary Paget Disease (EFO_1000249), Myalgia (HP_0003326), Heart Disease (EFO_0003777), Lung Cancer (MONDO_0008903), Diabetic Neuropathy (EFO_1000783), Interstitial Cystitis (EFO_0008507), Burn (EFO_0009516), Glioblastoma Multiforme (EFO_0000519), Myofascial Pain Syndrome (EFO_1001054), Cancer (MONDO_0004992), Tendinopathy (EFO_1001434), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Anxiety (EFO_0005230), Morbid Obesity (EFO_0001074), Ileus (MONDO_0004567), Dysuria (EFO_0003901), Sinusitis (EFO_0007486), Nutritional Disorder (EFO_0001069), Pharyngitis (MONDO_0002258), Stroke (EFO_0000712), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Actinic Keratosis (EFO_0002496), Urethritis (EFO_0003878), Dysplasia Of Cervix (EFO_1000910), Epicondylitis (EFO_1001887), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Stomatitis (EFO_0009688), Low Back Pain (HP_0003419), Shoulder Impingement Syndrome (EFO_1001178), Neuralgia (EFO_0009430), Diabetes Mellitus (EFO_0000400), Peripheral Neuropathy (EFO_0003100), Carpal Tunnel Syndrome (EFO_0004143), Pulmonary Arterial Hypertension (EFO_0001361), Irritable Bowel Syndrome (EFO_0000555), Shoulder Pain (HP_0030834), Periarthritis (EFO_1001097), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Rotator Cuff Tear (EFO_1001250), Thalassemia (EFO_1001996), Parathyroid Disease (EFO_0005754), Osteoarthritis, Knee (EFO_0004616), Arthritis (EFO_0005856), Non-Allergic Rhinitis (EFO_0009364), Frozen Shoulder (EFO_1000941), Attention Deficit Hyperactivity Disorder (EFO_0003888), Spinal Fracture (EFO_0003902), Fibromyalgia (EFO_0005687), Cardiac Arrhythmia (EFO_0004269), Rib Fracture (EFO_0009620), Sunburn (EFO_0003958), Pancreatic Carcinoma (EFO_0002618), Common Cold (EFO_0007214), Premature Birth (EFO_0003917), Infertility (EFO_0000545), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Urinary Tract Infection (EFO_0003103), Sprain (EFO_0009582), Trigeminal Neuralgia (EFO_1001219), Age-Related Macular Degeneration (EFO_0001365), Leiomyoma (MONDO_0001572), Neoplasm (EFO_0000616), Postherpetic Neuralgia (MONDO_0041052), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Skin Disease (EFO_0000701), Oral Mucositis (EFO_1001904), Morton Neuroma (EFO_0010582), Lateral Epicondylitis (EFO_1001896), Complex Regional Pain Syndrome (EFO_1001998), Overactive Bladder (EFO_1000781), Covid-19 (MONDO_0100096), Cough (HP_0012735), Muscle Spasm (HP_0003394), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Parathyroid Adenoma (EFO_1001087), Radius Fracture (EFO_0003957), Breast Carcinoma (EFO_0000305), Muscular Disease (EFO_0002970), Colorectal Neoplasm (EFO_0004142), Septic Shock (EFO_0006834), Scoliosis (EFO_0004273), Cocaine Dependence (EFO_0002610), Thromboembolism (HP_0001907), Pruritus (HP_0000989), Cardiac Arrest (EFO_0009492), Back Pain (HP_0003418), Inflammation (MP_0001845), Ventricular Arrhythmia (HP_0004308), Skin Neoplasm (EFO_0004198), Urinary Incontinence (HP_0000020), Cystic, Mucinous, And Serous Neoplasm (EFO_1000889), Temporomandibular Joint Disorder (EFO_0005279), Cognitive Impairment (HP_0100543), Squamous Cell Carcinoma (EFO_0000707), Tinnitus (HP_0000360), Abnormality Of The Skin (HP_0000951)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_4126', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_string': 'Akten, Alphacaine hydrochloride, Anestacon, Anodesyn, Bismodyne, Bradosol plus, Calgel, Co-phenylcaine fte, Denela, Dequaspray, Emla, Germoloids, Germoloids complete, Glydo, Hemocane, Iglu, Instillagel, Laryng-o-jet kit, Laryngojet, Laryngotracheal anesthesia kit, Lido hcl, Lidocaine hydrochloride, Lidocaine hydrochloride preservative free, Lidocaine hydrochloride viscous, Lidocaine viscous, Lidocaton, Lidopen, Lignokent, Lignospan special, Lignostab, Lignostab a 100, Lignostab n, Lignostab-a, Lta ii kit, Medijel, Oragard, Pediatric lta kit, Preparation h, Rexocaine, Versatis, Xylocaine, Xylocaine dental, Xylocaine preservative free, Xylocaine viscous, Xylotox e80, Zingo', 'drugSynonyms_string': 'Anhydrous lidocaine hydrochloride, Lidocaine hcl, Lidocaine hydrochloride, Lidocaine hydrochloride anhydrous, Lidocaine hydrochloride monohydrate, Lidocaine hydrochloride usp, Lidocaini hydrochloridum, Lignocaine (as hydrochloride), Lignocaine hydrochloride, NSC-757420, Xylocaine hydrochloride', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Injury (EFO_0000546), Pregnancy (EFO_0002950), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Rotator Cuff Tear (EFO_1001250), Thalassemia (EFO_1001996), Hypertension (EFO_0000537), Pruritus (HP_0000989), Pancreatic Carcinoma (EFO_0002618), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Back Pain (HP_0003418), Liver Cancer (MONDO_0002691), Chronic Pain (HP_0012532), Mucositis (EFO_1001898)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.664 | Q17 | What gene does the drug Ramelteon target? | The drug Ramelteon targets 2 genes: MTNR1B and MTNR1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ramelteon%" OR LOWER(tradeNames_string) LIKE "%ramelteon%" OR LOWER(drugSynonyms_string) LIKE "%ramelteon%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5938', 'drugName': 'Ramelteon', 'tradeNames_string': 'Ramelteon, Rozerem', 'drugSynonyms_string': 'Ramelteon, TAK-375, TAK375', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Drug Dependence (EFO_0003890), Migraine With Aura (MONDO_0005475), Migraine Without Aura (MONDO_0100431), Nicotine Dependence (EFO_0003768), Obstructive Sleep Apnea (EFO_0003918), Burn (EFO_0009516), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cannabis Dependence (EFO_0007191), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTNR1A (ENSG00000168412), MTNR1B (ENSG00000134640)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.237 | Q17 | What gene does the drug Promazine target? | The drug Promazine targets 4 genes: DRD3, HTR2A, DRD4 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%promazine%" OR LOWER(tradeNames_string) LIKE "%promazine%" OR LOWER(drugSynonyms_string) LIKE "%promazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3300', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_string': 'Apo-go, Apo-go pen, Apo-go pfs, Apokyn, Apomorph hcl, Britaject, Bromophin, Dacepton, Diagesil, Diamorph hcl, Diamorph roche, Diamorph,cocaine,chlorpromazine, Diaphine, Euphorin, Kynmobi, Uprima', 'drugSynonyms_string': 'Apokinon, Apomine, Apomorphine HCl, Apomorphine hcl, Apomorphine hydrochloride, Apomorphine hydrochloride hemihydrate, Apomorphine hydrochloride hydrate, Apomorphinum muriaticum, Diamorphine hydrochloride , Ixense, Kw-6500, NSC-11442, NSC-755875, Taluvian', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Osteoporosis (EFO_0003882), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4039', 'drugName': 'Promazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Combelen, NSC-31447, Promazine', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4040', 'drugName': 'Promazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Combelen, NSC-31447, Promazine', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_36', 'drugName': 'Promazine Hydrochloride', 'tradeNames_string': 'Prazine, Promazine Granules, Promazine hydrochloride, Protactyl, Sparine, Tranquazine, Verophene', 'drugSynonyms_string': 'NSC-17468, Promazine chloride, Promazine hcl, Promazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2783', 'drugName': 'Chlorpromazine Hydrochloride', 'tradeNames_string': 'Chloractil, Chlorazine, Chlorpromazine hydrochloride, Chlorpromazine hydrochloride intensol, Largactil, Largactil fte, Promapar, Rimazine, Sonazine, Thorazine', 'drugSynonyms_string': 'Chlorpromazine HCl, Chlorpromazine hcl, Chlorpromazine hydrochloride, Chlorpromazini hydrochloridum, Klorproman, Marazine, NSC-17479, Nci-c05210, Norcozine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2784', 'drugName': 'Chlorpromazine Hydrochloride', 'tradeNames_string': 'Chloractil, Chlorazine, Chlorpromazine hydrochloride, Chlorpromazine hydrochloride intensol, Largactil, Largactil fte, Promapar, Rimazine, Sonazine, Thorazine', 'drugSynonyms_string': 'Chlorpromazine HCl, Chlorpromazine hcl, Chlorpromazine hydrochloride, Chlorpromazini hydrochloridum, Klorproman, Marazine, NSC-17479, Nci-c05210, Norcozine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2990', 'drugName': 'Chlorpromazine', 'tradeNames_string': 'Elmarin, Largactil, Megaphen, Thorazine', 'drugSynonyms_string': 'Aminazine, Chlorpromazine, Chlorpromazine hibenzate, Chlorpromazine phenolphthalinate, Chlorpromazine tannate, Chlorpromazinum, Esmind, Fenactil, J2.794D, Largactilothiazine, NSC-167745, NSC-226514, Novomazina, Propaphenin, SKF-2601A, Sanopron, Sonazine, Wintermin', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Porphyria (MONDO_0037939), Mental Or Behavioural Disorder (EFO_0000677), Nausea And Vomiting (HP_0002017), Neonatal Abstinence Syndrome (EFO_0005799), Delirium (EFO_0009267), Covid-19 (MONDO_0100096), Schizophrenia (MONDO_0005090), Glioblastoma Multiforme (EFO_0000519), Conduct Disorder (EFO_0004216), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_3705', 'drugName': 'Trimeprazine Tartrate', 'tradeNames_string': 'Temaril, Trimeprazine tartrate, Vallergan, Vallergan fte', 'drugSynonyms_string': 'Alimemazine hemitartrate, Alimemazine tartrate, Methylpromazine tartrate, NSC-17475, NSC-757358, Panectyl, Repeltin, Theralene, Trimeprazine hemitartrate, Trimeprazine tartrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4009', 'drugName': 'Triflupromazine Hydrochloride', 'tradeNames_string': 'Vesprin', 'drugSynonyms_string': 'MC-4703, NSC-14959, NSC-17473, Triflupromazine hcl, Triflupromazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_203', 'drugName': 'Triflupromazine', 'tradeNames_string': 'Fluopromazine, Nivoman, Vesprin, Vetame', 'drugSynonyms_string': 'Fluopromazine, Triflupromazine', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_37', 'drugName': 'Promazine Hydrochloride', 'tradeNames_string': 'Prazine, Promazine Granules, Promazine hydrochloride, Protactyl, Sparine, Tranquazine, Verophene', 'drugSynonyms_string': 'NSC-17468, Promazine chloride, Promazine hcl, Promazine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2989', 'drugName': 'Chlorpromazine', 'tradeNames_string': 'Elmarin, Largactil, Megaphen, Thorazine', 'drugSynonyms_string': 'Aminazine, Chlorpromazine, Chlorpromazine hibenzate, Chlorpromazine phenolphthalinate, Chlorpromazine tannate, Chlorpromazinum, Esmind, Fenactil, J2.794D, Largactilothiazine, NSC-167745, NSC-226514, Novomazina, Propaphenin, SKF-2601A, Sanopron, Sonazine, Wintermin', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Porphyria (MONDO_0037939), Mental Or Behavioural Disorder (EFO_0000677), Nausea And Vomiting (HP_0002017), Neonatal Abstinence Syndrome (EFO_0005799), Delirium (EFO_0009267), Covid-19 (MONDO_0100096), Schizophrenia (MONDO_0005090), Glioblastoma Multiforme (EFO_0000519), Conduct Disorder (EFO_0004216), Malignant Colon Neoplasm (MONDO_0021063)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_676', 'drugName': 'Levomepromazine', 'tradeNames_string': 'Levomepromazine, Levoprome, Nirvan, Tisercin', 'drugSynonyms_string': 'CL 36467, CL 39743, CL-36467, CL-39743, Levomepromazine, Methotrimeprazine, N05AA02, NSC-226516, Neozine, Nirvan, RP 7044, RP-7044, SK&F 5116, SK&F-5116, XP-03, XP03', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2846', 'drugName': 'Methylpromazine', 'tradeNames_string': '', 'drugSynonyms_string': 'Alimemazine, BAYER-1219, Dl-trimeprazine, Methylpromazine, RP-6549, Temaril, Trimeprazine', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.739 | Q17 | What gene does the drug Cerivastatin target? | The drug Cerivastatin targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cerivastatin%" OR LOWER(tradeNames_string) LIKE "%cerivastatin%" OR LOWER(drugSynonyms_string) LIKE "%cerivastatin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_877', 'drugName': 'Cerivastatin', 'tradeNames_string': 'Lipobay', 'drugSynonyms_string': 'Baycol, Cerivastatin, Lipobay', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3117', 'drugName': 'Cerivastatin Sodium', 'tradeNames_string': 'Baycol', 'drugSynonyms_string': 'BAY W 6228, BAY-W-6228, Cerivastatin sodium, Cerivastatin sodium salt', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1989 | Q17 | What gene does the drug Isosorbide Mononitrate target? | The drug Isosorbide Mononitrate targets 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isosorbide mononitrate%" OR LOWER(tradeNames_string) LIKE "%isosorbide mononitrate%" OR LOWER(drugSynonyms_string) LIKE "%isosorbide mononitrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2828', 'drugName': 'Isosorbide Mononitrate', 'tradeNames_string': 'Angeze 10, Angeze 20, Angeze 40, Angeze sr 40, Angeze sr 60, Angitate, Astrodur mr, Carmil xl, Chemydur 60 xl, Cibral 10, Cibral 20, Cibral 40, Cibral xl 60, Dynamin, Dynamin xl 25, Dynamin xl 50, Elantan 10, Elantan 20, Elantan 40, Elantan la 25, Elantan la 50, Eumon 40 xl, Eumon 60 xl, Imdur, Imo la, Isib 20, Isib 40, Isib 50 xl, Isib 60 xl, Ismo, Ismo 10, Ismo 20, Ismo 40, Ismo ret, Isodur, Isodur 25 xl, Isodur 50 xl, Isosorbide mononitrate, Isotard 25 xl, Isotard 40 xl, Isotard 50 xl, Isotard 60 xl, Isotrate, Ketanodur, Mcr 50, Modisal 40 xl, Modisal 60 xl, Modisal la 25, Modisal la 50, Monigen xl 60, Monit, Monit ls, Monit sr, Monit xl 60, Mono-cedocard 10, Mono-cedocard 20, Mono-cedocard 40, Monodur, Monoket, Monomax sr 40, Monomax sr 60, Monomax xl, Monomil xl, Monosorb xl 60, Pertil ret, Phasonit la 50, Relosorb xl, Slomon xl 60, Tardisc xl, Tenkosorb, Trangina xl, Vasotrate 60 sr, Xismox xl 60, Zemon 40 xl, Zemon 60 xl, Ziotan xl', 'drugSynonyms_string': '1,1-diureidisobutane, AHR-4698, BM 22.145, BM 22.145IS 5-MNAHR-4698, BM-22-145, BM-22.145, BM-22145, Corangin, Diluted isosorbide mononitrate, IS 5-MN, IS-5-MN, IS-5MN, Iso-5-mononitrate, Isobutyldiurea, Isobutylenediurea, Isosorbide 5-mononitrate, Isosorbide 5-nitrate, Isosorbide dinitrate isosorbide-5-mononitrate, Isosorbide mononitrate, Isosorbide-5-mononitrate, Monocord, NSC-758619', 'linkedDiseasesDrug_string': 'Premature Rupture Of Membranes (HP_0001788), Coronary Artery Disease (EFO_0001645), Angina Pectoris (EFO_0003913), Anal Fissure (HP_0012390), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Vascular Disease (EFO_0004264), Oligohydramnios (EFO_0007401), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1633 | Q17 | What gene does the drug Medroxyprogesterone Acetate target? | The drug Medroxyprogesterone Acetate targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%medroxyprogesterone acetate%" OR LOWER(tradeNames_string) LIKE "%medroxyprogesterone acetate%" OR LOWER(drugSynonyms_string) LIKE "%medroxyprogesterone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2722', 'drugName': 'Medroxyprogesterone Acetate', 'tradeNames_string': 'Adgyn medro, Amen, Climanor, Curretab, Cycrin, Depo-progevera, Depo-provera, Depo-provera oncology, Depo-subq provera 104, Farlutal, Farlutal 100, Farlutal 200, Farlutal 250, Farlutal 500, Lunelle, Medroxyprogesterone acetate, Provera, Sayana press', 'drugSynonyms_string': 'Amen, Depot-medroxyprogesterone acetate, Farlutal inyectable, G03AC06, Medroxiprogesterone acetate, Medroxyprogesterone, Medroxyprogesterone 17-acetate, Medroxyprogesterone Acetate, Medroxyprogesterone acetate, Medroxyprogesteroni acetas, NSC-21171, NSC-26386, NSC-27408, Prempro, Provera, TV-46046', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Hemorrhage (MP_0001914), Pain (EFO_0003843), Systemic Lupus Erythematosus (MONDO_0007915), Myelodysplastic Syndrome (EFO_0000198), Endometrial Cancer (MONDO_0011962), Pregnancy (EFO_0002950), Hot Flashes (HP_0031217), Prostate Adenocarcinoma (EFO_0000673), Myocardial Ischemia (EFO_1001375), Osteoporosis (EFO_0003882), Hypertension (EFO_0000537), Premature Ovarian Insufficiency (HP_0008209), Renal Carcinoma (EFO_0002890), Thrombotic Disease (MONDO_0000831), Endometriosis (EFO_0001065), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Hypercholesterolemia (HP_0003124), Renal Cell Carcinoma (EFO_0000681), Hiv-1 Infection (EFO_0000180), Endometrial Neoplasm (EFO_0004230), Hyperplasia (EFO_0000536), Menorrhagia (HP_0000132), Sleep Apnea (EFO_0003877), Hiv Infection (EFO_0000764), Heart Disease (EFO_0003777), Neoplasm (EFO_0000616), Kidney Cancer (MONDO_0002367)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1166 | Q17 | What gene does the drug Vonoprazan Fumarate target? | The drug Vonoprazan Fumarate targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vonoprazan fumarate%" OR LOWER(tradeNames_string) LIKE "%vonoprazan fumarate%" OR LOWER(drugSynonyms_string) LIKE "%vonoprazan fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5640', 'drugName': 'Vonoprazan Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'TAK-438, TAK-438 monofumarate, Tak 438, Vonoprazan fumarate, Vonoprazan fumurate, Vonoprazan monofumarate', 'linkedDiseasesDrug_string': 'Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Gastroesophageal Reflux Disease (EFO_0003948), Helicobacter Pylori Infectious Disease (EFO_1000961)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1471 | Q17 | What gene does the drug Cc-401 target? | The drug Cc-401 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: MAPK10, MAPK9 and MAPK8 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cc-401%" OR LOWER(tradeNames_string) LIKE "%cc-401%" OR LOWER(drugSynonyms_string) LIKE "%cc-401%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2632', 'drugName': 'Cc-401', 'tradeNames_string': '', 'drugSynonyms_string': 'CC-401, Cc-401', 'linkedDiseasesDrug_string': 'Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK9 (ENSG00000050748), MAPK8 (ENSG00000107643), MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2633', 'drugName': 'Cc-401', 'tradeNames_string': '', 'drugSynonyms_string': 'CC-401, Cc-401', 'linkedDiseasesDrug_string': 'Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK9 (ENSG00000050748), MAPK8 (ENSG00000107643), MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2634', 'drugName': 'Cc-401', 'tradeNames_string': '', 'drugSynonyms_string': 'CC-401, Cc-401', 'linkedDiseasesDrug_string': 'Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK9 (ENSG00000050748), MAPK8 (ENSG00000107643), MAPK10 (ENSG00000109339)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1913 | Q17 | What gene does the drug Bretylium Tosylate target? | The drug Bretylium Tosylate targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bretylium tosylate%" OR LOWER(tradeNames_string) LIKE "%bretylium tosylate%" OR LOWER(drugSynonyms_string) LIKE "%bretylium tosylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_904', 'drugName': 'Bretylium Tosylate', 'tradeNames_string': 'Bretylium tosylate, Bretylol', 'drugSynonyms_string': 'ASL-603, Bretylium tosilate, Bretylium tosylate, NSC-62164', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Ventricular Arrhythmia (HP_0004308), Ventricular Fibrillation (EFO_0004287)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1628 | Q17 | What gene does the drug Mab-425 target? | The drug Mab-425 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mab-425%" OR LOWER(tradeNames_string) LIKE "%mab-425%" OR LOWER(drugSynonyms_string) LIKE "%mab-425%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2082', 'drugName': 'Mab-425', 'tradeNames_string': '', 'drugSynonyms_string': 'MAB-425, Mab-425', 'linkedDiseasesDrug_string': 'Central Nervous System Cancer (EFO_0000326)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.943 | Q17 | What gene does the drug Diclofenac Sodium target? | The drug Diclofenac Sodium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diclofenac sodium%" OR LOWER(tradeNames_string) LIKE "%diclofenac sodium%" OR LOWER(drugSynonyms_string) LIKE "%diclofenac sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2818', 'drugName': 'Diclofenac Sodium', 'tradeNames_string': 'Acoflam, Acoflam ret, Acoflam sr, Arthronac, Arthrotec 50, Arthrotec 75, Closteril 100, Defanac, Defanac retard, Defanac sr, Dexomon ret, Dexomon sr, Diclofenac sodium, Dicloflex, Dicloflex ret, Dicloflex sr, Diclomax ret, Diclomax sr, Diclotard 100 mr, Diclotard 75 mr, Diclovol, Diclovol ret, Diclovol sr, Diclozip 25, Diclozip 50, Difenor xl, Digenac xl 100, Dyloject, Econac, Econac sr, Econac xl, Enstar sr, Enstar xl, Enzed, Fenactol, Fenactol ret, Fenactol sr, Flamatak mr, Flamrase, Flamrase sr, Flexotard mr, Isclofen, Lofensaid 25, Lofensaid 50, Lofensaid ret 100, Lofensaid ret 75, Masidemen, Misofen, Mobigel, Mobigel paineze, Motifene, Pennsaid, Rheumatac ret 75, Rhumalgan, Rhumalgan cr 100, Rhumalgan cr 75, Rhumalgan sr, Rhumalgan xl, Slofenac, Solaraze, Valdic 100 ret, Valdic 75 ret, Valenac, Volraman, Volsaid ret 100, Volsaid ret 75, Voltaren, Voltaren arthritis pain, Voltaren emulgel, Voltaren ret, Voltaren-xr, Voltarene, Voltarene emulgel, Voltarene l.p., Voltarene ret, Voltarol, Voltarol 12 hour emulgel p, Voltarol active, Voltarol emulgel, Voltarol emulgel p, Voltarol gel patch, Voltarol ophtha, Voltarol pain-eze emulgel, Voltarol ret, Voltarol sr', 'drugSynonyms_string': 'Abitren, Benfofen, Dealgic, Deflamat, Delphinac, Diclofenac diethylamine, Diclofenac diethylamine salt, Diclofenac diethylammonium, Diclofenac diethylammonium salt, Diclofenac sod, Diclofenac sodium, Diclofenac sodium salt, Diclomax, Diclophenac sodium, Diclophlogont, Dicloreum, Duravolten, Ecofenac, Effekton, GP 45840, GP-45840, Lexobene, NSC-756725, Neriodin, Novapirina, Primofenac, Prophenatin, Rewodina, Sodium diclofenac, Voldal, Xenid', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Toothache (EFO_0010072), Osteoarthritis (MONDO_0005178), Muscular Disease (EFO_0002970), Anemia (Phenotype) (EFO_0004272), Urinary Bladder Cancer (MONDO_0001187), Hemorrhage (MP_0001914), Pain (EFO_0003843), Chronic Pain (HP_0012532), Radiculopathy (MONDO_0002959), Osteoarthritis, Knee (EFO_0004616), Otitis Externa (EFO_0009560), Actinic Keratosis (EFO_0002496), Sprain (EFO_0009582), Inflammation (MP_0001845), Low Back Pain (HP_0003419), Rheumatoid Arthritis (EFO_0000685), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1219 | Q17 | What gene does the drug Hexafluorenium target? | The drug Hexafluorenium targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hexafluorenium%" OR LOWER(tradeNames_string) LIKE "%hexafluorenium%" OR LOWER(drugSynonyms_string) LIKE "%hexafluorenium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4011', 'drugName': 'Hexafluorenium', 'tradeNames_string': '', 'drugSynonyms_string': 'Hexafluorenium, Hexafluorenium cation, Hexafluorenium ion, Hexafluronium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4592', 'drugName': 'Hexafluorenium Bromide', 'tradeNames_string': 'Mylaxen', 'drugSynonyms_string': 'Hexafluorenium bromide, Hexaflurone bromide, Hexafluronium bromide, NSC-19477', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1074 | Q17 | What gene does the drug Larazotide Acetate target? | The drug Larazotide Acetate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CHRNB4 and CHRNA3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%larazotide acetate%" OR LOWER(tradeNames_string) LIKE "%larazotide acetate%" OR LOWER(drugSynonyms_string) LIKE "%larazotide acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1963', 'drugName': 'Larazotide Acetate', 'tradeNames_string': '', 'drugSynonyms_string': 'AT-1001, AT-1001 (LARAZOTIDE ACETATE), Larazotide acetate', 'linkedDiseasesDrug_string': 'Celiac Disease (EFO_0001060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.111 | Q17 | What gene does the drug Dexmethylphenidate target? | The drug Dexmethylphenidate targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexmethylphenidate%" OR LOWER(tradeNames_string) LIKE "%dexmethylphenidate%" OR LOWER(drugSynonyms_string) LIKE "%dexmethylphenidate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2117', 'drugName': 'Serdexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Serdexmethylphenidate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4161', 'drugName': 'Serdexmethylphenidate Chloride', 'tradeNames_string': '', 'drugSynonyms_string': 'KP415 Cl, Serdexmethylphenidate chloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5957', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5779', 'drugName': 'Dexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexmethylphenidate, Methylphenidate d-threo-form', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5778', 'drugName': 'Dexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexmethylphenidate, Methylphenidate d-threo-form', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4160', 'drugName': 'Serdexmethylphenidate Chloride', 'tradeNames_string': '', 'drugSynonyms_string': 'KP415 Cl, Serdexmethylphenidate chloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2116', 'drugName': 'Serdexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Serdexmethylphenidate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5956', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1944 | Q17 | What gene does the drug Telbermin target? | The drug Telbermin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: FLT1 and KDR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%telbermin%" OR LOWER(tradeNames_string) LIKE "%telbermin%" OR LOWER(drugSynonyms_string) LIKE "%telbermin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3157', 'drugName': 'Telbermin', 'tradeNames_string': '', 'drugSynonyms_string': 'RH VEGF, RH-VEGF, RHVEG-F, RHVEGF, SNN0029, Telbermin, Vegf-a165, Vegf165', 'linkedDiseasesDrug_string': 'Diabetic Foot (EFO_1001459), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), KDR (ENSG00000128052)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.574 | Q17 | What gene does the drug Dextroamphetamine Sulfate target? | The drug Dextroamphetamine Sulfate targets 3 genes: SLC6A2, SLC6A3 and SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dextroamphetamine sulfate%" OR LOWER(tradeNames_string) LIKE "%dextroamphetamine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%dextroamphetamine sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1031', 'drugName': 'Dextroamphetamine Sulfate', 'tradeNames_string': 'Dexampex, Dexedrine, Dextroamphetamine sulfate, Dextrostat, Ferndex', 'drugSynonyms_string': 'Amphetamine sulfate, dextro, D-amphetamine hemisulfate salt, Dexamfetamine sulfate, Dexamphetamine sulfate, Dexamphetamine sulphate, Dextroamphetamine sulfate, Dextroamphetamine sulfate cii, Dextroamphetamine sulphate, NSC-27104', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1032', 'drugName': 'Dextroamphetamine Sulfate', 'tradeNames_string': 'Dexampex, Dexedrine, Dextroamphetamine sulfate, Dextrostat, Ferndex', 'drugSynonyms_string': 'Amphetamine sulfate, dextro, D-amphetamine hemisulfate salt, Dexamfetamine sulfate, Dexamphetamine sulfate, Dexamphetamine sulphate, Dextroamphetamine sulfate, Dextroamphetamine sulfate cii, Dextroamphetamine sulphate, NSC-27104', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1033', 'drugName': 'Dextroamphetamine Sulfate', 'tradeNames_string': 'Dexampex, Dexedrine, Dextroamphetamine sulfate, Dextrostat, Ferndex', 'drugSynonyms_string': 'Amphetamine sulfate, dextro, D-amphetamine hemisulfate salt, Dexamfetamine sulfate, Dexamphetamine sulfate, Dexamphetamine sulphate, Dextroamphetamine sulfate, Dextroamphetamine sulfate cii, Dextroamphetamine sulphate, NSC-27104', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1177 | Q17 | What gene does the drug Ipatasertib target? | The drug Ipatasertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: AKT2, AKT1 and AKT3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ipatasertib%" OR LOWER(tradeNames_string) LIKE "%ipatasertib%" OR LOWER(drugSynonyms_string) LIKE "%ipatasertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2935', 'drugName': 'Ipatasertib', 'tradeNames_string': '', 'drugSynonyms_string': 'GDC-0068, Ipatasertib, RG-7440, RG7440, Rg-7440', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Cancer (MONDO_0004992), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Gastric Adenocarcinoma (EFO_0000503), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Triple-Negative Breast Cancer (EFO_0005537), Ovarian Neoplasm (EFO_0003893), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'AKT2 (ENSG00000105221), AKT3 (ENSG00000117020), AKT1 (ENSG00000142208)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1184 | Q17 | What gene does the drug Merethoxylline Procaine target? | The drug Merethoxylline Procaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%merethoxylline procaine%" OR LOWER(tradeNames_string) LIKE "%merethoxylline procaine%" OR LOWER(drugSynonyms_string) LIKE "%merethoxylline procaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3148', 'drugName': 'Merethoxylline Procaine', 'tradeNames_string': '', 'drugSynonyms_string': 'Merethoxyline procaine, Merethoxylline procaine, Procaine merethoxylline', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.897 | Q17 | What gene does the drug Tetrahydrozoline target? | The drug Tetrahydrozoline targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tetrahydrozoline%" OR LOWER(tradeNames_string) LIKE "%tetrahydrozoline%" OR LOWER(drugSynonyms_string) LIKE "%tetrahydrozoline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1295', 'drugName': 'Tetrahydrozoline Hydrochloride', 'tradeNames_string': 'Tyzine', 'drugSynonyms_string': 'NSC-757339, Tetrahydrozoline hydrochloride, Tetrahydrozoline nitrate, Tetryzoline, Tetryzoline hydrochloride', 'linkedDiseasesDrug_string': 'Pterygium (EFO_0000678), Inflammation (MP_0001845)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_545', 'drugName': 'Tetrahydrozoline', 'tradeNames_string': '', 'drugSynonyms_string': 'Caltheon, Tetrahydrozoline, Tetryzoline, Tyzine', 'linkedDiseasesDrug_string': 'Dry Eye Syndrome (EFO_1000906), Inflammation (MP_0001845), Nasal Congestion (HP_0001742), Eye Allergy (EFO_0005751), Pterygium (EFO_0000678)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.956 | Q17 | What gene does the drug Vorinostat target? | The drug Vorinostat targets 4 genes: HDAC2, HDAC6, HDAC3 and HDAC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vorinostat%" OR LOWER(tradeNames_string) LIKE "%vorinostat%" OR LOWER(drugSynonyms_string) LIKE "%vorinostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2373', 'drugName': 'Vorinostat', 'tradeNames_string': 'Zolinza', 'drugSynonyms_string': 'MK-0683, MK0683, NSC-701852, NSC-748799, NSC-759852, Suberoylanilide hydroxamic acid, Vorinostat', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2372', 'drugName': 'Vorinostat', 'tradeNames_string': 'Zolinza', 'drugSynonyms_string': 'MK-0683, MK0683, NSC-701852, NSC-748799, NSC-759852, Suberoylanilide hydroxamic acid, Vorinostat', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2375', 'drugName': 'Vorinostat', 'tradeNames_string': 'Zolinza', 'drugSynonyms_string': 'MK-0683, MK0683, NSC-701852, NSC-748799, NSC-759852, Suberoylanilide hydroxamic acid, Vorinostat', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2374', 'drugName': 'Vorinostat', 'tradeNames_string': 'Zolinza', 'drugSynonyms_string': 'MK-0683, MK0683, NSC-701852, NSC-748799, NSC-759852, Suberoylanilide hydroxamic acid, Vorinostat', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1057 | Q17 | What gene does the drug Mk-6913 target? | The drug Mk-6913 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ESR2 and ESR1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mk-6913%" OR LOWER(tradeNames_string) LIKE "%mk-6913%" OR LOWER(drugSynonyms_string) LIKE "%mk-6913%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3696', 'drugName': 'Mk-6913', 'tradeNames_string': '', 'drugSynonyms_string': 'Mk-6913', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1354 | Q17 | What gene does the drug Lixisenatide target? | The drug Lixisenatide targets the gene GLP1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lixisenatide%" OR LOWER(tradeNames_string) LIKE "%lixisenatide%" OR LOWER(drugSynonyms_string) LIKE "%lixisenatide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5357', 'drugName': 'Lixisenatide', 'tradeNames_string': 'Adlyxin, Lyxumia', 'drugSynonyms_string': 'AVE 010, AVE-0010, AVE-010, AVE0010, Lixisenatide, ZP 10, ZP-10', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Parkinson Disease (MONDO_0005180), Acute Coronary Syndrome (EFO_0005672), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1373 | Q17 | What gene does the drug Vericiguat target? | The drug Vericiguat targets 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vericiguat%" OR LOWER(tradeNames_string) LIKE "%vericiguat%" OR LOWER(drugSynonyms_string) LIKE "%vericiguat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2605', 'drugName': 'Vericiguat', 'tradeNames_string': 'Verquvo', 'drugSynonyms_string': 'BAY 1021189, BAY-1021189, MK-1242, Vericiguat', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1448 | Q17 | What gene does the drug Visilizumab target? | The drug Visilizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD3E. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%visilizumab%" OR LOWER(tradeNames_string) LIKE "%visilizumab%" OR LOWER(drugSynonyms_string) LIKE "%visilizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3333', 'drugName': 'Visilizumab', 'tradeNames_string': 'Nuvion', 'drugSynonyms_string': 'HUM-291, Visilizumab, huM291', 'linkedDiseasesDrug_string': "Crohn'S Disease (EFO_0000384), Graft Versus Host Disease (MONDO_0013730), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Acute Graft Vs. Host Disease (EFO_0004599), Ulcerative Colitis (EFO_0000729)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.891 | Q17 | What gene does the drug Ly-2606368 target? | The drug Ly-2606368 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CHEK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ly-2606368%" OR LOWER(tradeNames_string) LIKE "%ly-2606368%" OR LOWER(drugSynonyms_string) LIKE "%ly-2606368%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2443', 'drugName': 'Ly-2606368', 'tradeNames_string': '', 'drugSynonyms_string': 'Ly-2606368', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHEK1 (ENSG00000149554)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1673 | Q17 | What gene does the drug Rg-7256 target? | The drug Rg-7256 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene BRAF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rg-7256%" OR LOWER(tradeNames_string) LIKE "%rg-7256%" OR LOWER(drugSynonyms_string) LIKE "%rg-7256%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_564', 'drugName': 'Rg-7256', 'tradeNames_string': '', 'drugSynonyms_string': 'PLX-3603, Rg-7256, Ro-5212054', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'BRAF (ENSG00000157764)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.857 | Q17 | What gene does the drug Pascolizumab target? | The drug Pascolizumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pascolizumab%" OR LOWER(tradeNames_string) LIKE "%pascolizumab%" OR LOWER(drugSynonyms_string) LIKE "%pascolizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5968', 'drugName': 'Pascolizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'ANTI-IL4, Anti-il-4 antibody, Pascolizumab, SB-240683', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Tuberculosis (MONDO_0018076)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL4 (ENSG00000113520)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.741 | Q17 | What gene does the drug Ipilimumab target? | The drug Ipilimumab targets the gene CTLA4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ipilimumab%" OR LOWER(tradeNames_string) LIKE "%ipilimumab%" OR LOWER(drugSynonyms_string) LIKE "%ipilimumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6378', 'drugName': 'Ipilimumab', 'tradeNames_string': 'Yervoy', 'drugSynonyms_string': 'BMS-734016, BMS734016, Ipilimumab, MDX-010, MDX-010 MDX-CTLA4, MDX-101, MDX-CTLA-4, MDX010', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Nevoid Basal Cell Carcinoma Syndrome (MONDO_0007187), Skin Cancer (MONDO_0002898), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Nerve Sheath Neoplasm (MONDO_0002547), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Lung Adenocarcinoma (EFO_0000571), Clear Cell Renal Carcinoma (EFO_0000349), Carcinoma (EFO_0000313), Lung Cancer (MONDO_0008903), Classic Hodgkin Lymphoma (MONDO_0009348), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Gastric Adenocarcinoma (EFO_0000503), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Basal Cell Carcinoma (EFO_0004193), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dedifferentiated Liposarcoma (EFO_0003085), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Salivary Gland Cancer (MONDO_0004669), Hodgkins Lymphoma (EFO_0000183), Metastatic Neoplasm (EFO_0009709), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Merkel Cell Skin Cancer (EFO_1001471), Hiv Infection (EFO_0000764), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Retroperitoneal Cancer (EFO_0007466), Neuroblastoma (EFO_0000621), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Undifferentiated Pleomorphic Sarcoma (EFO_1001972), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Biliary Tract Neoplasm (EFO_0003891), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Grade Iii Meningioma (MONDO_0020634), Colon Carcinoma (EFO_1001950), Metastatic Melanoma (EFO_0002617), Pituitary Adenocarcinoma (MONDO_0017582), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Cervical Carcinoma (EFO_0001061), Endometrial Carcinoma (EFO_1001512), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Head And Neck Malignant Neoplasia (EFO_0006859), Squamous Cell Carcinoma (EFO_0000707), Meningioma (MONDO_0016642), Nasopharyngeal Neoplasm (EFO_0004252), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CTLA4 (ENSG00000163599)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.724 | Q17 | What gene does the drug Danburstotug target? | The drug Danburstotug is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD274. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%danburstotug%" OR LOWER(tradeNames_string) LIKE "%danburstotug%" OR LOWER(drugSynonyms_string) LIKE "%danburstotug%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2776', 'drugName': 'Danburstotug', 'tradeNames_string': '', 'drugSynonyms_string': 'Danburstotug, IMC-001, Imc-001, STI-3031, Sti-3031', 'linkedDiseasesDrug_string': 'Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Cancer (MONDO_0004992)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD274 (ENSG00000120217)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.460 | Q17 | What gene does the drug Capecitabine target? | The drug Capecitabine targets the gene TYMS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%capecitabine%" OR LOWER(tradeNames_string) LIKE "%capecitabine%" OR LOWER(drugSynonyms_string) LIKE "%capecitabine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1702', 'drugName': 'Capecitabine', 'tradeNames_string': 'Capecitabine, Xeloda', 'drugSynonyms_string': 'Capecitabine, Capecitabine accord, Capecitabine medac, Capecitabine sun, Capecitabine teva, Capecitibine, Capecytabine, Capiibine, Captabin, Ecansya, NSC-759853, RO 09-1978/000, RO-09-1978000, RO-091978000, Xeloda', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Pseudomyxoma Peritonei (EFO_0007456), Skin Cancer (MONDO_0002898), Malignant Colon Neoplasm (MONDO_0021063), Hand-Foot Syndrome (EFO_1001893), Gallbladder Carcinoma (EFO_1001956), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Lung Cancer (MONDO_0008903), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Gastric Adenocarcinoma (EFO_0000503), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Gallbladder Cancer (MONDO_0005411), Colorectal Cancer (MONDO_0005575), Mesothelioma (EFO_0000588), Skin Carcinoma (EFO_0009259), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Biliary Tract Neoplasm (EFO_0003891), Oropharyngeal Carcinoma (MONDO_0044926), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Colon Adenocarcinoma (EFO_1001949), Stomach Neoplasm (EFO_0003897), Metastatic Melanoma (EFO_0002617), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Esophageal Cancer (MONDO_0007576), Rectal Neoplasm (MONDO_0002165), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Brain Cancer (MONDO_0001657), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Pancreatic Neoplasm (EFO_0003860), Pancreatic Endocrine Carcinoma (EFO_0007416)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TYMS (ENSG00000176890)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5438', 'drugName': 'Doxifluridine', 'tradeNames_string': '', 'drugSynonyms_string': "5'-Deoxy-5-Fluorouridine, Capecitabine related compound b, Doxifluridine, Flutron, Fulturon, Furtulon, NSC-758890, RO 219738, RO-219738", 'linkedDiseasesDrug_string': 'Gastric Cancer (MONDO_0001056)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TYMS (ENSG00000176890)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.267 | Q17 | What gene does the drug Fenoldopam target? | The drug Fenoldopam targets the gene DRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fenoldopam%" OR LOWER(tradeNames_string) LIKE "%fenoldopam%" OR LOWER(drugSynonyms_string) LIKE "%fenoldopam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4966', 'drugName': 'Fenoldopam', 'tradeNames_string': '', 'drugSynonyms_string': 'Carlacor, Fenoldopam, SK&F-82526, SK-82526', 'linkedDiseasesDrug_string': 'Acute Kidney Injury (HP_0001919), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD1 (ENSG00000184845)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4006', 'drugName': 'Fenoldopam Mesylate', 'tradeNames_string': 'Corlopam, Fenoldopam mesylate', 'drugSynonyms_string': 'Fendolopam mesylate, Fenoldopam mesilate, Fenoldopam mesylate, Fenoldopam methanesulfonate, NSC-759860, SK&F 82526-J, SK&F-82526J, SK-82526-J', 'linkedDiseasesDrug_string': 'Acute Kidney Injury (HP_0001919), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD1 (ENSG00000184845)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.78 | Q17 | What gene does the drug Acetaminophen target? | The drug Acetaminophen targets 4 genes: PTGS2, FAAH, TRPV1 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acetaminophen%" OR LOWER(tradeNames_string) LIKE "%acetaminophen%" OR LOWER(drugSynonyms_string) LIKE "%acetaminophen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_146', 'drugName': 'Acetaminophen', 'tradeNames_string': "Abdine, Acephen, Acetaminophen, Alvedon, Angiers, Calpol, Calpol six plus, Calpol six plus fastmelts, Child lemsip, Cupanol, Dafalgan, Datril, Disprol, Disprol infant, Disprol jnr, Disprol paed, Fennings, Galpamol, Hedex, Infadrops, Infants' feverall, Injectapap, Junior parapaed, Mandanol, Medinol, Medinol for children, Medinol over 6, Medinol under 6, Medised plain, Miradol, Neopap, Ofirmev, Paldesic, Panadol, Panadol actifast, Panadol actifast solb, Panadol advan, Panadol jnr, Panadol oa, Panaleve, Panaleve 6 plus, Paracetamol, Paramin, Parapaed jnr, Parapaed six plus, Paravict, Perfalgan, Phenaphen, Placidex, Rimadol, Salzone, Tixymol, Tramil 500, Tylenol", 'drugSynonyms_string': 'Acetaminophen, Apap, Biocetamol, Doliprane, Efferalgan, N-acetyl-p-aminophenol, NSC-109028, NSC-3991, P-hydroxy-acetanilid, Paracetamol, Paracetamolum, Vermidon', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Nephrolithiasis (EFO_0004253), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Hypertrophy (EFO_0002460), Neuropathic Pain (EFO_0005762), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Malignant Glioma (MONDO_0100342), Neck Pain (HP_0030833), Borderline Personality Disorder (HP_0012076), Streptococcal Infection (EFO_1001476), Renal Colic (EFO_1001412), T-Lymphoblastic Lymphoma (MONDO_0044917), Extramammary Paget Disease (EFO_1000249), Diabetic Neuropathy (EFO_1000783), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Myopia (HP_0000545), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Myelodysplastic Syndrome (EFO_0000198), Headache (HP_0002315), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Morbid Obesity (EFO_0001074), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Pharyngitis (MONDO_0002258), Delirium (EFO_0009267), Influenza (EFO_0007328), Bacterial Meningitis (EFO_1000831), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Tract Infectious Disorder (MONDO_0024355), Vomiting (HP_0002013), Low Back Pain (HP_0003419), Plasmodium Falciparum Malaria (EFO_0007444), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Gastrointestinal Disease (EFO_0010282), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Rotator Cuff Tear (EFO_1001250), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Arthritis (EFO_0005856), Cardiac Arrhythmia (EFO_0004269), Patent Ductus Arteriosus (HP_0001643), Concussion (EFO_0011023), Common Cold (EFO_0007214), Neoplasm Of Mature B-Cells (EFO_0000096), Fever (HP_0001945), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Ankle Fracture (EFO_0009615), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Toothache (EFO_0010072), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Crohn'S Disease (EFO_0000384), Tooth Disease (EFO_1001216), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Sepsis (HP_0100806), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Cleft Palate (HP_0000175), Recurrent Tonsillitis (HP_0011110), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592)", 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_147', 'drugName': 'Acetaminophen', 'tradeNames_string': "Abdine, Acephen, Acetaminophen, Alvedon, Angiers, Calpol, Calpol six plus, Calpol six plus fastmelts, Child lemsip, Cupanol, Dafalgan, Datril, Disprol, Disprol infant, Disprol jnr, Disprol paed, Fennings, Galpamol, Hedex, Infadrops, Infants' feverall, Injectapap, Junior parapaed, Mandanol, Medinol, Medinol for children, Medinol over 6, Medinol under 6, Medised plain, Miradol, Neopap, Ofirmev, Paldesic, Panadol, Panadol actifast, Panadol actifast solb, Panadol advan, Panadol jnr, Panadol oa, Panaleve, Panaleve 6 plus, Paracetamol, Paramin, Parapaed jnr, Parapaed six plus, Paravict, Perfalgan, Phenaphen, Placidex, Rimadol, Salzone, Tixymol, Tramil 500, Tylenol", 'drugSynonyms_string': 'Acetaminophen, Apap, Biocetamol, Doliprane, Efferalgan, N-acetyl-p-aminophenol, NSC-109028, NSC-3991, P-hydroxy-acetanilid, Paracetamol, Paracetamolum, Vermidon', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Nephrolithiasis (EFO_0004253), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Hypertrophy (EFO_0002460), Neuropathic Pain (EFO_0005762), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Malignant Glioma (MONDO_0100342), Neck Pain (HP_0030833), Borderline Personality Disorder (HP_0012076), Streptococcal Infection (EFO_1001476), Renal Colic (EFO_1001412), T-Lymphoblastic Lymphoma (MONDO_0044917), Extramammary Paget Disease (EFO_1000249), Diabetic Neuropathy (EFO_1000783), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Myopia (HP_0000545), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Myelodysplastic Syndrome (EFO_0000198), Headache (HP_0002315), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Morbid Obesity (EFO_0001074), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Pharyngitis (MONDO_0002258), Delirium (EFO_0009267), Influenza (EFO_0007328), Bacterial Meningitis (EFO_1000831), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Tract Infectious Disorder (MONDO_0024355), Vomiting (HP_0002013), Low Back Pain (HP_0003419), Plasmodium Falciparum Malaria (EFO_0007444), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Gastrointestinal Disease (EFO_0010282), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Rotator Cuff Tear (EFO_1001250), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Arthritis (EFO_0005856), Cardiac Arrhythmia (EFO_0004269), Patent Ductus Arteriosus (HP_0001643), Concussion (EFO_0011023), Common Cold (EFO_0007214), Neoplasm Of Mature B-Cells (EFO_0000096), Fever (HP_0001945), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Ankle Fracture (EFO_0009615), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Toothache (EFO_0010072), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Crohn'S Disease (EFO_0000384), Tooth Disease (EFO_1001216), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Sepsis (HP_0100806), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Cleft Palate (HP_0000175), Recurrent Tonsillitis (HP_0011110), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592)", 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_148', 'drugName': 'Acetaminophen', 'tradeNames_string': "Abdine, Acephen, Acetaminophen, Alvedon, Angiers, Calpol, Calpol six plus, Calpol six plus fastmelts, Child lemsip, Cupanol, Dafalgan, Datril, Disprol, Disprol infant, Disprol jnr, Disprol paed, Fennings, Galpamol, Hedex, Infadrops, Infants' feverall, Injectapap, Junior parapaed, Mandanol, Medinol, Medinol for children, Medinol over 6, Medinol under 6, Medised plain, Miradol, Neopap, Ofirmev, Paldesic, Panadol, Panadol actifast, Panadol actifast solb, Panadol advan, Panadol jnr, Panadol oa, Panaleve, Panaleve 6 plus, Paracetamol, Paramin, Parapaed jnr, Parapaed six plus, Paravict, Perfalgan, Phenaphen, Placidex, Rimadol, Salzone, Tixymol, Tramil 500, Tylenol", 'drugSynonyms_string': 'Acetaminophen, Apap, Biocetamol, Doliprane, Efferalgan, N-acetyl-p-aminophenol, NSC-109028, NSC-3991, P-hydroxy-acetanilid, Paracetamol, Paracetamolum, Vermidon', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Migraine Disorder (MONDO_0005277), Nephrolithiasis (EFO_0004253), Hypospadias (EFO_0004209), Hypertension (EFO_0000537), Hypertrophy (EFO_0002460), Neuropathic Pain (EFO_0005762), Tension-Type Headache (HP_0012228), Bone Fracture (EFO_0003931), Malignant Glioma (MONDO_0100342), Neck Pain (HP_0030833), Borderline Personality Disorder (HP_0012076), Streptococcal Infection (EFO_1001476), Renal Colic (EFO_1001412), T-Lymphoblastic Lymphoma (MONDO_0044917), Extramammary Paget Disease (EFO_1000249), Diabetic Neuropathy (EFO_1000783), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761), Cancer (MONDO_0004992), Myopia (HP_0000545), Chronic Lymphocytic Leukemia (EFO_0000095), Nausea (HP_0002018), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Myelodysplastic Syndrome (EFO_0000198), Headache (HP_0002315), Acute Lymphoblastic Leukemia (EFO_0000220), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Morbid Obesity (EFO_0001074), Diffuse Large B-Cell Lymphoma (EFO_0000403), Sinusitis (EFO_0007486), Pharyngitis (MONDO_0002258), Delirium (EFO_0009267), Influenza (EFO_0007328), Bacterial Meningitis (EFO_1000831), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Respiratory Tract Infectious Disorder (MONDO_0024355), Vomiting (HP_0002013), Low Back Pain (HP_0003419), Plasmodium Falciparum Malaria (EFO_0007444), Mast-Cell Leukemia (EFO_0007359), Glaucoma (MONDO_0005041), Gastrointestinal Disease (EFO_0010282), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Rotator Cuff Tear (EFO_1001250), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Lymphoma (EFO_0000574), Arthritis (EFO_0005856), Cardiac Arrhythmia (EFO_0004269), Patent Ductus Arteriosus (HP_0001643), Concussion (EFO_0011023), Common Cold (EFO_0007214), Neoplasm Of Mature B-Cells (EFO_0000096), Fever (HP_0001945), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Brain Injury (MONDO_0043510), Cutaneous Melanoma (EFO_0000389), Ankle Fracture (EFO_0009615), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Chronic Pain (HP_0012532), Mucositis (EFO_1001898), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Toothache (EFO_0010072), Covid-19 (MONDO_0100096), Abdominal Pain (HP_0002027), Post Operative Nausea And Vomiting (EFO_0004888), Systemic Lupus Erythematosus (MONDO_0007915), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Chronic Myelogenous Leukemia (EFO_0000339), Malaria (EFO_0001068), Crohn'S Disease (EFO_0000384), Tooth Disease (EFO_1001216), Parkinson Disease (MONDO_0005180), Scoliosis (EFO_0004273), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Pruritus (HP_0000989), Sepsis (HP_0100806), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Cleft Palate (HP_0000175), Recurrent Tonsillitis (HP_0011110), Rheumatoid Arthritis (EFO_0000685), Igg4-Related Disease (MONDO_0017287), Head And Neck Malignant Neoplasia (EFO_0006859), T-Cell Leukemia (EFO_0005592)", 'yearOfFirstApproval': 1968, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303), TRPV1 (ENSG00000196689), FAAH (ENSG00000117480)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1785 | Q17 | What gene does the drug Gedatolisib target? | The drug Gedatolisib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 9 genes: PIK3CB, PIK3R3, PIK3R5, PIK3CG, PIK3R2, PIK3R1, PIK3CA, MTOR and PIK3CD | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gedatolisib%" OR LOWER(tradeNames_string) LIKE "%gedatolisib%" OR LOWER(drugSynonyms_string) LIKE "%gedatolisib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4797', 'drugName': 'Gedatolisib', 'tradeNames_string': '', 'drugSynonyms_string': 'Gedatolisib, PF-05212384, PKI-587', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Acute Myeloid Leukemia (EFO_0000222), Myelodysplastic Syndrome (EFO_0000198), Endometrial Neoplasm (EFO_0004230)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_4798', 'drugName': 'Gedatolisib', 'tradeNames_string': '', 'drugSynonyms_string': 'Gedatolisib, PF-05212384, PKI-587', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Triple-Negative Breast Cancer (EFO_0005537), Acute Myeloid Leukemia (EFO_0000222), Myelodysplastic Syndrome (EFO_0000198), Endometrial Neoplasm (EFO_0004230)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MTOR (ENSG00000198793), PIK3R1 (ENSG00000145675), PIK3CB (ENSG00000051382), PIK3CG (ENSG00000105851), PIK3CA (ENSG00000121879), PIK3R2 (ENSG00000105647), PIK3CD (ENSG00000171608), PIK3R5 (ENSG00000141506), PIK3R3 (ENSG00000117461)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.450 | Q17 | What gene does the drug Montelukast Sodium target? | The drug Montelukast Sodium targets the gene CYSLTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%montelukast sodium%" OR LOWER(tradeNames_string) LIKE "%montelukast sodium%" OR LOWER(drugSynonyms_string) LIKE "%montelukast sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2453', 'drugName': 'Montelukast Sodium', 'tradeNames_string': 'Montelukast sodium, Singulair', 'drugSynonyms_string': 'MK-476, Montelukast (as sodium), Montelukast monosodium salt, Montelukast sodium, NSC-759107', 'linkedDiseasesDrug_string': 'Rhinitis (EFO_0008521), Asthma (MONDO_0004979), Sepsis (HP_0100806), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Neonatal Sepsis (HP_0040187), Chronic Obstructive Pulmonary Disease (EFO_0000341), Eosinophilic Esophagitis (EFO_0004232), Allergic Rhinitis (EFO_0005854), Bronchiolitis Obliterans (EFO_0007183), Bronchiolitis (HP_0011950)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYSLTR1 (ENSG00000173198)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.401 | Q17 | What gene does the drug Sotagliflozin target? | The drug Sotagliflozin targets 2 genes: SLC5A1 and SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sotagliflozin%" OR LOWER(tradeNames_string) LIKE "%sotagliflozin%" OR LOWER(drugSynonyms_string) LIKE "%sotagliflozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4365', 'drugName': 'Sotagliflozin', 'tradeNames_string': '', 'drugSynonyms_string': 'LP-802034, LX-4211, LX4211, Sar-439954, Sar439954, Sotagliflozin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Liver Disease (EFO_0001421), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A1 (ENSG00000100170), SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4366', 'drugName': 'Sotagliflozin', 'tradeNames_string': '', 'drugSynonyms_string': 'LP-802034, LX-4211, LX4211, Sar-439954, Sar439954, Sotagliflozin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Liver Disease (EFO_0001421), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC5A1 (ENSG00000100170), SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.179 | Q17 | What gene does the drug Avacopan target? | The drug Avacopan targets the gene C5AR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%avacopan%" OR LOWER(tradeNames_string) LIKE "%avacopan%" OR LOWER(drugSynonyms_string) LIKE "%avacopan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5921', 'drugName': 'Avacopan', 'tradeNames_string': 'Tavneos', 'drugSynonyms_string': 'Avacopan, CCX-168, CCX168, Ccx168', 'linkedDiseasesDrug_string': 'Microscopic Polyangiitis (EFO_1000784), Atypical Hemolytic-Uremic Syndrome (MONDO_0016244), Vasculitis (EFO_0006803), Iga Glomerulonephritis (EFO_0004194), Granulomatosis With Polyangiitis (EFO_0005297), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (MONDO_0015492), Hidradenitis Suppurativa (EFO_1000710), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'C5AR1 (ENSG00000197405)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1051 | Q17 | What gene does the drug Levorphanol Tartrate target? | The drug Levorphanol Tartrate targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levorphanol tartrate%" OR LOWER(tradeNames_string) LIKE "%levorphanol tartrate%" OR LOWER(drugSynonyms_string) LIKE "%levorphanol tartrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5454', 'drugName': 'Levorphanol Tartrate', 'tradeNames_string': 'Dromoran, Levo-dromoran, Levorphanol tartrate', 'drugSynonyms_string': 'Levorphanol tartrate, Levorphanol tartrate anhydrous, Levorphanol tartrate dihydrate, NSC-91012', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1737 | Q17 | What gene does the drug Nazartinib target? | The drug Nazartinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nazartinib%" OR LOWER(tradeNames_string) LIKE "%nazartinib%" OR LOWER(drugSynonyms_string) LIKE "%nazartinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_982', 'drugName': 'Nazartinib', 'tradeNames_string': '', 'drugSynonyms_string': 'EGF-816, EGF816, Egf816, NVP-EGF816-NX, Nazartinib', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Bronchial Neoplasm (EFO_1000849), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1609 | Q17 | What gene does the drug Difenoxin Hydrochloride target? | The drug Difenoxin Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%difenoxin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%difenoxin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%difenoxin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3761', 'drugName': 'Difenoxin Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Difenoxin hcl, Difenoxin hydrochloride, Difenoxine hydrochloride, R 15,403, R-15403', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1869 | Q17 | What gene does the drug Somatostatin target? | The drug Somatostatin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 5 genes: SSTR5, SSTR3, SSTR4, SSTR1 and SSTR2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%somatostatin%" OR LOWER(tradeNames_string) LIKE "%somatostatin%" OR LOWER(drugSynonyms_string) LIKE "%somatostatin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1300', 'drugName': 'Somatostatin', 'tradeNames_string': '', 'drugSynonyms_string': 'SRIF-14, Somatostatin, Somatostatin-14', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Pancreatic Neuroendocrine Tumor (EFO_1000045), Gallbladder Neoplasm (EFO_0004606), Hypoglycemia (HP_0001943), Hepatic Failure (HP_0001399), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Portal Hypertension (EFO_0000666), Carcinoid Tumor (EFO_0004243), Acute Pancreatitis (EFO_1000652), Type 1 Diabetes Mellitus (MONDO_0005147), Peptic Ulcer (HP_0004398), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR4 (ENSG00000132671), SSTR1 (ENSG00000139874), SSTR3 (ENSG00000278195)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.